

Protein Sequence Searches - February 2005

All of the sequence databases on ABSS have recently been updated.

- Please note that the curators of the UniProt database have purged some temporary accession numbers from the most recent version of UniProt. These sequences have been assigned new permanent accession numbers. The new UniProt record may not contain the previous temporary accession number.
- If you encounter an accession number from an older search run against UniProt (results file extension .rnp) that can no longer be found in the database, the permanent record with the new accession number can be found by searching the old accession number in the UniProt Protein Archive database (UniPARC) at:

<http://www.pir.uniprot.org/database/archive.shtml>

If you have any questions regarding this information or your results, please contact any STIC searcher.

When submitting sequence search results for scanning into IFW, please include a copy of this attachment to assist any future Examiners or members of the public who may encounter UniProt temporary accession numbers.

THIS PAGE BLANK (USPTO)

GenCore version 5.1.6
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: December 21, 2005, 12:44:31 ; Search time 54.0459 Seconds
(without alignments)
484.925 Million cell updates/sec

Title: US-09-211-297-39

Perfect score: 1685

Sequence: 1 MRBASRDYTKYLRCSEMG.....LLDPDQATYGCAGKVRDID 317

Scoring table:

Gapop 10.0 , Gapext 0.5

Searched: 572060 seqs, 82675679 residues

Total number of hits satisfying chosen parameters: 572060

Minimum DB seq length: 0

Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Issued Patents, AA:*
1: /cgn2_6/prodata/1/1aa/5.COMB.pep:*
2: /cgn2_6/prodata/1/1aa/6.COMB.pep:*
3: /cgn2_6/prodata/1/1aa/H.COMB.pep:*
4: /cgn2_6/prodata/1/1aa/CTTUS.COMB.pep:*
5: /cgn2_6/prodata/1/1aa/RE.COMB.pep:*
6: /cgn2_6/prodata/1/1aa/backfillset.pep.*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	1685	100.0	317	2	US-08-996-139-13
2	1685	100.0	317	2	US-08-995-659-13
3	1685	100.0	317	2	US-09-215-649A-13
4	1685	100.0	317	2	US-09-052-521C-4
5	1685	100.0	317	2	US-09-577-780-13
6	1685	100.0	317	2	US-09-577-800-13
7	1685	100.0	317	2	US-09-466-96-13
8	1685	100.0	317	2	US-09-871-856-13
9	1685	100.0	317	2	US-09-871-291-13
10	1685	100.0	317	2	US-09-396-937-2
11	1685	100.0	317	2	US-09-877-650-13
12	1685	100.0	317	2	US-09-865-463-13
13	1685	100.0	317	2	US-09-688-459-13
14	1685	100.0	317	2	US-09-957-944-6
15	1424.5	84.5	316	2	US-09-957-944-8
16	1417.5	84.1	316	2	US-08-842-842-7
17	1417.5	84.1	316	2	US-08-989-362-2
18	1417.5	84.1	316	2	US-09-052-521C-2
19	1417.5	84.1	316	2	US-08-671-658A-2
20	1417.5	84.1	316	2	US-09-396-937-4
21	1417.5	84.1	316	2	US-09-396-937-6
22	1336.5	78.7	294	2	US-08-996-139-11
23	1336.5	78.7	294	2	US-08-995-659-11
24	1336.5	78.7	294	2	US-09-215-649A-11
25	1336.5	78.7	294	2	US-09-577-780-11
26	1336.5	78.7	294	2	US-09-577-800-11
27	1336.5	78.7	294	2	US-09-466-96-11

ALIGNMENTS

28	1326.5	78.7	294	2	US-09-871-856-11	Sequence 11, Appl
29	1326.5	78.7	294	2	US-09-871-291-11	Sequence 11, Appl
30	1326.5	78.7	294	2	US-09-877-650-11	Sequence 11, Appl
31	1326.5	78.7	294	2	US-09-865-363-11	Sequence 11, Appl
32	1326.5	78.7	294	2	US-09-688-459-11	Sequence 11, Appl
33	771	45.8	187	2	US-09-396-937-8	Sequence 10, Appl
34	769	45.6	173	2	US-09-396-937-10	Sequence 12, Appl
35	759	45.0	173	2	US-09-396-937-12	Sequence 14, Appl
36	721.5	42.8	188	2	US-09-396-937-14	Sequence 16, Appl
37	711.5	42.2	182	2	US-09-396-937-16	Sequence 18, Appl
38	691	41.0	173	2	US-09-396-937-18	Sequence 20, Appl
39	670	39.8	173	2	US-09-396-937-20	Sequence 8, Appl
40	538	31.9	109	2	US-09-911-777-8	Sequence 11, Appl
41	418	24.8	77	2	US-09-632-287A-11	Sequence 11, Appl
42	418	24.8	77	2	US-10-286-636-11	Sequence 11, Appl
43	363	21.5	77	2	US-09-632-287A-10	Sequence 10, Appl
44	363	21.5	77	2	US-10-286-636-10	Sequence 10, Appl
45	251.5	14.9	279	2	US-09-072-993C-3	Sequence 3, Appl

RESULT 1
US-08-996-139-13
Sequence 13, Application US/08996139
Patent No. 6017729
GENERAL INFORMATION:
APPLICANT: Anderson, Dirk M.
APPLICANT: Galibert, Laurent
APPLICANT: Marakovsky, Eugene
TITLE OF INVENTION: Receptor Activator of NF-kappaB
NUMBER OF SEQUENCES: 19
CORRESPONDENCE ADDRESSES:
ADDRESSEE: Immunex Corporation, Law Department
STREET: 51 University Street
CITY: Seattle
STATE: WA
COUNTRY: USA
ZIP: 98101
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: Apple Power Macintosh
OPERATING SYSTEM: Apple Operating System 7.5.5
SOFTWARE: Microsoft Word for Power Macintosh 6.0.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/996,139
FILING DATE: 22 DECEMBER 1997
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/60/064,671
FILING DATE: 14 OCTOBER 1997
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/813,509
FILING DATE: 07 MARCH 1997
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/772,330
FILING DATE: 23 DECEMBER 1996
ATTORNEY/AGENT INFORMATION:
NAME: Perkins, Patricia Anne
REGISTRATION NUMBER: 34,693
REFERENCE/DOCKET NUMBER: 2851-A
TELECOMMUNICATION INFORMATION:
TELEPHONE: (206)587-0430
TELEFAX: (206)233-0644
INFORMATION FOR SEQ ID NO: 13:
SEQUENCE CHARACTERISTICS:
LENGTH: 317 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: protein
US-08-996-139-13

Query Match 100.0%; Score 1685; DB 2; Length 317;
 Best Local Similarity 100.0%; Pred. No. 2e-163;
 Matches 317; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRRASRDYTKYLIRGSEEMGGGPGAPHGGPLHAPPAPPAHQPPAASRSFVALLGIGQOV 60
 DB 1 MRRASRDYTKYLIRGSEEMGGGPGAPHGGPLHAPPAPPAHQPPAASRSFVALLGIGQOV 60

QY 61 VCSVALFFYPRAQMDPNRISSEDTGHCYRILRLHENDFODTTLESODTKLIPSCRRIK 120
 DB 61 VCSVALFFYPRAQMDPNRISSEDTGHCYRILRLHENDFODTTLESODTKLIPSCRRIK 120

QY 121 QAFQGAQVQKELQHTVGSQHIRAEKAMVDGSMWDLAKRSKLEAOPFAHLTTINATDIPSGSH 180
 DB 121 QAFQGAQVQKELQHTVGSQHIRAEKAMVDGSMWDLAKRSKLEAOPFAHLTTINATDIPSGSH 180

QY 181 KVSLSWYHNRGMAKISNMTFSNGKLIYNODGFYLLYANICFRHETSGDLATEYLQLMV 240
 DB 181 KVSLSWYHNRGMAKISNMTFSNGKLIYNODGFYLLYANICFRHETSGDLATEYLQLMV 240

QY 241 VYTKTSIKIPSSHTLMKGSSTKYWSGNSSEPHFYSINVGGFFKLRSGEISIEVSNPSLLD 300
 DB 241 VYTKTSIKIPSSHTLMKGSSTKYWSGNSSEPHFYSINVGGFFKLRSGEISIEVSNPSLLD 300

QY 301 PDODATYFGAFKVRDID 317
 DB 301 PDODATYFGAFKVRDID 317

RESULT 2
 US-08-995-659-13
 ; Sequence 13, Application US/08995659
 ; Patent No. 6242213

GENERAL INFORMATION:
 APPLICANT: Anderson, Dirk M.
 APPLICANT: Galibert, Laurent
 APPLICANT: Maraskovsky, Eugene
 TITLE OF INVENTION: Ligand for Receptor Activator of NF-kappaB
 NUMBER OF SEQUENCES: 19
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: Immunex Corporation, Law Department
 STREET: 51 University Street
 CITY: Seattle
 STATE: WA
 COUNTRY: USA
 ZIP: 98101

COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 OPERATING SYSTEM: Apple Power Macintosh
 SOFTWARE: Microsoft Word for Power Macintosh 6.0.1
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/995,659
 FILING DATE: 22 DECEMBER 1997

CLASSIFICATION:
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: USSN 60/064,671
 FILING DATE: 14 OCTOBER 1997

CLASSIFICATION:
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: USSN 08/813,509
 FILING DATE: 07 MARCH 1997

CLASSIFICATION:
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: USSN 08/772,330
 FILING DATE: 23 DECEMBER 1996

CLASSIFICATION:
 ATTORNEY/AGENT INFORMATION:
 NAME: Perkins, Patricia Anne
 REGISTRATION NUMBER: 34,693
 REFERENCE/DOCKET NUMBER: 2852-A
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (206) 587-0430

TELEFAX: (206) 233-0644
 ; INFORMATION FOR SEQ ID NO: 13:
 ; SEQUENCE CHARACTERISTICS:
 ; LENGTH: 317 amino acids
 ; TYPE: amino acid
 ; TOPOLOGY: linear
 ; MOLECULE TYPE: protein
 ; US-08-995-659-13

Query Match 100.0%; Score 1685; DB 2; Length 317;
 Best Local Similarity 100.0%; Pred. No. 2e-163;
 Matches 317; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRRASRDYTKYLIRGSEEMGGGPGAPHGGPLHAPPAPPAHQPPAASRSFVALLGIGQOV 60
 DB 1 MRRASRDYTKYLIRGSEEMGGGPGAPHGGPLHAPPAPPAHQPPAASRSFVALLGIGQOV 60

QY 61 VCSVALFFYPRAQMDPNRISSEDTGHCYRILRLHENDFODTTLESODTKLIPSCRRIK 120
 DB 61 VCSVALFFYPRAQMDPNRISSEDTGHCYRILRLHENDFODTTLESODTKLIPSCRRIK 120

QY 121 QAFQGAQVQKELQHTVGSQHIRAEKAMVDGSMWDLAKRSKLEAOPFAHLTTINATDIPSGSH 180
 DB 121 QAFQGAQVQKELQHTVGSQHIRAEKAMVDGSMWDLAKRSKLEAOPFAHLTTINATDIPSGSH 180

QY 181 KVSLSWYHNRGMAKISNMTFSNGKLIYNODGFYLLYANICFRHETSGDLATEYLQLMV 240
 DB 181 KVSLSWYHNRGMAKISNMTFSNGKLIYNODGFYLLYANICFRHETSGDLATEYLQLMV 240

QY 241 VYTKTSIKIPSSHTLMKGSSTKYWSGNSSEPHFYSINVGGFFKLRSGEISIEVSNPSLLD 300
 DB 241 VYTKTSIKIPSSHTLMKGSSTKYWSGNSSEPHFYSINVGGFFKLRSGEISIEVSNPSLLD 300

QY 301 PDODATYFGAFKVRDID 317
 DB 301 PDODATYFGAFKVRDID 317

RESULT 3
 US-09-215-649A-13
 ; Sequence 13, Application US/09215649A
 ; Patent No. 6271349

GENERAL INFORMATION:
 APPLICANT: Anderson, Dirk M.
 APPLICANT: Galibert, Laurent
 APPLICANT: Maraskovsky, Eugene
 TITLE OF INVENTION: Receptor Activator of NF-kappaB
 NUMBER OF SEQUENCES: 19
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: Immunex Corporation, Law Department
 STREET: 51 University Street
 CITY: Seattle
 STATE: WA
 COUNTRY: USA
 ZIP: 98101

COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 OPERATING SYSTEM: Apple Power Macintosh
 SOFTWARE: Microsoft Word for Power Macintosh 6.0.1
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/09/215,649A
 FILING DATE: 17-Dec-1998

CLASSIFICATION:
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: 08/996,139
 FILING DATE: <Unknown>

CLASSIFICATION:
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: USSN 08/813,509
 FILING DATE: 07 MARCH 1997

CLASSIFICATION:
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: USSN 08/772,330
 FILING DATE: 23 DECEMBER 1996

ATTORNEY/AGENT INFORMATION:
 NAME: Perkins, Patricia Anne

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: December 21, 2005, 12:35:06 ; Search time 218.262 Seconds
(without alignments)
1024.696 Million cell updates/sec

Title: US-09-211-297-39
Perfect score: 1685
Sequence: 1 MRRASRDYTKYRGSEMG.....LLDPDQATYFGAFKVRDID 317

Scoring table: BLOSUM62
Gapop 10.0, Gapext 0.5

Searched: 2166443 seqs, 705528306 residues
Total number of hits satisfying chosen parameters: 2166443

Minimum DB seq length: 0
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database: 1: uniprot_sprot.*
2: uniprot_trembl.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	1685	100.0	317	1	TNFI1 HUMAN
2	1685	100.0	317	2	OST9Y4 HUMAN
3	1417.5	84.1	316	1	TNFI1 MOUSE
4	1396.5	82.9	318	1	TNFI1 RAT
5	1292	76.7	244	2	Q54A98 HUMAN
6	559.5	33.2	290	2	Q5H2R8 XENLA
7	470	27.9	117	2	Q5X1H0 RABIT
8	273.5	16.2	289	2	Q4VSR6 PIG
9	266	15.8	317	2	Q7ZYX9 BRARE
10	265	15.7	304	2	Q7TIF2 CHICK
11	262.5	15.6	292	2	Q5ZK93 CHICK
12	251.5	14.9	281	1	TNFI1 HUMAN
13	251.5	14.9	281	2	Q61BA9 HUMAN
14	249.5	14.8	299	2	Q6DH93 BRARE
15	249.5	14.8	303	2	Q5XK93 MOUSE
16	248	14.7	291	1	TNFI1 MOUSE
17	245.5	14.6	264	2	Q4SD94 TETNG
18	240.5	14.3	214	2	Q9DDE5 BRARE
19	234	13.9	300	2	Q5U675 HUMAN
20	216.5	12.8	287	2	Q9QWT9 CHICK
21	215.5	12.8	285	2	Q8K3G0 RAT
22	211	12.5	282	1	Q4SK14 TETNG
23	200	11.9	282	1	TNFI6 PIG
24	194.5	11.5	280	2	Q61W5 FELIS
25	190.5	11.3	253	2	Q5CAQ0 CHICK
26	189	11.2	281	1	TNFI6 HUMAN
27	189	11.2	281	2	Q53ZL1 HUMAN
28	187.5	11.1	279	2	Q7TMY9 MOUSE
29	186	11.0	280	1	TNFI6 MACFA
30	186	11.0	280	1	TNFI6 MACMU
31	186	11.0	280	1	TNFI6_MACNE

32	184.5	10.9	252	2	Q8K3Y8 MOUSE
33	184.5	10.9	279	1	TNFI6 MOUSE
34	184.5	10.9	279	2	Q54A98 MOUSE
35	182.5	10.8	278	2	Q4STX9 TETNG
36	182.5	10.8	280	1	TNFI6 CERTO
37	181	10.7	95	2	Q6UML7 HUMAN
38	181	10.7	95	2	Q6UY13 HUMAN
39	179.5	10.7	252	2	Q8QY20 MOUSE
40	177.5	10.5	252	2	Q8K3Y7 RAT
41	176.5	10.5	261	1	TNFI5 BOVIN
42	175.5	10.4	278	1	TNFI6 RAT
43	169.5	10.1	261	1	TNFI5 CALJA
44	167.5	9.9	261	1	TNFI5 AORTA
45	162	9.6	239	2	Q5OL61 CHICK

ALIGNMENTS

RESULT 1
ID TNFI1 HUMAN STANDARD; PRT; 317 AA.
AC 014788; 014723; Q96Q17; Q9P2Q3;
DT 16-OCT-2001 (Rel. 40, Last sequence update)
DT 16-OCT-2001 (Rel. 48, Last annotation update)
DE Tumor necrosis factor ligand superfamily member 11 (Receptor activator
DE of nuclear factor kappa B ligand) (RANKL) (TNF-related activation-
DE induced cytokine) (TRANCE) (Osteoprotegerin ligand) (OPGL) (Osteoclast
DE differentiation factor) (ODF) (Contains: Tumor necrosis factor ligand
DE superfamily member 11, membrane form; Tumor necrosis factor ligand
DE superfamily member 11, soluble form).
GN Name=TNFSF11; Synonyms=OPGL, RANKL, TRANCE;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE (ISOFORM 1).
RC TISSUE=Bone marrow, and peripheral blood;
RX MEDLINE=98032977; PubMed=936715; DOI=10.1038/36593;
RA Anderson D.M., Maraskovsky E., Billingsley W.L., Dougan W.C.,
RA Tomesko M.E., Roux E.R., Teepe M.C., Dubose R.F., Cosman D.,
RA Gilbert L.;
RT "A homologue of the TNF receptor and its ligand enhance T-cell growth
RT and dendritic-cell function.";
RL Nature 390:175-179(1997).
[2]
RN NUCLEOTIDE SEQUENCE (ISOFORM 1).
RP TISSUE=Lymph node;
RX MEDLINE=9827661; PubMed=9568710; DOI=10.1016/S0092-8674(00)81569-X;
RA Lacey D.L., Timms E., Tan H.-L., Kelley M.J., Dunstan C.R.,
RA Burgess T., Elliott R., Colombero A., Elliott G., Scully S., Hu H.,
RA Sullivan J., Hawkins N., Davy E., Capparello C., Eli A., Olan Y.-X.,
RA Kaufman S., Sarosi I., Shalhoub V., Senaldi G., Guo J., Delaney J.,
RA Boyle W.J.;
RT "Osteoprotegerin ligand is a cytokine that regulates osteoclast
RT differentiation and activation.";
RL Cell 93:165-176(1998).
[3]
RN NUCLEOTIDE SEQUENCE (ISOFORMS 1, 2 AND 3).
RP TISSUE=Tongue;
RX MEDLINE=2015237; PubMed=10708588; DOI=10.1006/dbrc.2000.2314;
RA Nagai M., Kyakumoto S., Sato N.;
RT "Cancer cells responsible for humoral hypercalcemia express mRNA
RT encoding a secreted form of ODF/TRANCE that induces osteoclast
RT formation.";

RL Biochem. Biophys. Res. Commun. 269:532-536(2000).
 RN [5]
 RC NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
 RX TISSUE=Lung;
 RX MEDLINE=2238257; PubMed=12477932; DOI=10.1073/pnae.242603899;
 RA Strusberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
 RA Klausner R.D., Collins F.S., Wagner L., Shemen C.M., Schuler G.D.,
 RA Altschul S.F., Zeeberg B., Buecor K.H., Schaefer C.F., Bat N.K.,
 RA Hopline R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
 RA Diachenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
 RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
 RA Brownstein M.J., Uedlin T.B., Toshiyuki S., Carninci P., Prange C.,
 RA Raha S.S., Locantello N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
 RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
 RA Richards S., Morley D.M., Sodergren E.J., Lu X., Gibbs R.A.,
 RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
 RA Fahy J., Helton B., Kettelman M., Madan A., Rodrigues S., Sanchez A.,
 RA Whitting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
 RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
 RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
 RA Butterfield Y.S.N., Krzywinski M.I., Skalek U., Smallos D.E.,
 RA Schermer A., Schein J.E., Jones S.J.M., Marra M.A.,
 RT "Generation and initial analysis of more than 15,000 full-length human
 RT and mouse cDNA sequences.";
 RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
 RN [6]
 RC NUCLEOTIDE SEQUENCE OF 73-317.
 RX TISSUE=Thymocyte; PubMed=9312132; DOI=10.1074/jbc.272.40.25190;
 RX MEDLINE=97460112; PubMed=97460112; DOI=10.1074/jbc.272.40.25190;
 RA Wong B.R., Rho J., Arron J., Robinson E., Orlinick J., Chao M.,
 RA Kalichkov S., Cayani E., Bartlett F.S. III, Frankel W.N., Lee S.Y.,
 RA Choi Y.;
 RT "TRANCE is a novel ligand of the tumor necrosis factor receptor family
 RT that activates c-Jun N-terminal kinase in T cells.";
 RL J. Biol. Chem. 272:25190-25194(1997).
 CC -1- FUNCTION: Cytokine that binds to TNFRSF11B/OPG and to
 CC TNFRSF11A/RANK. Osteoclast differentiation and activation factor.
 CC Augments the ability of dendritic cells to stimulate naive T-cell
 CC proliferation. May be an important regulator of interactions
 CC between T cells and dendritic cells and may play a role in the
 CC regulation of the T cell-dependent immune response. May also play
 CC an important role in enhanced bone-resorption in humoral
 CC hypercalcemia of malignancy.
 CC -1- SUBUNIT: Homotrimer (By similarity).
 CC -1- SUBCELLULAR LOCATION: Type II membrane protein (isoforms 1 and 3);
 CC Secreted (isoform 2). A soluble form of isoform 1 arises by
 CC proteolytic processing (By similarity).
 CC -1- ALTERNATIVE PRODUCTS:
 CC Name=1;
 CC IsoId=014788-1; Sequence=Displayed;
 CC Name=2; Synonyms=SODP;
 CC IsoId=014788-2; Sequence=VSP_006447;
 CC Name=3;
 CC IsoId=014788-3; Sequence=VSP_006446;
 CC -1- TISSUE SPECIFICITY: Highest in the peripheral lymph nodes, weak in
 CC spleen, peripheral blood leukocytes, bone marrow, heart, placenta,
 CC skeletal muscle, stomach and thyroid.
 CC -1- INDUCTION: Up-regulated by T cell receptor stimulation.
 CC -1- PTM: The soluble form of isoform 1 derives from the membrane form
 CC by proteolytic processing (By similarity). The cleavage may be
 CC catalyzed by ADAM17.
 CC -1- SIMILARITY: Belongs to the tumor necrosis factor family.
 CC -----
 CC This Swiss-Prot entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation-
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use as long as its content is in no way modified and this statement is not
 CC removed.
 CC EMBL, AF019047, AAB86811.1; -; mRNA.
 CC EMBL, AF053712, AAC39731.1; -; mRNA.
 CC EMBL, AB064269, BAB79694.1; -; mRNA.

DR EMBL, AB061227; BAB71768.1; -; mRNA.
 DR EMBL, AB064270; BAB79695.1; -; mRNA.
 DR EMBL, AB037599; BAA90488.1; -; mRNA.
 DR EMBL, BC074823; AAT74823.1; -; mRNA.
 DR EMBL, BC074850; AAT74850.1; -; mRNA.
 DR EMBL, AF013171; AAC51762.1; -; mRNA.
 DR HSSP, O35235, 1JTY2.
 DR SMR, O14788, 162-317.
 DR Ensembl, ENSG00000120659; Homo sapiens.
 DR HGNC, HGNC:11926; TNFRSF11.
 DR MIM, 602642; -;
 DR GO, GO:0005576; C:extracellular region; NAS.
 DR GO, GO:0005887; C:integral to plasma membrane; NAS.
 DR GO, GO:0005164; F:tumor necrosis factor receptor binding; NAS.
 DR GO, GO:0006955; P:immune response; NAS.
 DR GO, GO:0030316; P:osteoclast differentiation; NAS.
 DR InterPro, IPR006052; TNF_family.
 DR InterPro, IPR003636; TNF_subf.
 DR Pfam, PF00229; TNF; 1.
 DR Prodom, PD002012; TNF_subf; 1.
 DR SMART, SM00207; TNF; 1.
 DR PROSITE, PS00251; TNF_1; FALSE_NEG.
 DR PROSITE, PS0049; TNF_2; 1.
 KW Alternative splicing; Cytokine; Developmental protein;
 KW Differentiation; Glycoprotein; Receptor; Signal-anchor; Transmembrane.
 FT CHAIN 1 317
 FT member 11, membrane form.
 FT member 11, soluble form (By similarity).
 FT TOPO_DOM 1 47
 FT TRANSMEM 48 68
 FT SIGNAL 1 47
 FT TOPO_DOM 69 317
 FT SITE 139 140
 FT CARBOXD 171 171
 FT CARBOXD 198 198
 FT VARSPLIC 1 73
 FT VARSPLIC 1 47
 FT CONFLICT 194 194 A -> G (in Ref. 6).
 FT SEQUENCE 317 AA; 35478 MW; 76617646348097f CRC64;
 SQ
 Query Match 100.0%; Score 1685; DB 1; Length 317;
 Best Local Similarity 100.0%; Pred. No. 6,5e-136;
 Matches 317; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MRRASRDYTKYLRSSEMGSGGPGAPHHGPRLLA PPPAPPHQPPAASRSFVALLGLGLGV 60
 DB 1 MRRASRDYTKYLRSSEMGSGGPGAPHHGPRLLA PPPAPPHQPPAASRSFVALLGLGLGV 60
 QY 61 VCSVALFFYPRAQMDPNRISSEDTGHCYRI RLRLHENDPFODTTESODTKLIPSCRRIK 120
 DB 61 VCSVALFFYPRAQMDPNRISSEDTGHCYRI RLRLHENDPFODTTESODTKLIPSCRRIK 120
 QY 61 VCSVALFFYPRAQMDPNRISSEDTGHCYRI RLRLHENDPFODTTESODTKLIPSCRRIK 120
 DB 61 VCSVALFFYPRAQMDPNRISSEDTGHCYRI RLRLHENDPFODTTESODTKLIPSCRRIK 120
 QY 121 QAFQAGVQKELOHIVGSGHIAERKAMVDGSLDLAKSKLEAOPFAHLITNATDIPSSGH 180
 DB 121 QAFQAGVQKELOHIVGSGHIAERKAMVDGSLDLAKSKLEAOPFAHLITNATDIPSSGH 180
 QY 121 QAFQAGVQKELOHIVGSGHIAERKAMVDGSLDLAKSKLEAOPFAHLITNATDIPSSGH 180
 DB 121 QAFQAGVQKELOHIVGSGHIAERKAMVDGSLDLAKSKLEAOPFAHLITNATDIPSSGH 180
 QY 181 KVSLSWHDGKAKISNMTFSNGKLIYNQGFYYLIANTCPRIHETSGLATEYLQIMV 240
 DB 181 KVSLSWHDGKAKISNMTFSNGKLIYNQGFYYLIANTCPRIHETSGLATEYLQIMV 240
 QY 181 KVSLSWHDGKAKISNMTFSNGKLIYNQGFYYLIANTCPRIHETSGLATEYLQIMV 240
 DB 181 KVSLSWHDGKAKISNMTFSNGKLIYNQGFYYLIANTCPRIHETSGLATEYLQIMV 240
 QY 241 VYTKTSIKIPSSHTLMGSGTKYKWSGSEFFYSINVGFFPKLRSGERISIEVNSPLSD 300
 DB 241 VYTKTSIKIPSSHTLMGSGTKYKWSGSEFFYSINVGFFPKLRSGERISIEVNSPLSD 300
 QY 301 PDODATYFGAFKVDID 317
 DB 301 PDODATYFGAFKVDID 317
 RESULT 2

GenCore version 5.1.6.
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: December 21, 2005, 12:34:10 ; Search time 215.664 Seconds
(without alignments)
645.834 Million cell updates/sec

Title: US-09-211-297-39
Perfect score: 1685
Sequence: 1 MRASRDYTKYLRGSEEMAG.....LIDPDQATYFGAFKVRDID 317

Scoring table: BLOSUM62
Gapop 10.0, Gapext 0.5

Searched: 2443163 reqs, 439378781 residues

Total number of hits satisfying chosen parameters: 2443163

Minimum DB seq length: 0
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database:

A_Geneseq_21:*
1: geneseqp1980s:*
2: geneseqp1990s:*
3: geneseqp2000s:*
4: geneseqp2001s:*
5: geneseqp2002s:*
6: geneseqp2003as:*
7: geneseqp2003bs:*
8: geneseqp2004s:*
9: geneseqp2005s:*

Prod. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	1685	100.0	317	2	AAW83195 Aaw83195 Human ost
2	1685	100.0	317	2	AAW69957 Aaw69957 NF-KB rec
3	1685	100.0	317	2	AAW68293 Aaw68293 NF-KB rec
4	1685	100.0	317	2	AAE08738 Aae08738 Human rec
5	1685	100.0	317	3	AAV84417 Aay84417 Amino aci
6	1685	100.0	317	4	AAE04426 Aae04426 Human rec
7	1685	100.0	317	5	AAE01993 Aae01993 Human ful
8	1685	100.0	317	5	ABBO8134 Abb08134 Human RAN
9	1685	100.0	317	5	AAE26103 Aae26103 Human RAN
10	1685	100.0	317	5	ABG31631 Abg31631 Human RAN
11	1685	100.0	317	5	AAU78285 Aau78285 Human TRA
12	1685	100.0	317	5	AAO19096 Aao19096 C neoform
13	1685	100.0	317	5	ADR29336 Adr29336 Human RAN
14	1685	100.0	317	6	ABP55108 Abp55108 Human ost
15	1685	100.0	317	6	AAE34364 Aae34364 Human rec
16	1685	100.0	317	6	ABR42314 Abr42314 Human RAN
17	1685	100.0	317	7	ADB16988 Adb16988 Human rec
18	1685	100.0	317	7	ADC35204 Adc35204 Human TNF
19	1685	100.0	317	7	ADC73002 Adc73002 Human RAN
20	1685	100.0	317	7	ADG78268 Adg78268 Human RAN
21	1685	100.0	317	7	ABW02277 Abw02277 Human RAN
22	1685	100.0	317	7	ADG46723 Adg46723 Human RAN
23	1685	100.0	317	7	ADJ82112 Adj82112 Protein f
24	1685	100.0	317	8	ADM96241 Adm96241 Human rec

25	1685	100.0	317	8	ADT08155 Adt08155 Human RAN
26	1685	100.0	317	8	ADU06570 Adu06570 Novel bro
27	1685	100.0	317	9	ADM09029 Adm09029 Human rec
28	1685	100.0	317	9	ADY16469 Ady16469 PRO polyp
29	1685	100.0	317	9	ADY74714 Ady74714 Human rec
30	1685	100.0	317	9	ADY74714 Ady74714 Human can
31	1685	100.0	317	9	ADZ12661 Adz12661 Human RAN
32	1685	100.0	317	9	ADY97756 Ady97756 Human RAN
33	1677	99.5	317	2	AAW83018 Aaw83018 Osteoclas
34	1424.5	84.5	316	5	ADR29338 Adr29338 Mouse RAN
35	1424.5	84.5	316	8	ADT08153 Adt08153 Murine RA
36	1422	84.4	270	7	ADJ82113 Adj82113 Protein f
37	1417.5	84.1	316	2	AAW83017 Aaw83017 Osteoclas
38	1417.5	84.1	316	2	AAW83194 Aaw83194 Human ost
39	1417.5	84.1	316	2	AAV17874 Aav17874 Murine TR
40	1417.5	84.1	316	2	AAV91024 Aav91024 Mouse OBM
41	1417.5	84.1	316	3	AAV84418 Aav84418 Amino aci
42	1417.5	84.1	316	3	AAV84419 Aav84419 Amino aci
43	1417.5	84.1	316	5	AAU78289 Aau78289 Mouse TRA
44	1417.5	84.1	316	6	ABR42071 Abr42071 Human RAN
45	1417.5	84.1	316	6	ABB99477 Abb99477 Amino aci

ALIGNMENTS

RESULT 1
ID AAW83195 standard; protein; 317 AA.
XX AAW83195;
AC AAW83195;
DT 11-FEB-1999 (first entry)
DE Human osteoprotegerin binding protein from the pcDNA/nuOCPb1.insert.
XX Human, osteoprotegerin binding protein; OPG binding protein; arthritis;
XX osteoporosis; osteoclast maturation; bone disease; metastasis; ODR;
XX hypercalcaemia; osteoclast differentiation and activation receptor;
XX Paget's disease.
OS Homo sapiens.
XX
XX
XX PN WO9846751-A1.
XX
XX PD 22-OCT-1998.
XX
XX PF 15-APR-1998; 98WO-US007584.
XX
XX PR 16-APR-1997; 97US-00842842.
XX PR 23-JUN-1997; 97US-00880855.
XX PR 30-MAR-1998; 98US-00052521.
XX
XX PA (AMGE-) AMGEN INC.
XX
XX PI Boyle WJ;
XX DR WPI; 1998-594578/50.
XX DR N-PSDB; AAV70285.
XX
XX PT Nucleic acid encoding osteoprotegerin binding protein - useful for, e.g.
XX PT treating bone diseases by modulating osteoclast differentiation and for
XX PT diagnosis.
XX
XX PS Claim 19; Fig 4; 47pp; English.
XX
XX CC The present sequence is human osteoprotegerin (OPG) binding protein. Host
XX CC cells transfected with vectors containing nucleic acid molecules encoding
XX CC OPG binding protein are used to produce recombinant OPG binding protein.
XX CC OPG binding protein is used in binding assays to determine osteoprotegerin
XX CC (OG) in biological samples; to screen for specific binding agents
XX CC (particularly agonists and antagonists, including intracellular proteins)
XX CC ; to raise Ab (useful in immunoassays for detection of OPG binding

protein) and to identify compounds that modulate binding of OPG binding protein to osteoclast differentiation and activation receptor (ODAR). The nucleic acid molecule encoding OPG binding protein can be used to detect OPG binding protein-encoding sequences, e.g., screening for related sequences, also to produce transgenic animal models, while complementary sequences are used for antisense regulation of OPG binding protein expression. Modulators of OPG binding protein, particularly soluble forms of OPG binding protein or Ab, are used to treat or prevent bone diseases, e.g., osteoporosis, bone loss caused by arthritis or metastases, hypercalcemia, Paget's disease, periodontal disease, osteoporosis, loosening of prostheses, optionally in combination with agents that promote bone growth

Sequence 317 AA;

Query Match 100.0%; Score 1685; DB 2; Length 317;
Best Local Similarity 100.0%; Pred. No. 7.5e-154;
Matches 317; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRRASRDYTKYLKRGSEEMGGPGAPHEGRLHAPPAPPAHOPPAASRSMFVALLGLGLGQV 60
DB 1 MRRASRDYTKYLKRGSEEMGGPGAPHEGRLHAPPAPPAHOPPAASRSMFVALLGLGLGQV 60
QY 61 VCSVALFFYFRAQMDPNRISDEGTHCIYRILRLHENDFODTTLESODTKLIPDSCRIRK 120
DB 61 VCSVALFFYFRAQMDPNRISDEGTHCIYRILRLHENDFODTTLESODTKLIPDSCRIRK 120
QY 121 QAFQGAVOKELOHIVGSGHIAEKAMVDSWLDLAKRSKLEAOPFAHLLTNATDIPSGSH 180
DB 121 QAFQGAVOKELOHIVGSGHIAEKAMVDSWLDLAKRSKLEAOPFAHLLTNATDIPSGSH 180
QY 121 QAFQGAVOKELOHIVGSGHIAEKAMVDSWLDLAKRSKLEAOPFAHLLTNATDIPSGSH 180
DB 121 QAFQGAVOKELOHIVGSGHIAEKAMVDSWLDLAKRSKLEAOPFAHLLTNATDIPSGSH 180
QY 181 KVSLSWYHDSGMWAKISNMTFSNGKLIYNODGFYLYANICFRHETSGDLATEYLQLMV 240
DB 181 KVSLSWYHDSGMWAKISNMTFSNGKLIYNODGFYLYANICFRHETSGDLATEYLQLMV 240
QY 241 VYTKTSIKIPSSHTLMKSGSTKYWSGSEFHFYSINVGFFPKLRSGBEISIEVNSPDL 300
DB 241 VYTKTSIKIPSSHTLMKSGSTKYWSGSEFHFYSINVGFFPKLRSGBEISIEVNSPDL 300
QY 301 PDDATYFGAFKVRDID 317
DB 301 PDDATYFGAFKVRDID 317

RESULT 2

AAW69957 standard; protein; 317 AA.

AAW69957;

08-OCT-1998 (first entry)

NF-kB receptor activator RANK ligand (RANKL).

RANK; necrosis factor-kappa B; NF-kB; receptor activator; human;

immune response; inflammatory response; toxic shock; sepsis; RANKL;

RANK ligand; tumour necrosis factor; TNF.

Homo sapiens.

WO9828426-A2.

02-JUL-1998.

22-DEC-1997; 97WO-US023775.

23-DEC-1996; 96US-0059378P.

07-MAR-1997; 97US-0081350P.

14-OCT-1997; 97US-0064671P.

(IMMUNEX CORP.

Anderson DM, Galibert LJ, Maraskovsky E;

XX WPI: 1998-377657/32.

DR N-PSDB: AAV41378.

PT New isolated ligand for receptor activator of NF-kappa B - used to

PT develop products for augmenting an immune response for inhibiting an

PT inflammatory response and for protection of cells.

PS Claim 27; Page 59-60; 80pp; English.

XX This represents a human RANKL, a ligand for the RANK (receptor activator
CC of necrosis factor-kappa B (NF-kB)) polypeptide. RANK is a member of the
CC tumour necrosis factor (TNF) family. A soluble RANK may be used for
CC inhibiting activation of NF-kB, by contacting a cell expressing membrane-
CC associated RANK with a soluble RANK which binds to RANK ligand (RANKL).
CC RANKL polypeptides can activate RANK and can be used to induce maturation
CC of dendritic cells and enhance their allo-stimulatory capacity, thereby
CC augmenting an immune response. The soluble RANK polypeptide composition
CC may also be used for regulating an immune or inflammatory response.
CC Inhibition of NF-kB by RANK antagonists may be useful in ameliorating
CC negative effects of an inflammatory response that result from triggering
CC of RANK, e.g. in treating toxic shock or sepsis, graft-versus-host
CC reactions, or acute inflammatory reactions. They can also be used in
CC adjunct therapy for disease characterised by neoplastic cells that
CC express RANK. RANKL polypeptides can also be used to identify inhibitors
CC of RANK and thus inhibitors of an inflammatory response, and also for
CC protecting RANK-expressing cells from the negative effects of
CC chemotherapy or the presence of high levels of TNF-alpha. The products
CC can also be used for detection and drug screening

Sequence 317 AA;

Query Match 100.0%; Score 1685; DB 2; Length 317;
Best Local Similarity 100.0%; Pred. No. 7.5e-154;
Matches 317; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRRASRDYTKYLKRGSEEMGGPGAPHEGRLHAPPAPPAHOPPAASRSMFVALLGLGLGQV 60
DB 1 MRRASRDYTKYLKRGSEEMGGPGAPHEGRLHAPPAPPAHOPPAASRSMFVALLGLGLGQV 60
QY 61 VCSVALFFYFRAQMDPNRISDEGTHCIYRILRLHENDFODTTLESODTKLIPDSCRIRK 120
DB 61 VCSVALFFYFRAQMDPNRISDEGTHCIYRILRLHENDFODTTLESODTKLIPDSCRIRK 120
QY 121 QAFQGAVOKELOHIVGSGHIAEKAMVDSWLDLAKRSKLEAOPFAHLLTNATDIPSGSH 180
DB 121 QAFQGAVOKELOHIVGSGHIAEKAMVDSWLDLAKRSKLEAOPFAHLLTNATDIPSGSH 180
QY 121 QAFQGAVOKELOHIVGSGHIAEKAMVDSWLDLAKRSKLEAOPFAHLLTNATDIPSGSH 180
DB 121 QAFQGAVOKELOHIVGSGHIAEKAMVDSWLDLAKRSKLEAOPFAHLLTNATDIPSGSH 180
QY 181 KVSLSWYHDSGMWAKISNMTFSNGKLIYNODGFYLYANICFRHETSGDLATEYLQLMV 240
DB 181 KVSLSWYHDSGMWAKISNMTFSNGKLIYNODGFYLYANICFRHETSGDLATEYLQLMV 240
QY 241 VYTKTSIKIPSSHTLMKSGSTKYWSGSEFHFYSINVGFFPKLRSGBEISIEVNSPDL 300
DB 241 VYTKTSIKIPSSHTLMKSGSTKYWSGSEFHFYSINVGFFPKLRSGBEISIEVNSPDL 300
QY 301 PDDATYFGAFKVRDID 317
DB 301 PDDATYFGAFKVRDID 317

RESULT 3

AAW68293 standard; protein; 317 AA.

AAW68293;

08-OCT-1998 (first entry)

NF-kB receptor activator RANK ligand (RANKL).

RANK; necrosis factor-kappa B; NF-kB; receptor activator; human;

immune response; inflammatory response; toxic shock; sepsis; RANKL;

GenCore version 5.1.6
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: December 21, 2005, 12:47:51 / Search time 35.8574 Seconds
(without alignment)
850.612 Million cell updates/sec

Title: US-09-211-297-39

Perfect score: 1685
Sequence: 1 MRRASRDYTKYLRGSEEMG.....LIDPDQATYFGAFKVRDID 317

Scoring table: BLOSUM62
Gapop 10.0, Gapext 0.5

Searched: 283416 seqs, 96216763 residues

Total number of hits satisfying chosen parameters: 283416

Minimum DB seq length: 0
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database: PIR 80:*

1: p1r1:*
2: p1r2:*
3: p1r3:*
4: p1r4:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query	Length	DB	ID	Description
1	189	11.2	281	2	I38707	Fas ligand - human
2	184.5	10.9	279	2	A53062	Fas ligand - mouse
3	176.5	10.5	261	2	S53090	CD40 ligand - bovi
4	175.5	10.4	278	2	A49286	Fas ligand - rat
5	158.5	9.4	261	2	I53476	CD40 ligand - huma
6	141.5	8.4	235	1	OMMSN	tumor necrosis fac
7	141	8.4	234	1	A25451	tumor necrosis fac
8	137	8.1	234	1	JH0529	tumor necrosis fac
9	133	7.9	233	1	QMHUN	tumor necrosis fac
10	132.5	7.9	235	2	I54490	tumor necrosis fac
11	131.5	7.8	235	2	JU0029	tumor necrosis fac
12	130.5	7.7	306	2	I49139	lymphotoxin-beta -
13	130	7.7	233	1	S22052	tumor necrosis fac
14	128	7.6	234	1	J01344	tumor necrosis fac
15	126.5	7.5	233	1	S24642	tumor necrosis fac
16	126	7.5	232	1	S12606	tumor necrosis fac
17	125.5	7.4	185	2	S52715	tumor necrosis fac
18	122	7.2	193	2	S06192	CD40 ligand - mous
19	120	7.1	260	2	S21738	tumor necrosis fac
20	117	6.9	233	2	S11688	tumor necrosis fac
21	117	6.9	244	2	A46066	lymphotoxin beta -
22	97.5	5.8	1464	1	CGHUIS	collagen alpha 1(I
23	94.5	5.6	664	1	CG4747	probable protein k
24	92.5	5.5	205	1	QMHUX	lymphotoxin alpha
25	92.5	5.5	450	2	S38114	hypothetical prote
26	91.5	5.4	3848	2	T17414	TRPC protein - ali
27	91	5.4	493	2	AC0937	probable GPCR-fam
28	90.5	5.4	1694	2	S50065	siatoadhesin - mou
29	90	5.3	730	2	JC1456	gelatinase B (EC 3

30	89.5	5.3	331	2	AF3526	homoprotocactinuat
31	89.5	5.3	379	2	A47659	farneesyl-protein t
32	89	5.3	202	1	B27303	tumor necrosis fac
33	89	5.3	440	2	I49681	glyceroldehyde-3-p
34	89	5.3	479	2	A25052	fibrinogen beta ch
35	89	5.3	639	2	C83624	probable two-compo
36	88.5	5.3	565	2	C89893	hypothetical prote
37	88.5	5.3	578	2	S51379	probable phosphoes
38	88.5	5.3	684	2	T01267	leucine-rich repea
39	88.5	5.3	883	2	A49733	[heparan sulfate] -
40	87.5	5.2	610	2	T06690	galactonolactone d
41	87.5	5.2	1466	1	CGHUL	collagen alpha 1(I
42	87	5.2	639	2	A32935	protein p1 - Entlam
43	87	5.2	1114	2	JH0284	125K surface antiq
44	87	5.2	1315	2	G96722	hypothetical prote
45	86.5	5.1	279	2	F72339	hypothetical prote

ALIGNMENTS

RESULT 1
138707
Fas ligand - human
C:Species: Homo sapiens (man)
C:Date: 29-May-1998 #sequence revision 29-May-1998 #text_change 09-Jul-2004
C:Accession: I38707; J02340; S57565; I38554
R:Takehashi, T.; Tanaka, M.; Inazawa, J.; Abe, T.; Suda, T.; Nagata, S.
Int. Immunol. 6, 1567-1574, 1994
A>Title: Human Fas ligand: gene structure, chromosomal location and species specificity.
A:Reference number: I38707; MUID:95127560; PMID:7826947
A:Accession: I38707
A:Status: preliminary; translated from GB/EMBL/DBJ
A:Molecule type: DNA
A:Residues: 1-281 <RES>
A:Cross-references: UNIPROT:P48023; UNIPARC:UPI000000D91A; EMBL:U11821; NID:G555430; PID
R:Mittra, E.; Hayashi, N.; Iio, S.; Takehara, T.; Hijioka, T.; Kasahara, A.; Fusemoto, H.,
Biochem. Biophys. Res. Commun. 204, 468-474, 1994
A>Title: Role of Fas ligand in apoptosis induced by hepatitis C virus infection.
A:Reference number: J02340; MUID:95071350; PMID:7980502
A:Accession: J02340
A:Molecule type: DNA
A:Residues: 1-281 <MIT>
A:Cross-references: UNIPARC:UPI000000D91A; GB:D38122; DBJ:D29820; NID:G61892; PIDN:BA
R:Schatzlein, C.B.
submitted to the EMBL Data Library, June 1995
A:Reference number: S57565
A:Accession: S57565
A:Status: preliminary
A:Molecule type: mRNA
A:Residues: 1-281 <SCH>
A:Cross-references: UNIPARC:UPI000000D91A; EMBL:X89102; NID:G887455; PID:G887456
R:Alderson, M.R.; Tough, T.W.; Davis-Smith, T.; Braddy, S.; Falk, B.; Schooley, K.A.; G
J. Exp. Med. 181, 71-77, 1995
A>Title: Fas ligand mediates activation-induced cell death in human T lymphocytes.
A:Reference number: I38554; MUID:95105731; PMID:7528780
A:Accession: I38554
A:Status: preliminary
A:Molecule type: mRNA
A:Residues: 1-281 <RE2>
A:Cross-references: UNIPARC:UPI000000D91A; EMBL:U08137; NID:G624627; PIDN:AACS0071.1; P
C:Genetic:
A:Gene: FasL
A:Introns: 151/1, 116/3
C:Keywords: glycoprotein; transmembrane protein
F:80-102/Domain: transmembrane #status predicted <TM>
F:76,184,250,260/Binding site: carbohydrate (Aen) (covalent) #status predicted

Query Match 11.2% Score 189; DB 2; Length 281;
Best Local Similarity 21.7%; Pred. No. 2e-08;
Matches 69; Conservative 43; Mismatches 98; Indels 108; Gaps 11;
22 PGAPHGCPHAPPPAP---HQPAPASRS-----MFVALIGLIGLVGVCS 63

```
Db      46 PPPPPPPPLPPPPPPPLPPLPLPKKRGHNSTGCLLWPFMVLVALVGLG----- 100
Qy      64 VALFFYFRQMDPNRISEGDTHCIYRLAHENADQDTTLESQDTKLIPDSCKRIKQAF 123
Db      101 --MFQFLHQ-----KSLAELERESTQWHA----- 124
Qy      124 OGAVQKLOHIVGSOHIRAEKAMVDGSMWDLAKRSKLEAPFAHLT--INATDIPSGSHK 181
Db      125 -SLEKQIGH-----PSPPEKKEIKRYAHLTGKSNRSM----- 159
Qy      182 VLSLSWYHDRGWAKISNMTFSNGKLIYNODGFYYLYANICFRHHETSGDLATEYLQLMVY 241
Db      160 ---LEWEDTYGIVLISGVKKKGGLVINEGTGLYFYVSKYFRGQSCN-----LPLSHK 210
Qy      242 YKTSIKTIPSSHLMKSGSTKY-----WSGSEHFHYIINVGGFPKLRSGEISIEVSN 295
Db      211 VYMRNSKYPQDILVMEGKMMSYCTTGQMWARS-----YLGAVFNLTSADHLVYVNS 263
Qy      296 PSLIDPDODATYFGAFKV 313
Db      264 LSLVNFESQTFPGLYKL 281
```

```
RESULT 2
A:3062
Fae ligand - mouse
C:Species: Mus musculus (house mouse)
C:Date: 06-Jan-1995 #sequence_revision 06-Jan-1995 #text_change 09-Jul-2004
C:Accession: A53062
R:Takehashi, T.; Tanaka, M.; Brannan, C.I.; Jenkins, N.A.; Copeland, N.G.; Suda, T.; Nag
Cell 76, 969-976, 1994
A:Title: Generalized lymphoproliferative disease in mice, caused by a point mutation in
A:Reference number: A53062; MUID:94185175; PMID:7511063
A:Accession: A53062
A:Status: preliminary
A:Molecule type: mRNA
A:Residues: 1-279 <TAK>
A:Cross-references: UNIPROT:P41047; UNIPARC:UPI0000004022; GB:U06948; NID:g473564; PIDN:
```

```
Query Match      10.9%; Score 184.5; DB 2; Length 279;
Best Local Similarity 21.7%; Pred. No. 4,9e-08;
Matches 70; Conservative 45; Mismatches 106; Indels 101; Gaps 11;

Qy      13 RSEEMGGGPGAGPHGGRPLHAPPPRPHQ-----PAASRSMVALLGL 57
Db      38 RPPDQRRPPPPPPVSPRPSPQRLPRLPLTKKKDHNTLMILVVFPMVLVALVGMGL 97
Qy      58 GQVCSVALFFYFRAQMDPNRISEGDTHCIYRLAHENADQDTTLESQDTKLIPDSGR 117
Db      98 G-----MYQLPHL----- 105
Qy      118 RIKQAFQAVQKLOHIT--VSGQHTRA--EKAMVDGSMWDLAKRSKLEAPFAHLTINA 172
Db      106 -----QKELAELEFRTNQSLKVSFEKQIANPS---TPSEKKEPRSVAILTGN- 150
Qy      173 TDIPSGSHKVSLS-SWYHDRGWAKISNMTFSNGKLIYNODGFYYLYANICFRHHETSD 231
Db      151 -----PHSRSLPLEMEDTYGTALISGVYKKKGGLVINEGTGLYFYVSKYFRGQSCN--- 201
Qy      232 ATEYLQLMVYVTKTSIKTIPSSHLMKSGSTKYWSGSEHFHYIINVGGFPKLRSGEISI 291
Db      202 -NQPLNHKKYMNNS--KYREDLVIMEBKRLNYCT--TGQIMASSYLGAVFNLTSADHLV 257
Qy      292 EVSNPSLLDPDODATYFGAFKV 313
Db      258 NISQSLINFEESKTFPGLYKL 279
```

```
RESULT 3
S53090
CD40 ligand - bovine
C:Species: Bos primigenius taurus (cattle)
```

```
C:Date: 08-Jul-1995 #sequence_revision 21-Jul-1995 #text_change 09-Jul-2004
C:Accession: S53090
R:Mertens, B.E.L.C.; Murtuki, M.
Submitted to the EMBL Data Library, February 1995
A:Description: Cloning of bovine CD40L and homology to bovine TNFA and TNFB.
A:Reference number: S53090
A:Accession: S53090
A:Status: preliminary
A:Molecule type: mRNA
A:Residues: 1-261 <MER>
A:Cross-references: UNIPROT:P51749; UNIPARC:UPI00001370A9; EMBL:Z48469; NID:g732569; PIDN:
```

```
Query Match      10.5%; Score 176.5; DB 2; Length 261;
Best Local Similarity 24.2%; Pred. No. 2,1e-07;
Matches 70; Conservative 54; Mismatches 122; Indels 43; Gaps 13;

Qy      33 PPPAPHPQPPAASRSMFVALLGLG-QGVCSVALFFYFRAQMDPNRISEGDTHCIYRIL 91
Db      8 PSPRSVATGPPVSKIRFMVLLTVFLITOMIGSALFAVYLHRRLD--KIEDE-----R 57
Qy      92 RLHENADPQDT--TLSESQDTKLIPDSCKRIKQAFQAVQKLOHIVGSOHIRAEKAVDG 149
Db      58 NLHEDFVFMKTIQRCKNGESLSLNCBEIRSPEDLVKQIMQ---NKEVKKKKKNE- 112
Qy      150 SWDLAKRSKLEAPFAHLTINATDIPSGSHKVSLSWYHDRGWAKISN--MTFSNGK-L 206
Db      113 -----MKGDQEPRIAAHVISEAS-----SKTYSVLQW-APKGYTSLNNLVLTENGKQL 161
Qy      207 IYNODGFYYLYANICFRHHETSGDLATEYLQLMVYVTKTSIKIP--SSHTLMKGGSTKYW 264
Db      162 AVKQGFYYIYTYQTFPCSNR-----ETLSQAPFIASLCKSPSGSERILLRAANTH-- 212
Qy      265 GSGNEHFHYIINVGGFPKLRSGEISIEVSNPSLLDPDODATYFGAFKV 313
Db      213 SSSKPCGQGSQSLHGGVFELOSASVFVAVTDPDSOVSHGCTGFTSGFLKL 261
```

```
RESULT 4
A49266
fas ligand - rat
C:Species: Rattus norvegicus (Norway rat)
C:Date: 13-Jan-1995 #sequence_revision 13-Jan-1995 #text_change 09-Jul-2004
C:Accession: A49266
R:Suda, T.; Takehashi, T.; Goletz, P.; Nagata, S.
Cell 75, 1169-1178, 1993
A:Title: Molecular cloning and expression of the fas ligand, a novel member of the tumor
A:Reference number: A49266; MUID:94084792; PMID:7505205
A:Accession: A49266
A:Status: preliminary
A:Molecule type: mRNA
A:Residues: 1-278 <STD>
A:Cross-references: UNIPROT:P36940; UNIPARC:UPI00001370B5; GB:U03470; NID:g440178; PIDN:
C:Keywords: glycoprotein, transmembrane protein
```

```
Query Match      10.4%; Score 175.5; DB 2; Length 278;
Best Local Similarity 20.3%; Pred. No. 2,8e-07;
Matches 64; Conservative 47; Mismatches 106; Indels 99; Gaps 10;

Qy      21 GPGAPHGGRPLHAPPPRPHQPPAASRSM-----FVALLGLGL 57
Db      39 GPGGRPPPP--PPRPSPPLPPSPQRLPRLPLSKKDNITELMVLVIFMVLVALVGMGL 96
Qy      58 GQVCSVALFFYFRAQMDPNRISEGDTHCIYRLAHENADPQDTTLESQDTKLIPDSGR 117
Db      97 G-----MYQLPHQKELAELEFRTNHSL-RVSSFEKQIANPSTPSETKPPRSV----- 143
Qy      118 RIKQAFQAVQKLOHIVGSOHIRAEKAMVDGSMWDLAKRSKLEAPFAHLTINATDIPS 177
Db      144 -----AHLTGNPR----- 151
Qy      178 GSHKVSLSWYHDRGWAKISNMTFSNGKLIYNODGFYYLYANICFRHHETSGDLATEYLQ 237
Db      152 -SREIPL-EMEDTYGTALISGVYKKKGGLVINEAGLYFYVSKYFRGQSCN-----SQPLS 205
```

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: December 21, 2005, 13:02:07, Search time 174.61 Seconds
(without alignments)
758.559 Million cell updates/sec

Title: US-09-211-297-39

Sequence: 1 MRRASRDYTKYLKRGSEEMCG.....LDDPDQATYFGAFKVRDID 317

Scoring table: BLOSUM62
Gapop 10.0, Gapext 0.5

Searched: 1867569 seqs, 417829326 residues

Total number of hits satisfying chosen parameters: 1867569

Minimum DB seq length: 0
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database: Published Applications_AA_Main:
1: /cgn2_6/ptodaca/1/pubppaa/US07_PUBCOMB.pep:
2: /cgn2_6/ptodaca/1/pubppaa/US08_PUBCOMB.pep:
3: /cgn2_6/ptodaca/1/pubppaa/US09_PUBCOMB.pep:
4: /cgn2_6/ptodaca/1/pubppaa/US10A_PUBCOMB.pep:
5: /cgn2_6/ptodaca/1/pubppaa/US10B_PUBCOMB.pep:
6: /cgn2_6/ptodaca/1/pubppaa/US11_PUBCOMB.pep:

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	1685	100.0	317	3	US-09-813-329-7
2	1685	100.0	317	3	US-09-871-856-13
3	1685	100.0	317	3	US-09-957-944-6
4	1685	100.0	317	3	US-09-865-363-13
5	1685	100.0	317	3	US-09-871-291-13
6	1685	100.0	317	3	US-09-877-650-13
7	1685	100.0	317	3	US-09-933-915A-2
8	1685	100.0	317	4	US-10-151-071-10
9	1685	100.0	317	4	US-10-218-547-22
10	1685	100.0	317	4	US-10-167-182-11
11	1685	100.0	317	4	US-10-405-878-13
12	1685	100.0	317	4	US-10-310-793-28
13	1685	100.0	317	4	US-10-460-623-11
14	1685	100.0	317	4	US-10-289-456-79
15	1685	100.0	317	4	US-10-202-062-22
16	1685	100.0	317	4	US-10-664-801-2
17	1685	100.0	317	4	US-10-381-160-6
18	1685	100.0	317	4	US-10-799-345-12
19	1685	100.0	317	5	US-10-399-116-6
20	1685	100.0	317	5	US-10-802-133-13
21	1685	100.0	317	5	US-10-825-898-4
22	1685	100.0	317	5	US-10-854-300-11
23	1685	100.0	317	5	US-10-129-595-1
24	1685	100.0	317	5	US-10-451-200-6
25	1685	100.0	317	5	US-10-999-523-8
26	1685	100.0	317	6	US-11-028-780-22
27	1685	100.0	317	6	US-11-099-059-6

28	1685	100.0	317	6	US-11-135-521-11	Sequence 11, Appl
29	1685	100.0	317	6	US-11-142-736-7	Sequence 7, Appl
30	1424.5	84.5	316	3	US-09-957-944-8	Sequence 8, Appl
31	1424.5	84.5	316	4	US-10-799-345-10	Sequence 10, Appl
32	1424.5	84.5	316	6	US-11-099-059-8	Sequence 8, Appl
33	1422	84.4	270	4	US-10-289-456-80	Sequence 80, Appl
34	1417.5	84.1	316	3	US-09-079-569-7	Sequence 7, Appl
35	1417.5	84.1	316	3	US-09-873-829-4	Sequence 4, Appl
36	1417.5	84.1	316	3	US-09-933-915A-16	Sequence 16, Appl
37	1417.5	84.1	316	4	US-10-017-910-4	Sequence 2, Appl
38	1417.5	84.1	316	4	US-10-105-057-2	Sequence 2, Appl
39	1417.5	84.1	316	4	US-10-272-411-19	Sequence 19, Appl
40	1417.5	84.1	316	4	US-10-272-328A-19	Sequence 19, Appl
41	1417.5	84.1	316	4	US-10-326-052-2	Sequence 2, Appl
42	1417.5	84.1	316	4	US-10-167-182-1	Sequence 1, Appl
43	1417.5	84.1	316	4	US-10-460-623-1	Sequence 1, Appl
44	1417.5	84.1	316	4	US-10-664-801-4	Sequence 4, Appl
45	1417.5	84.1	316	4	US-10-664-801-6	Sequence 6, Appl

ALIGNMENTS

```
RESULT 1
US-09-813-329-7
Sequence 7, Application US/09813329
Patent No. US20020012968A1
GENERAL INFORMATION:
APPLICANT: Bristol-Myers Squibb Company
TITLE OF INVENTION: No. US20020012968A1 Drosophila Tumor Necrosis Factor Class Mole
FILE OR INVENTION: Variants Thereof
CURRENT APPLICATION NUMBER: US/09/813,329
CURRENT FILING DATE: 2001-03-20
PRIOR APPLICATION NUMBER: 60/190, 816
PRIOR FILING DATE: 2000-03-21
NUMBER OF SEQ ID NOS: 65
SOFTWARE: Patentin version 3.0
SEQ ID NO 7
LENGTH: 317
TYPE: PRT
ORGANISM: Drosophila melanogaster
US-09-813-329-7
```

Query Match	100.0%	Score 1685	DB 3	Length 317
Best Local Similarity	100.0%	Pred. No. 4,9e-149		
Matches	317	Conservative	0	Mismatches 0; Indels 0; Gaps 0;
QY	1	MRRASRDYTKYLKRGSEEMCGGPGAPHEGRLHAPPPAPHPQPPASRSMFVALIGLIGOV	60	Sequence 7, Appl
DB	1	MRRASRDYTKYLKRGSEEMCGGPGAPHEGRLHAPPPAPHPQPPASRSMFVALIGLIGOV	60	Sequence 7, Appl
QY	61	VCSVALFFYFRAQMDNRISEDDTHCIYRILRLHENAADQDTTLESQDTKLIPDSGRRIK	120	Sequence 13, Appl
DB	61	VCSVALFFYFRAQMDNRISEDDTHCIYRILRLHENAADQDTTLESQDTKLIPDSGRRIK	120	Sequence 13, Appl
QY	121	QAFQAVQKELQHVIGSQHRAEKAMVDSWLDLAKRSKLEAPFALHTLNATDIPSGSH	180	Sequence 13, Appl
DB	121	QAFQAVQKELQHVIGSQHRAEKAMVDSWLDLAKRSKLEAPFALHTLNATDIPSGSH	180	Sequence 13, Appl
QY	181	KVLSWYHNRGAKISNMTFSNGKLIVNODGYVYIYANICFPHHTSGDLATEYQLWY	240	Sequence 22, Appl
DB	181	KVLSWYHNRGAKISNMTFSNGKLIVNODGYVYIYANICFPHHTSGDLATEYQLWY	240	Sequence 22, Appl
QY	241	YVTKTSIKIPSSHTLKKGSGTKYWSGNSEFFHYISINVGCFKLRSGBEISIEVSNPLSD	300	Sequence 11, Appl
DB	241	YVTKTSIKIPSSHTLKKGSGTKYWSGNSEFFHYISINVGCFKLRSGBEISIEVSNPLSD	300	Sequence 11, Appl
QY	301	PDQATYFGAFKVRDID 317		Sequence 6, Appl
DB	301	PDQATYFGAFKVRDID 317		Sequence 6, Appl

RESULT 2
US-09-871-856-13
Sequence 13, Application US/09871856
Patent No. US20020081720A1
GENERAL INFORMATION:
APPLICANT: Anderson, Dirk M.
Galibbert, Laurent
Maraskovsky, Eugene
TITLE OF INVENTION: Receptor Activator of NF-kappa B
NUMBER OF SEQUENCES: 19
CORRESPONDENCE ADDRESS:
ADDRESSEE: Immunex Corporation, Law Department
STREET: 51 University Street
CITY: Seattle
STATE: WA
COUNTRY: USA
ZIP: 98101
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: Apple Power Macintosh
OPERATING SYSTEM: Apple Operating System 7.5.5
SOFTWARE: Microsoft Word for Power Macintosh 6.0.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/871,856
FILING DATE: 31-May-2001
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/996,139
FILING DATE: <Unknown>
APPLICATION NUMBER: USSN 08/813,509
FILING DATE: 07 MARCH 1997
APPLICATION NUMBER: USSN 08/772,330
FILING DATE: 23 DECEMBER 1996
ATTORNEY/AGENT INFORMATION:
NAME: Perkins, Patricia Anne
REGISTRATION NUMBER: 34,693
REFERENCE/DOCKET NUMBER: 2851-A
TELECOMMUNICATION INFORMATION:
TELEPHONE: (206)587-0430
TELEFAX: (206)233-0644
INFORMATION FOR SEQ ID NO: 13:
SEQUENCE CHARACTERISTICS:
LENGTH: 317 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: protein
SEQUENCE DESCRIPTION: SEQ ID NO: 13:
US-09-871-856-13
Query Match 100.0%; Score 1685; DB 3; Length 317;
Best Local Similarity 100.0%; Pred. No. 4.9e-149;
Matches 317; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRASRDYTKYLGRSEEMGGPGAPHEGPLHAPPPAPHPHOPPAASRMFVALGLGLQGV 60
DB 1 MRASRDYTKYLGRSEEMGGPGAPHEGPLHAPPPAPHPHOPPAASRMFVALGLGLQGV 60
QY 61 VCSVALFFYFRAQMDPNRISBDGTHCIYRILRLHENDFODTTLESQDTKLIIPSCRIK 120
DB 61 VCSVALFFYFRAQMDPNRISBDGTHCIYRILRLHENDFODTTLESQDTKLIIPSCRIK 120
QY 121 QAFQAVQKELQHVGSQHIRAEKAMVDGSLDLAKRSKLEAOPFAHLTINATDIPSGSH 180
DB 121 QAFQAVQKELQHVGSQHIRAEKAMVDGSLDLAKRSKLEAOPFAHLTINATDIPSGSH 180
QY 181 KVSLSWYHGRGMAKISNMTFSGNKLIVNODGFYLLYANICFRHETSGDLATEYLQLMV 240
DB 181 KVSLSWYHGRGMAKISNMTFSGNKLIVNODGFYLLYANICFRHETSGDLATEYLQLMV 240
QY 241 VYTKTSIKIPSSHTLMKGGSTKYWGSNSFHFYSINVGFFKLRSGBEISIEVSNPSILD 300
DB 241 VYTKTSIKIPSSHTLMKGGSTKYWGSNSFHFYSINVGFFKLRSGBEISIEVSNPSILD 300

QY 301 PDODATYFGAFKVRDID 317
DB 301 PDODATYFGAFKVRDID 317
RESULT 3
US-09-957-944-6
Sequence 6, Application US/09957944
Publication No. US20020086312A1
GENERAL INFORMATION:
APPLICANT: Dougall, William C.
TITLE OF INVENTION: SCREENING ASSAYS FOR AGONISTS AND ANTAGONISTS OF RECEPTOR ACTIVAT
FILE REFERENCE: 3109-A
CURRENT APPLICATION NUMBER: US/09/957,944
PRIOR FILING DATE: 2001-09-20
NUMBER OF SEQ ID NOS: 13
SOFTWARE: PatentIn version 3.1
SEQ ID NO 6
LENGTH: 317
TYPE: PRT
ORGANISM: Homo sapiens
US-09-957-944-6
Query Match 100.0%; Score 1685; DB 3; Length 317;
Best Local Similarity 100.0%; Pred. No. 4.9e-149;
Matches 317; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRASRDYTKYLGRSEEMGGPGAPHEGPLHAPPPAPHPHOPPAASRMFVALGLGLQGV 60
DB 1 MRASRDYTKYLGRSEEMGGPGAPHEGPLHAPPPAPHPHOPPAASRMFVALGLGLQGV 60
QY 61 VCSVALFFYFRAQMDPNRISBDGTHCIYRILRLHENDFODTTLESQDTKLIIPSCRIK 120
DB 61 VCSVALFFYFRAQMDPNRISBDGTHCIYRILRLHENDFODTTLESQDTKLIIPSCRIK 120
QY 121 QAFQAVQKELQHVGSQHIRAEKAMVDGSLDLAKRSKLEAOPFAHLTINATDIPSGSH 180
DB 121 QAFQAVQKELQHVGSQHIRAEKAMVDGSLDLAKRSKLEAOPFAHLTINATDIPSGSH 180
QY 181 KVSLSWYHGRGMAKISNMTFSGNKLIVNODGFYLLYANICFRHETSGDLATEYLQLMV 240
DB 181 KVSLSWYHGRGMAKISNMTFSGNKLIVNODGFYLLYANICFRHETSGDLATEYLQLMV 240
QY 241 VYTKTSIKIPSSHTLMKGGSTKYWGSNSFHFYSINVGFFKLRSGBEISIEVSNPSILD 300
DB 241 VYTKTSIKIPSSHTLMKGGSTKYWGSNSFHFYSINVGFFKLRSGBEISIEVSNPSILD 300
QY 301 PDODATYFGAFKVRDID 317
DB 301 PDODATYFGAFKVRDID 317
RESULT 4
US-09-865-363-13
Sequence 13, Application US/09865363
Publication No. US20020086826A1
GENERAL INFORMATION:
APPLICANT: Anderson, Dirk M.
Galibbert, Laurent
Maraskovsky, Eugene
TITLE OF INVENTION: Ligand for Receptor Activator of NF-kappa B
NUMBER OF SEQUENCES: 19
CORRESPONDENCE ADDRESS:
ADDRESSEE: Immunex Corporation, Law Department
STREET: 51 University Street
CITY: Seattle
STATE: WA
COUNTRY: USA
ZIP: 98101
COMPUTER READABLE FORM:

GenCore version 5.1.6
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: December 21, 2005, 13:03:52 / Search time 9.87377 Seconds
(without alignments)
226.978 Million cell updates/sec

Title: US-09-211-297-39

Perfect score: 1685

Sequence: 1 MKRASRDYTKYRGSEEMG.....LLDPDQATYFGAFKVRDID 317

Scoring table: BLOSUM62

Gapop 10.0, Gapext 0.5

Searched: 53982 seqs, 7132107 residues

Total number of hits satisfying chosen parameters: 53982

Minimum DB seq length: 0

Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%

Maximum Match 100%
Listing first 45 summaries

Database: Published Applications_AA_New.*
1: /cgn2_6/prodata/2/pubppaa/US09_NEW_PUB.pep.*
2: /cgn2_6/prodata/2/pubppaa/US06_NEW_PUB.pep.*
3: /cgn2_6/prodata/2/pubppaa/US07_NEW_PUB.pep.*
4: /cgn2_6/prodata/2/pubppaa/PCT_NEW_PUB.pep.*
5: /cgn2_6/prodata/2/pubppaa/US05_NEW_PUB.pep.*
6: /cgn2_6/prodata/2/pubppaa/US10_NEW_PUB.pep.*
7: /cgn2_6/prodata/2/pubppaa/US11_NEW_PUB.pep.*
8: /cgn2_6/prodata/2/pubppaa/US60_NEW_PUB.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	538	31.9	109	7 US-11-065-669-8	Sequence 8, Appl
2	251.5	14.9	281	6 US-10-821-234-1288	Sequence 1288, Ap
3	247.5	14.7	281	7 US-11-077-372-2	Sequence 2, Appl
4	235.5	14.0	266	7 US-11-082-544-10	Sequence 10, Appl
5	232.5	13.8	391	7 US-11-105-172-4	Sequence 4, Appl
6	147.5	8.8	359	7 US-11-105-172-2	Sequence 2, Appl
7	134	8.0	240	6 US-10-987-663-6	Sequence 6, Appl
8	133	7.9	157	7 US-11-010-954-1	Sequence 1, Appl
9	133	7.9	157	7 US-11-053-750-1	Sequence 1, Appl
10	133	7.9	157	7 US-11-053-749-1	Sequence 12, Appl
11	133	7.9	157	7 US-11-108-001-12	Sequence 4, Appl
12	133	7.9	158	7 US-11-082-544-4	Sequence 4, Appl
13	133	7.9	164	7 US-11-108-001-2	Sequence 2, Appl
14	133	7.9	180	7 US-11-082-544-8	Sequence 8, Appl
15	99.5	5.9	438	6 US-10-821-234-1051	Sequence 1051, Ap
16	97.5	5.8	1464	7 US-11-166-284-28	Sequence 28, Appl
17	97	5.8	1464	7 US-11-000-463-243	Sequence 243, Appl
18	97	5.8	1467	6 US-10-821-234-1096	Sequence 1096, Ap
19	96.5	5.7	371	6 US-10-995-561-572	Sequence 572, Appl
20	92.5	5.5	177	6 US-10-999-866-61	Sequence 61, Appl
21	92.5	5.5	205	6 US-10-995-561-1028	Sequence 1028, Ap
22	92.5	5.5	205	6 US-10-995-561-1029	Sequence 1029, Ap
23	90	5.3	432	7 US-11-140-417-4	Sequence 4, Appl
24	89	5.3	438	7 US-11-140-417-2	Sequence 2, Appl
25	88.5	5.3	1163	7 US-11-044-899-2	Sequence 2, Appl

26	88.5	5.3	1163	7 US-11-044-899-10	Sequence 30, Appl
27	87.5	5.2	100	6 US-10-606-302-1	Sequence 1, Appl
28	86.5	5.1	104	6 US-11-065-669-5	Sequence 5, Appl
29	86.5	5.1	1166	6 US-10-821-234-364	Sequence 964, Appl
30	86.5	5.1	1260	7 US-11-186-284-33	Sequence 33, Appl
31	85	5.0	220	7 US-11-054-515-3233	Sequence 3233, Ap
32	81.5	4.8	239	7 US-11-054-515-3232	Sequence 3232, Ap
33	81	4.8	484	6 US-10-821-234-933	Sequence 933, Appl
34	79.5	4.7	903	7 US-11-057-058-66	Sequence 65, Appl
35	79.5	4.7	1001	6 US-10-467-962B-81	Sequence 81, Appl
36	79	4.7	453	6 US-10-131-826A-270	Sequence 270, Appl
37	79	4.7	457	6 US-10-821-234-1185	Sequence 1185, Ap
38	78.5	4.7	400	7 US-11-186-284-155	Sequence 155, Appl
39	77.5	4.6	290	7 US-11-054-515-3231	Sequence 3231, Ap
40	77	4.6	200	6 US-10-524-198-2	Sequence 2, Appl
41	77	4.6	285	6 US-10-131-826A-24	Sequence 24, Appl
42	77	4.6	285	6 US-10-742-634-2	Sequence 2, Appl
43	77	4.6	285	7 US-11-065-669-1	Sequence 1, Appl
44	77	4.6	285	7 US-11-054-515-3228	Sequence 3228, Ap
45	76.5	4.5	219	7 US-11-054-515-3237	Sequence 3237, Ap

ALIGNMENTS

RESULT 1
US-11-065-669-8
; Sequence 8, Application US/11065669
; Publication No. US2005024441A1
GENERAL INFORMATION:
; APPLICANT: Mackay, Fabienne
; APPLICANT: Kallied, Susan
; TITLE OF INVENTION: BAPF, INHIBITORS THEREOF AND THEIR USE IN THE
; FILE REFERENCE: 08201.0024-04000
; CURRENT FILING DATE: 2005-02-24
; PRIOR FILING DATE: 2005-02-24
; PRIOR APPLICATION NUMBER: 10/045,574
; PRIOR FILING DATE: 2001-11-07
; PRIOR APPLICATION NUMBER: 09/911,777
; PRIOR FILING DATE: 2001-07-24
; PRIOR APPLICATION NUMBER: 60/143,228
; PRIOR FILING DATE: 2001-07-09
; PRIOR APPLICATION NUMBER: PCT/US00/01788
; PRIOR FILING DATE: 2000-01-25
; PRIOR APPLICATION NUMBER: 60/117,169
; PRIOR FILING DATE: 1999-01-25
; NUMBER OF SEQ ID NOS: 26
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 8
; LENGTH: 109
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-065-669-8
Query Match 31.9%; Score 538; DB 7; Length 109;
Best Local Similarity 75.5%; Pred. No. 5.9e-44;
Matches 108; Mismatches 0; Indels 1; Gaps 2;
YANI 43
221 CFFHHTSGDLATEYQLMYYVTKTSIKIPSSHTLTKGSGTKYSGNSEPHFYINVGCF 280
Db EADPFALHTNADIDPSGSHKYSLSWYHDGRGAKTSNNMTFSGNKLIYVQDFYYVYANI 220
YANI 43
44 CFFHHTSGDLATEYQLMYYVTKTSIKIPSSHTLTKGSGTKYSGNSEPHFYINVGCF 86
Db EADPFALHTNADIDPSGSHKYSLSWYHDGRGAKTSNNMTFSGNKLIYVQDFYYVYANI 220
YANI 43
281 FKLRSGEISIEVSNPSLDPDQ 303
Db FKLRSGEISIEVSNPSLDPDQ 109
RESULT 2

GenCore version 5.1.6
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM protein - protein search, using SW model

Run on: December 21, 2005, 12:34:10 ; Search time 169.402 Seconds
(without alignments)
645.834 Million cell updates/sec

Title: US-09-211-297-39_COPY_69_317

Sequence: 1 YFRQMIDPNRISBDCTHCITY.....LIDPDQATVYGAFFKVDID 249

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 2443163 seqs, 439378781 residues

Total number of hits satisfying chosen parameters: 2443163

Minimum DB seq length: 0
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database :
1: geneseqp1980s:*
2: geneseqp1990s:*
3: geneseqp2000s:*
4: geneseqp2001s:*
5: geneseqp2002s:*
6: geneseqp2003as:*
7: geneseqp2003bs:*
8: geneseqp2004s:*
9: geneseqp2005s:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match Length	ID	Description
1	1319	100.0	249 5	ABG94282 Human RAN
2	1319	100.0	249 5	ABG80594 Human rec
3	1319	100.0	249 7	ADJ82115 Protein f
4	1319	100.0	250 6	ADA50079 Human wil
5	1319	100.0	270 7	ADJ82113 Protein f
6	1319	100.0	317 2	AAW83018 Osteoclas
7	1319	100.0	317 2	AAW83195 Human ost
8	1319	100.0	317 2	AAW69957 NF-KB rec
9	1319	100.0	317 2	AAW68293 NF-KB rec
10	1319	100.0	317 2	AAW68293 NF-KB rec
11	1319	100.0	317 3	AAW84417 Amino aci
12	1319	100.0	317 4	AAE04426 Human rec
13	1319	100.0	317 4	AAE01993 Human ful
14	1319	100.0	317 5	ABB08134 Human RAN
15	1319	100.0	317 5	AAE26103 Human RAN
16	1319	100.0	317 5	ABG31631 Human RAN
17	1319	100.0	317 5	AAU78285 Human TRA
18	1319	100.0	317 5	AAO19096 C neoform
19	1319	100.0	317 5	ADR29336 Human RAN
20	1319	100.0	317 6	ABP55108 Human ost
21	1319	100.0	317 6	AAE33364 Human rec
22	1319	100.0	317 7	ABR43314 Human RAN
23	1319	100.0	317 7	ADB16988 Human rec
24	1319	100.0	317 7	ADC35204 Human TNF

25	1319	100.0	317 7	ADC73002 Human RAN
26	1319	100.0	317 7	ADC78268 Human RAN
27	1319	100.0	317 7	ABW02277 Human RAN
28	1319	100.0	317 7	ADG46723 Human RAN
29	1319	100.0	317 7	ADJ82112 Protein f
30	1319	100.0	317 8	ADM96241 Human rec
31	1319	100.0	317 8	ADT08155 Human RAN
32	1319	100.0	317 8	ADU06570 Novel pro
33	1319	100.0	317 9	ADW09029 Human rec
34	1319	100.0	317 9	ADY16469 PRO polyp
35	1319	100.0	317 9	ADY74714 Human rec
36	1319	100.0	317 9	ADZ12661 Human can
37	1319	100.0	317 9	ADY97756 Human RAN
38	1316	99.8	250 6	ADA50095 Human RAN
39	1316	99.8	250 6	ADA50094 Human RAN
40	1316	99.8	250 6	ADA50102 Human RAN
41	1316	99.8	250 6	ADA50098 Human RAN
42	1315	99.7	250 6	ADA50101 Human RAN
43	1315	99.7	250 6	ADA50089 Human RAN
44	1315	99.7	250 6	ADA50086 Human RAN
45	1315	99.7	250 6	ADA50099 Human RAN

ALIGNMENTS

RESULT 1
ABG94282
ID ABG94282 standard; protein; 249 AA.

AC ABG94282;
XX
DT 10-DEC-2002 (first entry)
XX
DE Human RANKL extracellular domain.
XX
KW Human, mouse; rat; antimicrobial; antiallergic; immunomodulatory;
KW cytosolic; antiviral; antidiabetic; hypoglycaemic; antigen array;
KW vaccine; infectious disease.
XX
OS Homo sapiens.
XX
PN WO200256905-A2.
XX
PD 25-JUL-2002.
XX
PF 21-JAN-2002; 2002WO-1B000166.
XX
PR 19-JAN-2001; 2001US-0262379P.
PR 04-MAY-2001; 2001US-0288549P.
PR 05-OCT-2001; 2001US-0326998P.
PR 07-NOV-2001; 2001US-0331045P.
XX
PA (CYTO-) CYTOS BIOTECHNOLOGY AG.
XX
PI Renner WA, Bachmann M, Tissot A, Maurer P, Lechner F, Sebbel P;
PI Ploeseck C;
XX
DR WPI; 2002-627351/67.
XX
PT Molecular antigen array used in the production of vaccines for infectious
XX diseases.
XX
PS Disclosure; Page 420; 441pp; English.
XX
CC This invention relates to a novel ordered and repetitive antigen array
CC used in the production of vaccines for infectious diseases. The invention
CC also discloses a composition comprising a non-natural molecular scaffold
CC comprising a core particle selected from a core particle of a non-natural
CC origin and a core particle of natural origin and an organiser comprising
CC at least one first attachment site, where the organiser is connected to
CC the core particle by at least one covalent bond. Also disclosed is an
CC antigen or antigenic determinant with at least one second attachment

CC site, where the antigen or antigenic determinant is amyloid beta peptide
 CC (Abeta1-42) or its fragment and where the second attachment site is
 CC selected from an attachment site not naturally occurring with the antigen
 CC or antigenic determinant and an attachment site naturally occurring with
 CC the antigen or antigenic determinant, where the second attachment site is
 CC capable of association through at least one non-peptide bond to the first
 CC attachment site and where the antigen or antigenic determinant and the
 CC scaffold interact through the association to form an ordered and
 CC repetitive antigen array. The invention also comprises a coat protein
 CC capable of forming a capsid which comprises mutant Qbeta coat proteins
 CC having an amino acid sequence selected from five amino acid sequences
 CC fully defined in the specification. The compounds of the invention may
 CC have antimicrobial, antiallergic, immunomodulatory, cytostatic,
 CC antiviral, antidiabetic, or hypoglycaemic activities and may be used in
 CC immunisation and as a vaccine. The present sequence represents a protein
 CC sequence used to create the compositions of the invention

CC Sequence 249 AA;

Query Match 100.0%; Score 1319; DB 5; Length 249;
 Best Local Similarity 100.0%; Pred. No. 9,4e-129;
 Matches 249; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 YFRAQMDPNRISSEGTGHCYRIILRLHFNADFDOTTLSESQDTKLIPDSGRRIKQAFQAVQ 60
 DB 1 YFRAQMDPNRISSEGTGHCYRIILRLHFNADFDOTTLSESQDTKLIPDSGRRIKQAFQAVQ 60
 QY 61 KELQHIIVGSOHIRAEKAMVDGSMWDLAKRSKLEAPFAHLTNTADIPSGSHKXSLSSWY 120
 DB 61 KELQHIIVGSOHIRAEKAMVDGSMWDLAKRSKLEAPFAHLTNTADIPSGSHKXSLSSWY 120
 QY 121 HDRGMAKISNMTFSGNKLIVNQDGFYYLYANICFRHHETSGLATEYLQIMVYVTKTSIK 180
 DB 121 HDRGMAKISNMTFSGNKLIVNQDGFYYLYANICFRHHETSGLATEYLQIMVYVTKTSIK 180
 QY 181 IPSSHITLMKGSSTKYWNGSEFHFYSINVGFFPKRSGEISIEVSNPSLDDPDADATYF 240
 DB 181 IPSSHITLMKGSSTKYWNGSEFHFYSINVGFFPKRSGEISIEVSNPSLDDPDADATYF 240
 QY 241 GAFKYRDIID 249
 DB 241 GAFKYRDIID 249

RESULT 2
 ABG80594
 ID ABG80594 standard; protein; 249 AA.

XX AC ABG80594;
 XX DT 29-NOV-2002 (first entry)
 XX DE Human receptor activator of NFkB ligand, RANKL, extracellular part.
 XX DB
 XX KW Molecular antigen array; vaccine; antigen; antimicrobial;
 KW molecular scaffold; amyloid beta; Abeta 1-42; influenza;
 KW graft versus host disease; IGE-mediated allergic reaction; anaphylaxis;
 KW adult respiratory distress syndrome; ARDS; Crohn's disease;
 KW allergic asthma; acute lymphoblastic leukaemia; non-Hodgkin's lymphoma;
 KW Grave's disease; systemic lupus erythematosus; osteoporosis;
 KW inflammatory immune disease; myasthenia gravis; multiple sclerosis;
 KW immunoproliferative disease lymphadenopathy; Alzheimer's disease;
 KW angioimmunoproliferative lymphadenopathy; immunoblastic lymphadenopathy;
 KW rheumatoid arthritis; diabetes; infectious disease; factor Xa;
 KW enterokinase; cysteine-containing linker.

XX OS Homo sapiens.
 XX PN WO200256907-A2.
 XX PD 25-JUL-2002.
 XX PF 21-JAN-2002; 2002WO-1B000168.

XX 19-JAN-2001; 2001US-0262379P.
 PR 04-MAY-2001; 2001US-0298549P.
 PR 05-OCT-2001; 2001US-0326998P.
 PR 07-NOV-2001; 2001US-0331045P.
 PA (CYTO-) CYTOS BIOTECHNOLOGY AG.
 PA (NOVS) NOVARTIS PHARMA AG.
 PA (MAUR/) MAURER P.
 PA (LECH/) LECHNER F.
 PA (ORTM/) ORTMANN R.
 PA (LUEB/) LUEBEND R.
 PA (STAU/) STAUFENBIEL M.
 PA (PREY/) PREY P.
 PI Maurer P, Lechner F, Ortmann R, Luegend R, Staufenbiel M, Frey P;
 PI Renner WA, Bachmann M, Tissot A, Seibel P, Plossak C;
 DR WPI, 2002-636514/68.
 XX
 PT Molecular antigen array used in the production of vaccines for infectious
 PT diseases.

PS Disclosure; Page 397; 418pp; English.

CC The invention relates to a composition comprising: (a) a non-natural
 CC molecular scaffold comprising: (i) a core particle selected from: (1) a
 CC core particle of a non-natural origin; and (2) a core particle of natural
 CC origin; and (ii) an organiser comprising at least one first attachment
 CC site, where the organiser is connected to the core particle by at least
 CC one covalent bond; (b) an antigen or antigenic determinant with at least
 CC one second attachment site, where the antigen or antigenic determinant is
 CC amyloid beta peptide (Abeta 1-42) or its fragment, and where the second
 CC attachment site is selected from: (i) an attachment site not naturally
 CC occurring with the antigen or antigenic determinant; and (ii) an
 CC attachment site naturally occurring with the antigen or antigenic
 CC determinant, where the second attachment site is capable of association
 CC through at least one non-peptide bond to the first attachment site; and
 CC where the antigen or antigenic determinant and the scaffold interact
 CC through the association to form an ordered and repetitive antigen array.
 CC Also included is a process for producing a non-naturally occurring
 CC ordered and repetitive antigen array. The composition is used in
 CC immunisation and as a vaccine for diseases such as influenza, graft
 CC versus host disease, IGE-mediated allergic reactions, anaphylaxis, adult
 CC respiratory distress syndrome (ARDS), Crohn's disease, allergic asthma,
 CC acute lymphoblastic leukaemia, non-Hodgkin's lymphoma, Grave's disease,
 CC systemic lupus erythematosus, inflammatory immune diseases, myasthenia
 CC gravis, immunoproliferative disease lymphadenopathy,
 CC angioimmunoproliferative lymphadenopathy, immunoblastic lymphadenopathy,
 CC rheumatoid arthritis, diabetes, multiple sclerosis, Alzheimer's disease,
 CC osteoporosis and infectious diseases. The present sequence is an antigen
 CC for use in the array of the invention. The antigen is modified to possess
 CC a cleavage site (enterokinase or factor Xa) and a cysteine-containing N-
 CC or C-terminal linker peptide which serves as the attachment point to a
 CC virus like particle or bacterial protein (the scaffold protein)

XX Sequence 249 AA;

Query Match 100.0%; Score 1319; DB 5; Length 249;
 Best Local Similarity 100.0%; Pred. No. 9,4e-129;
 Matches 249; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 YFRAQMDPNRISSEGTGHCYRIILRLHFNADFDOTTLSESQDTKLIPDSGRRIKQAFQAVQ 60
 DB 1 YFRAQMDPNRISSEGTGHCYRIILRLHFNADFDOTTLSESQDTKLIPDSGRRIKQAFQAVQ 60
 QY 61 KELQHIIVGSOHIRAEKAMVDGSMWDLAKRSKLEAPFAHLTNTADIPSGSHKXSLSSWY 120
 DB 61 KELQHIIVGSOHIRAEKAMVDGSMWDLAKRSKLEAPFAHLTNTADIPSGSHKXSLSSWY 120
 QY 121 HDRGMAKISNMTFSGNKLIVNQDGFYYLYANICFRHHETSGLATEYLQIMVYVTKTSIK 180
 DB 121 HDRGMAKISNMTFSGNKLIVNQDGFYYLYANICFRHHETSGLATEYLQIMVYVTKTSIK 180


```

Query Match          11.9%; Score 157; DB 2; Length 279;
Best Local Similarity 25.9%; Pred. No. 3e-06;
Matches 50; Conservative 38; Mismatches 81; Indels 24; Gaps 8;

OY 59 VKELQHI--VSGQHRA---EKAVDGSWLDLAKRSKLEAPFAHLTINATDIPSGSHK 113
   :|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|
Db 105 LQKELAELEREFNQSLKVSFEKQIANPS---TPSEKKEPRSAHLTGN-----PDS 153

OY 114 VLSL-SWYHNRGMAKISNMTFSGNGLVYNQDGFYLLYANICFRHETSGDLATEYLQLMV 172
   :|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|
Db 154 RSIPEWEDYGTALISGVKKYKGGVYNETGLYFVYSKVYFRGQSCN---NQLPNHKV 209

OY 173 YTTKTSIKIPSSHTLMKGGSTKYMSGNSEFHFTYSINVGGFPLKRSGEETIEVSNPSLLD 232
   :|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|
Db 210 YKRNK--KYPEDLVLMEEKRLNYCT--TGOYMAHSSYLGAVFNLTSADHLVYNISQLSLIN 266

OY 233 PDQDATYFGAFKV 245
   :|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|
Db 267 PEESKTFPGLYKL 279

```

RESULT 3

CD40 ligand - human

N.Alternate names: glycoprotein 39; hCD40-L protein; T-cell antigen gp39; TRAP protein

C.Species: Homo sapiens (man)

C.Date: 02-Jul-1996 #sequence revision 02-Jul-1996 #text_change 09-Jul-2004

C.Accession: S28017; JH0793; S26694; S28852; I53476; S25684; S30593

R.Holtenaungh, D.; Grosmaire, L.S.; Kullaa, C.D.; Chalupny, N.J.; Braesch-Andersen, S.;

EMBO J. 11, 4313-4321, 1992

A.Title: The human T cell antigen gp39, a member of the TNF gene family, is a ligand for

A.Reference number: S28017; MUID:93049181; PMID:1385114

A.Accession: S28017

A.Molecule type: mRNA

A.Residues: 1-261 <HOL>

A.Cross-references: UNIPROT:P29965; UNIPARC:UPI00000315E7; EMBL:Z15017; NID:G38483; PIDN

R.Spi1998, M.K.; Armitage, R.J.; Strockbine, L.; Clifford, K.N.; Macduff, B.M.; Sato, T.

J. Exp. Med. 176, 1543-1550, 1992

A.Title: Recombinant human CD40 ligand stimulates B cell proliferation and immunoglobulin

A.Reference number: JH0793; MUID:93094757; PMID:1281209

A.Accession: JH0793

A.Molecule type: mRNA

A.Residues: 1-261 <SPR>

A.Cross-references: UNIPARC:UPI00000315E7; GB:X67878; NID:G38411; PIDN:CAA48077.1; PID:G

R.Graf, D.; Korthauer, U.; Wages, H.W.; Senger, G.; Kroccek, R.A.

Eur. J. Immunol. 22, 3191-3194, 1992

A.Title: Cloning of TRAP, a ligand for CD40 on human T cells.

A.Reference number: S26694; MUID:93076854; PMID:1280226

A.Accession: S26694

A.Status: preliminary

A.Molecule type: mRNA

A.Residues: 1-261 <GRA>

A.Cross-references: UNIPARC:UPI00000315E7; EMBL:X68550; NID:G37269; PIDN:CAA48554.1; PID

R.Gauchat, J.F.; Aubry, J.P.; Mazzei, G.; Life, P.; Tomette, T.; Elsen, G.; Bonnefoy, J.

FEBS Lett. 315, 259-266, 1993

A.Title: Human CD40-ligand: molecular cloning, cellular distribution and regulation of e

A.Reference number: S28852; MUID:93138085; PMID:7678552

A.Accession: S28852

A.Molecule type: mRNA

A.Residues: 1-261 <GAU>

A.Cross-references: UNIPARC:UPI00000315E7; EMBL:L07414; NID:G180123; PIDN:AAA35662.1; PI

A.Note: the sequence from Fig. 3 is inconsistent with that from Fig. 2 in having 6-Gln

C.Genetics: GDB:CD40LG; HIGM1; IMD3

A.Cross-references: GDB:120632; OMIM:308230

A.Map position: Xq26-Xq26

C.Keywords: glycoprotein; transmembrane protein

F.13-44/Domain: transmembrane #status predicted <TM>

F.45-261/Domain: extracellular #status predicted <EX>

F.6,240/Binding site: carbohydrate (Asn) (covalent) #status predicted

```

Query Match          11.4%; Score 150; DB 2; Length 261;
Best Local Similarity 25.4%; Pred. No. 1.1e-05;
Matches 58; Conservative 43; Mismatches 95; Indels 32; Gaps 12;

OY 25 LHENADFDQT--TLSEQDTKILPDSCTRIKQAFGANVQKELQHVSGQHIAEKAMVDGS 82
   :|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|
Db 59 LHEDFVFMKTIQRCSNTERSLNLNCEIKSQFPGFV-KDIM-----LNKEETKENS 110

OY 83 WLDLAKRSKLEAPFAHLTINATDIPSGSHKVSLSWYHNRGMAKISN--MTFSGNK-LI 139
   :|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|
Db 111 F-EMQGDQ-NPQJAAAHYISAS-----SKTTSYLQW-AEKGYYTMSNNLVLTLENGKOLT 162

OY 140 VNQDGFYLLYANICFRHETSGDLATEYLQLMVYVTKTSIKIPS--SHTLMKGGSTKXYS 197
   :|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|
Db 163 VKRGGLYYIVAYQVFCNSREASSQAP-----PIASLCCKSPGRFERILLRAANTH--S 213

OY 198 GNSEFHFTYSINVGGFPLKRSGEETIEVSNPSLLDPPQDATYFGAFKV 245
   :|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|
Db 214 SAKPCGQGSIHILGCVFELQPGASVFVNVTPDSQVSHGTGFTSFGILKL 261

```

RESULT 4

Fas ligand - human

C.Species: Homo sapiens (man)

C.Date: 29-May-1998 #sequence revision 29-May-1998 #text_change 09-Jul-2004

C.Accession: J38707; J02340; S57565; I38554

R.Takahashi, T.; Tanaka, M.; Tanazawa, J.; Abe, T.; Suda, T.; Nagata, S.

Int. Immunol. 6, 1567-1574, 1994

A.Title: Human Fas ligand: gene structure, chromosomal location and species specificity.

A.Reference number: J38707; MUID:95127560; PMID:7826947

A.Accession: J38707

A.Status: preliminary; translated from GB/EMBL/DBJ

A.Molecule type: mRNA

A.Residues: 1-281 <RBS>

A.Cross-references: UNIPROT:P48023; UNIPARC:UPI000000D91A; EMBL:U1821; NID:G595430; PID:

R.Mita, E.; Hayashi, N.; Ito, S.; Takehara, T.; Hijioke, T.; Kasahara, A.; Fusanoto, H.;

Biochem. Biophys. Res. Commun. 204, 468-474, 1994

A.Title: Role of Fas ligand in apoptosis induced by hepatitis C virus infection.

A.Reference number: J02340; MUID:95071350; PMID:7980502

A.Accession: J02340

A.Molecule type: DNA

A.Residues: 1-281 <MIT>

A.Cross-references: UNIPARC:UPI000000D91A; GB:D38122; DBJ:D29820; NID:G601892; PIDN:BAV

R.Schattlein, C.E.

submitted to the EMBL Data Library, June 1995

A.Reference number: S57565

A.Accession: S57565

A.Status: preliminary

A.Molecule type: mRNA

A.Residues: 1-281 <SCH>

A.Cross-references: UNIPARC:UPI000000D91A; EMBL:X89102; NID:G887455; PID:G887456

R.Alderson, M.R.; Tough, T.N.; Daviss-Smith, T.; Braddy, S.; Falk, B.; Schooley, K.A.; Go

J. Exp. Med. 181, 71-77, 1995

A.Title: Fas ligand mediates activation-induced cell death in human T lymphocytes.

A.Reference number: I38554; MUID:95105731; PMID:7528780

A.Accession: I38554

A.Status: preliminary; translated from GB/EMBL/DBJ

A.Molecule type: mRNA

A.Residues: 1-281 <RE2>

A.Cross-references: UNIPARC:UPI000000D91A; EMBL:U08137; NID:G624627; PIDN:AAC50071.1; PI

C.Genetics: FasL

A.Introns: 151/1; 116/3

C.Keywords: glycoprotein; transmembrane protein

F.80-102/Domain: transmembrane #status predicted <TM>

F.76,184,250,260/Binding site: carbohydrate (Asn) (covalent) #status predicted

```

Query Match          11.3%; Score 149.5; DB 2; Length 281;
Best Local Similarity 23.9%; Pred. No. 1.4e-05;
Matches 47; Conservative 33; Mismatches 74; Indels 43; Gaps 6;

OY 71 HIRAEKAMVDGSWLDLAKRSKLEAQ-----PFAHLT--INATDIPSGSHKV 114

```

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: December 21, 2005, 12:35:06 / Search time 171.443 Seconds
(without alignment)
1024.696 Million cell updates/sec

Title: US-09-211-297-39_COPY_69_317
Perfect score: 1319
Sequence: 1 YFRAQMDPNRISEDETHICV.....LDDPDQATYFGAFKVRDID 249

Scoring table: BLOSUM62
Gapop 10.0, Gapext 0.5

Searched: 2166443 seqs, 705528306 residues
Total number of hits satisfying chosen parameters: 2166443

Minimum DB seq length: 0
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database: 1: uniprot_05.80.*
2: uniprot_sprot.*
3: uniprot_trembl.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	1319	100.0	317	1	TNFI1_HUMAN
2	1319	100.0	317	2	Q5T9Y4_HUMAN
3	1292	98.0	244	2	Q54A98_HUMAN
4	1127	85.4	316	1	TNFI1_MOUSE
5	1118	84.8	318	1	TNFI1_RAT
6	482	36.5	290	2	Q5H2R8_XENLA
7	470	35.6	117	2	Q5XLH0_BRABIT
8	253.5	19.2	317	2	Q7ZYX9_BRABIT
9	252.5	18.1	289	2	Q4VSR6_PIG
10	242	18.3	304	2	Q7T1P2_CHICK
11	241.5	18.3	303	2	Q5XKN3_MOUSE
12	240.5	18.2	214	2	Q9DD55_BRABIT
13	239.5	18.2	292	2	Q5ZKX3_CHICK
14	238.5	18.1	291	1	TNFI1_MOUSE
15	238	18.0	264	2	Q4S9Q4_TETNG
16	237	18.0	299	2	Q6DH99_BRABIT
17	236.5	17.9	281	1	TNFI1_HUMAN
18	236.5	17.9	281	2	Q61BA9_HUMAN
19	219	16.6	300	2	Q5U675_HUMAN
20	216.5	16.4	287	2	Q90W79_CHICK
21	211	16.0	285	2	Q4SKU4_TETNG
22	207.5	15.7	287	2	Q8K3G0_RAT
23	184.5	14.0	252	2	Q8K3Y8_MOUSE
24	181	13.7	95	2	Q6UWL7_HUMAN
25	181	13.7	95	2	Q6UY13_HUMAN
26	179.5	13.6	252	2	Q80Y20_MOUSE
27	177.5	13.5	252	2	Q8K3Y7_RAT
28	172.5	13.1	253	2	Q5CAQ0_CHICK
29	171	13.0	278	2	Q4STY9_CHICK
30	162	12.3	239	2	Q50L61_CHICK
31	160	12.1	207	2	Q58G74_CHICK

32	160	12.1	279	2	Q7TMV9_MOUSE
33	158	12.0	98	2	Q4T6H7_TETNG
34	157.5	11.9	282	1	TNFI6_PIG
35	157	11.9	261	1	TNFI6_BOVIN
36	157	11.9	279	1	TNFI6_MOUSE
37	157	11.9	279	2	Q544E3_MOUSE
38	156.5	11.9	192	2	Q5VJK8_HUMAN
39	156.5	11.9	251	2	Q8NFE9_HUMAN
40	155	11.8	280	2	Q861N5_FELCA
41	150	11.4	261	1	TNFI5_AOTTR
42	150	11.4	261	1	TNFI5_CALJA
43	150	11.4	261	1	TNFI5_HUMAN
44	149.5	11.3	280	1	TNFI6_MACPA
45	149.5	11.3	280	1	TNFI6_MACMU

ALIGNMENTS

RESULT 1
ID TNFI1_HUMAN STANDARD; PRT; 317 AA.
AC TNFI1_HUMAN 014788; 014723; Q96Q17; Q9P2Q3;
DT 16-OCT-2001 (Rel. 40, Created)
DT 16-OCT-2001 (Rel. 40, Last sequence update)
DT 13-SEP-2003 (Rel. 48, Last annotation update)
DE Tumor necrosis factor ligand superfamily member 11 (Receptor activator
DE of nuclear factor kappa B ligand) (RANKL) (TNF-related activation-
DE induced cytokine) (TRANCE) (Osteoprotegerin ligand) (OPGL) (Osteoclast
DE differentiation factor) (ODF) (Contains: Tumor necrosis factor ligand
DE superfamily member 11, membrane form; Tumor necrosis factor ligand
DE superfamily member 11, soluble form).
GN Name=TNFSF11; Synonyms=OPGL, RANKL, TRANCE;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE (ISOFORM 1).
RC TISSUE=Bone marrow, and Peripheral blood;
RX MEDLINE=98032977; PubMed=9367155; DOI=10.1038/36593;
RA Anderson D.M., Maraskovsky E., Billingsley W.L., Dougan M.C.,
RA Tomesko M.E., Roux E.R., Teepe M.C., Dubose R.F., Cosman D.,
RA Gilbert L.;
RT "A homologue of the TNF receptor and its ligand enhance T-cell growth
RT and dendritic-cell function.";
RL Nature 390:175-179(1997).
RN [2]
RP NUCLEOTIDE SEQUENCE (ISOFORM 1).
RC TISSUE=Lymph node;
RX MEDLINE=98227661; PubMed=9568710; DOI=10.1016/S0092-8674(00)81569-X;
RA Lacey D.L., Timms E., Tan H.-L., Kelley M.J., Dunstan C.R.,
RA Burgess T., Elliott R., Colombero A., Elliott G., Scully S., Hsu H.,
RA Sullivan J., Hawkins N., Davy E., Caparrelli C., Eli A., Olan Y.-X.,
RA Kaufman S., Sato T., Shalhoub V., Senaldi G., Guo J., Delaney J.,
RA Boyle W.J.;
RT "Osteoprotegerin ligand is a cytokine that regulates osteoclast
RT differentiation and activation.";
RL Cell 93:165-176(1998).
RN [3]
RP NUCLEOTIDE SEQUENCE (ISOFORMS 1, 2 AND 3).
RC TISSUE=tongue;
RX MEDLINE=2015237; PubMed=10708568; DOI=10.1006/bbrc.2000.2314;
RA Nagai M., Yakumoto S., Sato N.;
RT "Cancer cells responsible for humoral hypercalcemia express mRNA
RT encoding a secreted form of ODF/TRANCE that induces osteoclast
RT formation.";

RL Biochem. Biophys. Res. Commun. 269:532-536(2000).
[5]
RN NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RP TISSUE=Lung;
RC MEDLINE=22389257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RX Struhsberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Kleiner R.D., Collins F.S., Wagner L., Shemen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buecker K.H., Scheffer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh L.,
RA Diachenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Schetz T.E.,
RA Brownstein M.J., Uedini T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA Bosak S.A., McSwain P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Morley K.C., Hale S., Garcia A.M., Gay L.J., Huiyk S.W.,
RA Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahy J., Helton E., Kettelman W., Madan A., Rodriguez S., Sanchez A.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Buterfield V.S.N., Krzywinski M.I., Skalska U., Smalins D.E.,
RA Scherch A., Schein J.E., Jones S.J.M., Marra M.A.,
RT "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
[6]
RN NUCLEOTIDE SEQUENCE OF 73-317.
RP TISSUE=Thymocyte;
RX MEDLINE=97460112; PubMed=9312132; DOI=10.1074/jbc.272.40.25190;
RA Wong B.R., Rho J., Arron J., Robinson E., Orlinick J., Chao M.,
RA Kalchikov S., Cayani E., Bartlett F.S. III, Frankel W.N., Lee S.Y.,
RA Choi Y.;
RT "TRANCE is a novel ligand of the tumor necrosis factor receptor family
RT that activates c-Jun N-terminal kinase in T cells.";
RL J. Biol. Chem. 272:25190-25194(1997).
CC -1- FUNCTION: Cytokine that binds to TNFRSF1B/OPG and to
CC TNFRSF1A/RANK. Osteoclast differentiation and activation factor.
CC Augments the ability of dendritic cells to stimulate naive T-cell
CC proliferation. May be an important regulator of interactions
CC between T cells and dendritic cells and may play a role in the
CC regulation of the T cell-dependent immune response. May also play
CC an important role in enhanced bone-resorption in humoral
CC hypercalcemia of malignancy.
CC -1- SUBUNIT: Homotrimer (By similarity).
CC -1- SUBCELLULAR LOCATION: Type II membrane protein (isoforms 1 and 3);
CC Secreted (isoform 2). A soluble form of isoform 1 arises by
CC proteolytic processing (By similarity).
CC -1- ALTERNATIVE PRODUCTS:
CC Event=Alternative splicing; Named isoforms=3;
CC Name=1;
CC Name=2: Synonyms=SDPF;
CC Name=3: IsoId=014788-1; Sequence=Displayed;
CC Name=1: IsoId=014788-2; Sequence=VSP_006447;
CC Name=3: IsoId=014788-3; Sequence=VSP_006446;
CC -1- TISSUE SPECIFICITY: Highest in the peripheral lymph nodes, weak in
CC spleen, peripheral blood leukocytes, bone marrow, heart, placenta,
CC skeletal muscle, stomach and thyroid.
CC -1- INDUCTION: Up-regulated by T cell receptor stimulation.
CC -1- PTM: The soluble form of isoform 1 derives from the membrane form
CC by proteolytic processing (By similarity). The cleavage may be
CC catalyzed by ADAM17.
CC -1- SIMILARITY: Belongs to the tumor necrosis factor family.
CC -----
CC This Swiss-Prot entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation
CC the European Bioinformatics Institute. There are no restrictions on its
CC use as long as its content is in no way modified and this statement is not
CC removed.
CC -----
CC EMBL, AF019047, AAB86811.1, -, mRNA.
CC EMBL, AF053712, AAC39731.1, -, mRNA.
CC EMBL, AB064269, BAB79694.1, -, mRNA.

DR EMBL, AB064269, BAB79694.1, -, mRNA.
DR EMBL, AB064270, BAB79695.1, -, mRNA.
DR EMBL, AB037599, BAA90488.1, -, mRNA.
DR EMBL, BC074823, AAH74823.1, -, mRNA.
DR EMBL, BC074823, AAH74823.1, -, mRNA.
DR EMBL, AF013171, AAC51762.1, -, mRNA.
DR HSSP, O35235, 1JY2.
DR SMR, O14788, 162-317.
DR Ensembl, ENSG00000120659; Homo sapiens.
DR HGNC, HGNC:11926; TNFRSF11.
DR MIM, 602642; -.
DR GO, GO:0005576; C:extracellular region; NAS.
DR GO, GO:0005887; C:integral to plasma membrane; NAS.
DR GO, GO:0005164; F:tumor necrosis factor receptor binding; NAS.
DR GO, GO:0006955; P:immune response; NAS.
DR GO, GO:0030316; P:osteoclast differentiation; NAS.
DR InterPro, IPR006052; TNF_family.
DR InterPro, IPR003636; TNF_subf.
DR Pfam, PF00229; TNF, 1.
DR ProDom, PD002012; TNF_subf, 1.
DR SMART, SM00207; TNF, 1.
DR PROSITE, PS00251; TNF_1; FALSE_NEG.
DR PROSITE, PS00049; TNF_2; 1.
KW Alternative splicing; Cytokine; Developmental protein;
KW Differentiation; Glycoprotein; Receptor; Signal-anchor; Transmembrane.
FT CHAIN 1 317
FT Tumor necrosis factor ligand superfamily
FT member 11, membrane form.
FT CHAIN 140 317
FT Tumor necrosis factor ligand superfamily
FT member 11, soluble form (By similarity).
FT TOPO_DOM 1 47
FT Signal-anchor for type II membrane
FT TRANSMEM 48 68
FT protein (Potential).
FT TOPO_DOM 69 317
FT SITE 139 140
FT CLEAVAGE (By similarity).
FT CARBOHYD 171 171
FT N-linked (GlcNAc...) (Potential).
FT CARBOHYD 198 198
FT N-linked (GlcNAc...) (Potential).
FT VASPLIC 1 73
FT Missing (in isoform 2).
FT VASPLIC 1 47
FT Missing (in isoform 3).
FT /Frid=VSP_006447.
FT /Frid=VSP_006446.
FT /Frid=VSP_006445.
FT CONFLICT 194 194 A -> G (in Ref. 6).
FT SEQUENCE 317 AA; 35478 MW; 7661764634E097F CRC64;
SQ
Query Match 100.0%; Score 1319; DB 1; Length 317;
Best Local Similarity 100.0%; Pred. No. 4e-110;
Matches 249; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 YFRAQMDPNRISSEGTCTITRILRLHENDPQDTTLESQDTKLIIPDSRRIRKQAFQAVQ 60
DB 69 YFRAQMDPNRISSEGTCTITRILRLHENDPQDTTLESQDTKLIIPDSRRIRKQAFQAVQ 128
QY 61 KELQHVIGSCHIRAEKAMVDGSDWLDLAKRSKLEAOPFAHLTINTNDIPSGSHKVSLSMW 120
DB 129 KELQHVIGSCHIRAEKAMVDGSDWLDLAKRSKLEAOPFAHLTINTNDIPSGSHKVSLSMW 188
QY 121 HDRGMAKISNNTFSGNGLIVNQDFYLLYANICRHHETSGDLATEYLQLVVYTKTSIK 180
DB 189 HDRGMAKISNNTFSGNGLIVNQDFYLLYANICRHHETSGDLATEYLQLVVYTKTSIK 248
QY 181 IPSSHTLMKGGSTKYWGSNFEHFYISINVGFFLKRGSEIISIVNSPLDPPQDATYF 240
DB 249 IPSSHTLMKGGSTKYWGSNFEHFYISINVGFFLKRGSEIISIVNSPLDPPQDATYF 308
QY 241 GAFYVRDID 249
DB 309 GAFYVRDID 317
RESULT 2
OST9Y4 HUMAN
ID OST9Y4 HUMAN PRELIMINARY; PRT; 317 AA.
AC OST9Y4;
DT 01-FEB-2005 (TREMblrel, 29, Created)

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Comphen Ltd.

OM protein - protein search, using SW model

Run on: December 21, 2005, 12:44:31 ; Search time 42.4525 Seconds
(without alignments)
484.925 Million cell updates/sec

Title: US-09-211-297-39_COPY_69_317
Perfect score: 1339
Sequence: 1 YFRAGMDPNRISEDTGHCY.....LLDPQDATYFGAFKVRDID 249

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 572060 seqs, 82675679 residues

Total number of hits satisfying chosen parameters: 572060

Minimum DB seq length: 0
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Issued Patents AA:*
1: /cgn2_6/prodata/1/1aa/5 COMB.pep:*
2: /cgn2_6/prodata/1/1aa/6 COMB.pep:*
3: /cgn2_6/prodata/1/1aa/H COMB.pep:*
4: /cgn2_6/prodata/1/1aa/PCTUS COMB.pep:*
5: /cgn2_6/prodata/1/1aa/RE COMB.pep:*
6: /cgn2_6/prodata/1/1aa/backfillset.pep:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	1319	100.0	317	2	US-08-996-139-13 Sequence 13, Appl
2	1319	100.0	317	2	US-08-995-659-13 Sequence 13, Appl
3	1319	100.0	317	2	US-09-215-649A-13 Sequence 4, Appl
4	1319	100.0	317	2	US-09-052-521C-4 Sequence 13, Appl
5	1319	100.0	317	2	US-09-577-780-13 Sequence 13, Appl
6	1319	100.0	317	2	US-09-577-800-13 Sequence 13, Appl
7	1319	100.0	317	2	US-09-466-496-13 Sequence 13, Appl
8	1319	100.0	317	2	US-09-871-856-13 Sequence 13, Appl
9	1319	100.0	317	2	US-09-871-291-13 Sequence 13, Appl
10	1319	100.0	317	2	US-09-396-937-2 Sequence 2, Appl
11	1319	100.0	317	2	US-09-865-363-13 Sequence 13, Appl
12	1319	100.0	317	2	US-09-688-459-13 Sequence 13, Appl
13	1319	100.0	317	2	US-09-957-944-6 Sequence 6, Appl
14	1319	100.0	317	2	US-08-996-139-11 Sequence 11, Appl
15	1134	86.0	294	2	US-08-995-659-11 Sequence 11, Appl
16	1134	86.0	294	2	US-09-215-649A-11 Sequence 11, Appl
17	1134	86.0	294	2	US-09-577-780-11 Sequence 11, Appl
18	1134	86.0	294	2	US-09-577-800-11 Sequence 11, Appl
19	1134	86.0	294	2	US-09-466-496-11 Sequence 11, Appl
20	1134	86.0	294	2	US-09-871-856-11 Sequence 11, Appl
21	1134	86.0	294	2	US-09-871-291-11 Sequence 11, Appl
22	1134	86.0	294	2	US-09-877-650-11 Sequence 11, Appl
23	1134	86.0	294	2	US-09-865-363-11 Sequence 11, Appl
24	1134	86.0	294	2	US-09-688-459-11 Sequence 11, Appl
25	1134	86.0	316	2	US-09-957-944-8 Sequence 8, Appl
26	1134	86.0	316	2	US-08-842-842-7 Sequence 7, Appl

28	1127	85.4	316	2	US-08-989-362-2 Sequence 2, Appl
29	1127	85.4	316	2	US-09-052-521C-2 Sequence 2, Appl
30	1127	85.4	316	2	US-09-671-658A-2 Sequence 2, Appl
31	1127	85.4	316	2	US-09-396-937-4 Sequence 4, Appl
32	1127	85.4	316	2	US-09-396-937-6 Sequence 6, Appl
33	771	58.5	187	2	US-09-396-937-8 Sequence 8, Appl
34	769	58.3	173	2	US-09-396-937-10 Sequence 10, Appl
35	759	57.5	173	2	US-09-396-937-12 Sequence 12, Appl
36	721.5	54.7	188	2	US-09-396-937-14 Sequence 14, Appl
37	711.5	53.9	182	2	US-09-396-937-16 Sequence 16, Appl
38	691	52.4	173	2	US-09-396-937-18 Sequence 18, Appl
39	670	50.8	173	2	US-09-396-937-20 Sequence 20, Appl
40	638	40.8	109	2	US-09-911-777-8 Sequence 8, Appl
41	418	31.7	77	2	US-09-632-287A-11 Sequence 11, Appl
42	418	31.7	77	2	US-10-286-696-11 Sequence 11, Appl
43	363	27.5	77	2	US-09-632-287A-10 Sequence 10, Appl
44	363	27.5	77	2	US-10-286-696-10 Sequence 10, Appl
45	238.5	18.1	291	1	US-08-670-354-6 Sequence 6, Appl

ALIGNMENTS

RESULT 1
US-08-996-139-13
Sequence 13, Application US/08996139
Patent No. 6017729
GENERAL INFORMATION:
APPLICANT: Anderson, Dirk M.
APPLICANT: Galibert, Laurent
APPLICANT: Marakovsky, Eugene
TITLE OF INVENTION: Receptor Activator of NF-kappaB
NUMBER OF SEQUENCES: 19
CORRESPONDENCE ADDRESSES:
ADDRESSEE: Immunex Corporation, Law Department
STREET: 51 University Street
CITY: Seattle
STATE: WA
COUNTRY: USA
ZIP: 98101
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: Apple Power Macintosh
OPERATING SYSTEM: Apple Operating System 7.5.5
SOFTWARE: Microsoft Word for Power Macintosh 6.0.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/996,139
FILING DATE: 22 DECEMBER 1997
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: USSN 60/064,671
FILING DATE: 14 OCTOBER 1997
PRIOR APPLICATION DATA:
APPLICATION NUMBER: USSN 08/813,509
FILING DATE: 07 MARCH 1997
PRIOR APPLICATION DATA:
APPLICATION NUMBER: USSN 08/772,330
FILING DATE: 23 DECEMBER 1996
ATTORNEY/AGENT INFORMATION:
NAME: Perkins, Patricia Anne
REGISTRATION NUMBER: 34,693
REFERENCE/DOCKET NUMBER: 2851-A
TELECOMMUNICATION INFORMATION:
TELEPHONE: (206)587-0430
TELEFAX: (206)233-0644
INFORMATION FOR SEQ ID NO: 13:
SEQUENCE CHARACTERISTICS:
LENGTH: 317 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: protein
US-08-996-139-13

Query Match 100.0%; Score 1319; DB 2; Length 317;
Best Local Similarity 100.0%; Pred. No. 1.7e-139;
Matches 249; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 YFRAQMDPNRISSEDTGHCYIRILRLHFNADPQDTTLESQDTKLIPDSGRRIKQAFQGA VQ 60
DB 69 YFRAQMDPNRISSEDTGHCYIRILRLHFNADPQDTTLESQDTKLIPDSGRRIKQAFQGA VQ 128

QY 61 KELQHVSGQHIRAEKAMVDGSMWDLAKRSKLEAQPFAHLITINATDIPSGSHKYSLS S WY 120
DB 129 KELQHVSGQHIRAEKAMVDGSMWDLAKRSKLEAQPFAHLITINATDIPSGSHKYSLS S WY 188

QY 121 HDRGMAKISNMTFSGNGLIVNQDGFYLYANICFRHHETSGDLATEYLQLMVYVTKTSIK 180
DB 189 HDRGMAKISNMTFSGNGLIVNQDGFYLYANICFRHHETSGDLATEYLQLMVYVTKTSIK 248

QY 181 IPSSHTLMKGGSTKYWGSNGBFHFYSINVGFPLKRSGBEISIEVSNPSLLDPQDATYF 240
DB 249 IPSSHTLMKGGSTKYWGSNGBFHFYSINVGFPLKRSGBEISIEVSNPSLLDPQDATYF 308

QY 241 GAFKVRDID 249
DB 309 GAFKVRDID 317

RESULT 2
US-08-995-659-13
Sequence 13, Application US/08995659
Patent No. 6242213
GENERAL INFORMATION:
APPLICANT: Anderson, Dirk M.
APPLICANT: Marakovsky, Eugene
TITLE OF INVENTION: Ligand for Receptor Activator of NF-kappaB
NUMBER OF SEQUENCES: 19
CORRESPONDENCE ADDRESS:
ADDRESSEE: Immunex Corporation, Law Department
STREET: 51 University Street
CITY: Seattle
STATE: WA
COUNTRY: USA
ZIP: 98101
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: Apple Power Macintosh
OPERATING SYSTEM: Apple Operating System 7.5.5
SOFTWARE: Microsoft Word for Power Macintosh 6.0.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/995,659
FILING DATE: 22 DECEMBER 1997
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: USSN 60/064,671
FILING DATE: 14 OCTOBER 1997
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: USSN 08/813,509
FILING DATE: 07 MARCH 1997
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: USSN 08/772,330
FILING DATE: 23 DECEMBER 1996
CLASSIFICATION:
ATTORNEY/AGENT INFORMATION:
NAME: Perkins, Patricia Anne
REGISTRATION NUMBER: 34,693
REFERENCE/DOCKET NUMBER: 2852-A
TELECOMMUNICATION INFORMATION:
TELEPHONE: (206)587-0430
TELEFAX: (206)233-0644
INFORMATION FOR SEQ ID NO: 13:
SEQUENCE CHARACTERISTICS:
LENGTH: 317 amino acids

TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: protein
US-08-995-659-13

Query Match 100.0%; Score 1319; DB 2; Length 317;
Best Local Similarity 100.0%; Pred. No. 1.7e-139;
Matches 249; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 YFRAQMDPNRISSEDTGHCYIRILRLHFNADPQDTTLESQDTKLIPDSGRRIKQAFQGA VQ 60
DB 69 YFRAQMDPNRISSEDTGHCYIRILRLHFNADPQDTTLESQDTKLIPDSGRRIKQAFQGA VQ 128

QY 61 KELQHVSGQHIRAEKAMVDGSMWDLAKRSKLEAQPFAHLITINATDIPSGSHKYSLS S WY 120
DB 129 KELQHVSGQHIRAEKAMVDGSMWDLAKRSKLEAQPFAHLITINATDIPSGSHKYSLS S WY 188

QY 121 HDRGMAKISNMTFSGNGLIVNQDGFYLYANICFRHHETSGDLATEYLQLMVYVTKTSIK 180
DB 189 HDRGMAKISNMTFSGNGLIVNQDGFYLYANICFRHHETSGDLATEYLQLMVYVTKTSIK 248

QY 181 IPSSHTLMKGGSTKYWGSNGBFHFYSINVGFPLKRSGBEISIEVSNPSLLDPQDATYF 240
DB 249 IPSSHTLMKGGSTKYWGSNGBFHFYSINVGFPLKRSGBEISIEVSNPSLLDPQDATYF 308

QY 241 GAFKVRDID 249
DB 309 GAFKVRDID 317

RESULT 3
US-09-215-649A-13
Sequence 13, Application US/09215649A
Patent No. 6271349
GENERAL INFORMATION:
APPLICANT: Anderson, Dirk M.
APPLICANT: Galibert, Laurent
TITLE OF INVENTION: Receptor Activator of NF-kappaB
NUMBER OF SEQUENCES: 19
CORRESPONDENCE ADDRESS:
ADDRESSEE: Immunex Corporation, Law Department
STREET: 51 University Street
CITY: Seattle
STATE: WA
COUNTRY: USA
ZIP: 98101
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: Apple Power Macintosh
OPERATING SYSTEM: Apple Operating System 7.5.5
SOFTWARE: Microsoft Word for Power Macintosh 6.0.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/215,649A
FILING DATE: 17-Dec-1998
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/996,139
FILING DATE: <Unknown>
APPLICATION NUMBER: USSN 08/813,509
FILING DATE: 07 MARCH 1997
APPLICATION NUMBER: USSN 08/772,330
FILING DATE: 23 DECEMBER 1996
ATTORNEY/AGENT INFORMATION:
NAME: Perkins, Patricia Anne
REGISTRATION NUMBER: 34,693
REFERENCE/DOCKET NUMBER: 2851-A
TELECOMMUNICATION INFORMATION:
TELEPHONE: (206)587-0430
TELEFAX: (206)233-0644
INFORMATION FOR SEQ ID NO: 13:
SEQUENCE CHARACTERISTICS:
LENGTH: 317 amino acids

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using SW model

Run on: December 21, 2005, 13:02:07 / Search time 137.154 Seconds
(without alignments)
758.559 Million cell updates/sec

Title: US-09-211-297-39_COPY_69_317

Perfect score: 1319
Sequence: 1 YFRQMDPNRISBDTHCTIC.....LDDPDATYGAFAKVRDID 249

Scoring table: BLOSUM62
Gapop 10.0, Gapext 0.5

Searched: 1867569 seqs, 417829326 residues

Total number of hits satisfying chosen parameters: 1867569

Minimum DB seq length: 0

Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%
Maximum Match 100%

Listing first 45 summaries

Database : Published Applications_AA_Main:*

- 1: /cgn2_6/prodata/1/pubppaa/US07_PUBCOMB.pep.*
- 2: /cgn2_6/prodata/1/pubppaa/US08_PUBCOMB.pep.*
- 3: /cgn2_6/prodata/1/pubppaa/US09_PUBCOMB.pep.*
- 4: /cgn2_6/prodata/1/pubppaa/US10_PUBCOMB.pep.*
- 5: /cgn2_6/prodata/1/pubppaa/US10_PUBCOMB.pep.*
- 6: /cgn2_6/prodata/1/pubppaa/US11_PUBCOMB.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	1319	100.0	249	4	US-10-050-902-221 Sequence 221, App
2	1319	100.0	249	4	US-10-050-898-221 Sequence 221, App
3	1319	100.0	249	4	US-10-289-456-82 Sequence 82, Appl
4	1319	100.0	250	4	US-10-338-785A-1 Sequence 1, Appl1
5	1319	100.0	250	4	US-10-611-363-1 Sequence 1, Appl1
6	1319	100.0	270	4	US-10-289-456-80 Sequence 80, Appl
7	1319	100.0	317	3	US-09-813-329-7 Sequence 7, Appl
8	1319	100.0	317	3	US-09-871-856-13 Sequence 13, Appl
9	1319	100.0	317	3	US-09-957-944-6 Sequence 6, Appl1
10	1319	100.0	317	3	US-09-865-363-13 Sequence 13, Appl
11	1319	100.0	317	3	US-09-871-291-13 Sequence 13, Appl
12	1319	100.0	317	3	US-09-877-650-13 Sequence 13, Appl
13	1319	100.0	317	3	US-09-933-615A-2 Sequence 2, Appl1
14	1319	100.0	317	4	US-10-151-071-10 Sequence 10, Appl
15	1319	100.0	317	4	US-10-218-547-22 Sequence 22, Appl
16	1319	100.0	317	4	US-10-405-878-13 Sequence 13, Appl
17	1319	100.0	317	4	US-10-167-182-11 Sequence 11, Appl
18	1319	100.0	317	4	US-10-310-793-28 Sequence 28, Appl
19	1319	100.0	317	4	US-10-460-623-11 Sequence 11, Appl
20	1319	100.0	317	4	US-10-289-456-79 Sequence 79, Appl
21	1319	100.0	317	4	US-10-202-062-22 Sequence 22, Appl
22	1319	100.0	317	4	US-10-664-801-2 Sequence 2, Appl1
23	1319	100.0	317	4	US-10-381-160-6 Sequence 6, Appl1
24	1319	100.0	317	4	US-10-799-345-12 Sequence 12, Appl
25	1319	100.0	317	5	US-10-399-116-6 Sequence 6, Appl1
26	1319	100.0	317	5	US-10-802-133-13 Sequence 13, Appl
27	1319	100.0	317	5	US-10-825-898-4 Sequence 4, Appl1

ALIGNMENTS

28	1319	100.0	317	5	US-10-854-300-11	Sequence 11, Appl
29	1319	100.0	317	5	US-10-129-595-1	Sequence 1, Appl1
30	1319	100.0	317	5	US-10-451-200-6	Sequence 6, Appl1
31	1319	100.0	317	5	US-10-999-523-8	Sequence 8, Appl1
32	1319	100.0	317	6	US-11-028-780-22	Sequence 22, Appl
33	1319	100.0	317	6	US-11-099-059-6	Sequence 6, Appl1
34	1319	100.0	317	6	US-11-135-521-11	Sequence 11, Appl1
35	1319	100.0	317	6	US-11-142-726-7	Sequence 7, Appl1
36	1301	98.6	246	4	US-10-167-182-17	Sequence 17, Appl
37	1301	98.6	246	4	US-10-460-623-17	Sequence 17, Appl
38	1301	98.6	246	5	US-10-854-300-17	Sequence 17, Appl
39	1301	98.6	246	6	US-11-135-521-17	Sequence 17, Appl1
40	1293	98.0	245	3	US-09-873-829-2	Sequence 2, Appl1
41	1293	98.0	245	4	US-10-017-910-2	Sequence 2, Appl1
42	1292	98.0	244	3	US-09-933-615A-10	Sequence 10, Appl1
43	1292	98.0	244	4	US-10-210-951-42	Sequence 42, Appl
44	1292	98.0	244	4	US-10-050-902-222	Sequence 222, App
45	1292	98.0	244	4	US-10-050-898-222	Sequence 222, App

RESULT 1
US-10-050-902-221
Sequence 221, Application US/10050902
Publication No. US20030175290A1
GENERAL INFORMATION:
APPLICANT: Renner, Wolfgang A.
APPLICANT: Bachmann, Martin
APPLICANT: Tisoe, Alain
APPLICANT: Maurer, Patrick
APPLICANT: Legner, Franziska
APPLICANT: Seibel, Peter
APPLICANT: Piossek, Christine
TITLE OF INVENTION: Molecular Antigen Array
FILE REFERENCE: 1700.0190004
CURRENT APPLICATION NUMBER: US/10/050,902
CURRENT FILING DATE: 2002-01-18
PRIOR APPLICATION NUMBER: US 60/262,379
PRIOR FILING DATE: 2001-01-19
PRIOR APPLICATION NUMBER: US 60/288,549
PRIOR FILING DATE: 2001-05-04
PRIOR APPLICATION NUMBER: US 60/326,998
PRIOR FILING DATE: 2001-10-05
PRIOR APPLICATION NUMBER: US 60/331,045
PRIOR FILING DATE: 2001-11-07
NUMBER OF SEQ ID NOS: 350
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 221
TYPE: PRT
ORGANISM: Homo sapiens
US-10-050-902-221
Query Match 100.0%; Score 1319; DB 4; Length 249;
Best Local Similarity 100.0%; Pred. No. 5.3e-122;
Matches 249; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 YFRQMDPNRISBDTHCTICIRILRLHENDFODTTLESODTKLIPDSRRIRKQAFGAVQ 60
1 YFRQMDPNRISBDTHCTICIRILRLHENDFODTTLESODTKLIPDSRRIRKQAFGAVQ 60
Db 1 YFRQMDPNRISBDTHCTICIRILRLHENDFODTTLESODTKLIPDSRRIRKQAFGAVQ 60
QY 61 KELQHTVGSQHIRAEKAMVDGSLDIKRSKLEAOPFAHLTTNATDIPGSHKVSLSWY 120
61 KELQHTVGSQHIRAEKAMVDGSLDIKRSKLEAOPFAHLTTNATDIPGSHKVSLSWY 120
Db 61 KELQHTVGSQHIRAEKAMVDGSLDIKRSKLEAOPFAHLTTNATDIPGSHKVSLSWY 120
QY 121 HDRGAKKISNMTFSNKLIVNODGFYLYXANICFRHHTSGDLATYLDLQMYVTTSIK 180
121 HDRGAKKISNMTFSNKLIVNODGFYLYXANICFRHHTSGDLATYLDLQMYVTTSIK 180
Db 121 HDRGAKKISNMTFSNKLIVNODGFYLYXANICFRHHTSGDLATYLDLQMYVTTSIK 180
QY 181 IFSHTLMKGSQKTYSGNSEFHFYISINVGCFKLRSGEISIEVSNPSLDDPDATYF 240
181 IFSHTLMKGSQKTYSGNSEFHFYISINVGCFKLRSGEISIEVSNPSLDDPDATYF 240

Db 181 IPSSHLMKGGSTKWSGNSGFHFYSINVGFFLKRSGBEISIEVSNPSLLDPDQATYF 240
QY 241 GAFKVRDID 249
Db 241 GAFKVRDID 249

RESULT 2

US-10-050-898-221
; Sequence 221, Application US/10050898
; Publication No. US2003017571A1
; GENERAL INFORMATION:
; APPLICANT: Renner, Wolfgang A.
; APPLICANT: Bachmann, Martin
; APPLICANT: Tissot, Alain
; APPLICANT: Maurer, Patrick
; APPLICANT: Lechner, Franziska
; APPLICANT: Seibel, Peter
; APPLICANT: Ploesek, Christine
; APPLICANT: Ortman, Rainer
; APPLICANT: Luond, Rainer
; APPLICANT: Staufenbiel, Matthias
; APPLICANT: Frey, Peter
; TITLE OF INVENTION: Molecular Antigen Array
; FILE REFERENCE: 1700.0190005
; CURRENT APPLICATION NUMBER: US/10/050,898
; CURRENT FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: US 60/262,379
; PRIOR FILING DATE: 2001-01-19
; PRIOR APPLICATION NUMBER: US 60/288,549
; PRIOR FILING DATE: 2001-05-04
; PRIOR APPLICATION NUMBER: US 60/326,998
; PRIOR FILING DATE: 2001-10-05
; PRIOR APPLICATION NUMBER: US 60/331,045
; PRIOR FILING DATE: 2001-11-07
; NUMBER OF SEQ ID NOS: 350
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 221
; LENGTH: 249
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-050-898-221

Query Match 100.0%; Score 1319; DB 4; Length 249;
Best Local Similarity 100.0%; Pred. No. 5,3e-122;
Matches 249; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 YFRAQMDPNRISSEGTGHCYIRILRLHENADPQDTTLESQDTKLIPDSCRRIKQAFQAVQ 60
Db 1 YFRAQMDPNRISSEGTGHCYIRILRLHENADPQDTTLESQDTKLIPDSCRRIKQAFQAVQ 60
QY 61 KELQHVGSQHIRAEKAMVDGSMWDLAKRSKLEAQPFAHLTTINATDIPSGSHKSLSSWY 120
Db 61 KELQHVGSQHIRAEKAMVDGSMWDLAKRSKLEAQPFAHLTTINATDIPSGSHKSLSSWY 120
QY 121 HDRGMAKISNMTFSGNKLIVNQDGFYYLYANICFRHHETSGDLATEYQLQMWVYTKTSIK 180
Db 121 HDRGMAKISNMTFSGNKLIVNQDGFYYLYANICFRHHETSGDLATEYQLQMWVYTKTSIK 180
QY 181 IPSSHLMKGGSTKWSGNSGFHFYSINVGFFLKRSGBEISIEVSNPSLLDPDQATYF 240
Db 181 IPSSHLMKGGSTKWSGNSGFHFYSINVGFFLKRSGBEISIEVSNPSLLDPDQATYF 240
QY 241 GAFKVRDID 249
Db 241 GAFKVRDID 249

RESULT 3
US-10-289-456-82
; Sequence 82, Application US/10289456
; Publication No. US2004003321A1
; GENERAL INFORMATION:

; APPLICANT: Bachmann, Martin
; APPLICANT: Maurer, Patrick
; APPLICANT: Spohn, Gunther
; TITLE OF INVENTION: Antigen Arrays for Treatment of Bone Disease
; FILE REFERENCE: 1700.0330001
; CURRENT APPLICATION NUMBER: US/10/289,456
; CURRENT FILING DATE: 2002-11-07
; PRIOR APPLICATION NUMBER: PCT/IB02/00166
; PRIOR FILING DATE: 2002-01-21
; PRIOR APPLICATION NUMBER: US 10/050,902
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: US 60/396,635
; PRIOR FILING DATE: 2002-07-19
; PRIOR APPLICATION NUMBER: US 60/331,045
; PRIOR FILING DATE: 2001-11-07
; NUMBER OF SEQ ID NOS: 170
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 82
; LENGTH: 249
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-289-456-82

Query Match 100.0%; Score 1319; DB 4; Length 249;
Best Local Similarity 100.0%; Pred. No. 5,3e-122;
Matches 249; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 YFRAQMDPNRISSEGTGHCYIRILRLHENADPQDTTLESQDTKLIPDSCRRIKQAFQAVQ 60
Db 1 YFRAQMDPNRISSEGTGHCYIRILRLHENADPQDTTLESQDTKLIPDSCRRIKQAFQAVQ 60
QY 61 KELQHVGSQHIRAEKAMVDGSMWDLAKRSKLEAQPFAHLTTINATDIPSGSHKSLSSWY 120
Db 61 KELQHVGSQHIRAEKAMVDGSMWDLAKRSKLEAQPFAHLTTINATDIPSGSHKSLSSWY 120
QY 121 HDRGMAKISNMTFSGNKLIVNQDGFYYLYANICFRHHETSGDLATEYQLQMWVYTKTSIK 180
Db 121 HDRGMAKISNMTFSGNKLIVNQDGFYYLYANICFRHHETSGDLATEYQLQMWVYTKTSIK 180
QY 181 IPSSHLMKGGSTKWSGNSGFHFYSINVGFFLKRSGBEISIEVSNPSLLDPDQATYF 240
Db 181 IPSSHLMKGGSTKWSGNSGFHFYSINVGFFLKRSGBEISIEVSNPSLLDPDQATYF 240
QY 241 GAFKVRDID 249
Db 241 GAFKVRDID 249

RESULT 4
US-10-338-785A-1
; Sequence 1, Application US/10338785A
; Publication No. US20030219864A1
; GENERAL INFORMATION:
; APPLICANT: Desjarlais, John R.
; APPLICANT: Hubert, Rene S.
; TITLE OF INVENTION: No. US20030219864A1 Variants of RANKL Protein
; FILE REFERENCE: A-71486
; CURRENT APPLICATION NUMBER: US/10/338,785A
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US 60/345,805
; PRIOR FILING DATE: 2002-01-04
; PRIOR APPLICATION NUMBER: US 60/373,453
; PRIOR FILING DATE: 2002-04-17
; NUMBER OF SEQ ID NOS: 6
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1
; LENGTH: 250
; TYPE: PRT
; ORGANISM: Homo sapiens
; PUBLICATION INFORMATION:
; DATABASE ACCESSION NUMBER: Genbank Acc. No. US20030219864A1 AAB86811
; DATABASE ENTRY DATE: 1997-11-21

GenCore version 5.1.6
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM protein - protein search, using SW model

Run on: December 21, 2005, 13:03:52 ; Search time 7.75574 Seconds
(without alignments)
228.978 Million cell updates/sec

Title: US-09-211-297-39_COPY_69_317

Perfect score: 1319

Sequence: 1 YFRAGMDPNRISDGTGTCITY.....LIDPDQATYFGAFKVRDID 249

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 53982 seqs, 7132107 residues

Total number of hits satisfying chosen parameters: 53982

Minimum DB seq length: 0

Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Published Applications_AA_New.*
1: /cgn2_6/prodata/2/pubppaa/US09_NEW_PUB.pep.*
2: /cgn2_6/prodata/2/pubppaa/US06_NEW_PUB.pep.*
3: /cgn2_6/prodata/2/pubppaa/US07_NEW_PUB.pep.*
4: /cgn2_6/prodata/2/pubppaa/PCT_NEW_PUB.pep.*
5: /cgn2_6/prodata/2/pubppaa/US09_NEW_PUB.pep.*
6: /cgn2_6/prodata/2/pubppaa/US10_NEW_PUB.pep.*
7: /cgn2_6/prodata/2/pubppaa/US11_NEW_PUB.pep.*
8: /cgn2_6/prodata/2/pubppaa/US60_NEW_PUB.pep.*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	538	40.8	109	7 US-11-065-669-8	Sequence 8, Appl1
2	236.5	17.9	281	6 US-10-821-234-1288	Sequence 1288, Ap
3	235.5	17.9	266	7 US-11-082-544-10	Sequence 10, Appl
4	232.5	17.6	281	7 US-11-077-372-2	Sequence 2, Appl1
5	232.5	17.6	391	7 US-11-105-172-4	Sequence 4, Appl1
6	147.5	11.2	359	7 US-11-105-172-2	Sequence 2, Appl1
7	134	10.2	240	6 US-10-987-663-6	Sequence 6, Appl1
8	133	10.1	157	7 US-11-010-954-1	Sequence 1, Appl1
9	133	10.1	157	7 US-11-053-750-1	Sequence 1, Appl1
10	133	10.1	157	7 US-11-053-749-1	Sequence 12, Appl
11	133	10.1	157	7 US-11-108-001-12	Sequence 4, Appl1
12	133	10.1	158	7 US-11-082-544-4	Sequence 2, Appl1
13	133	10.1	164	7 US-11-108-001-2	Sequence 8, Appl1
14	133	10.1	180	7 US-11-082-544-8	Sequence 61, Appl
15	92.5	7.0	177	6 US-10-999-866-61	Sequence 1028, Ap
16	92.5	7.0	205	6 US-10-995-561-1028	Sequence 1029, Ap
17	92.5	7.0	205	6 US-11-065-669-5	Sequence 5, Appl1
18	86.5	6.6	104	7 US-11-054-515-3233	Sequence 3233, Ap
19	85	6.4	220	7 US-11-054-515-3231	Sequence 3231, Ap
20	77.5	5.9	290	7 US-10-524-198-2	Sequence 2, Appl1
21	77	5.8	200	6 US-11-054-515-3237	Sequence 3237, Ap
22	76.5	5.8	219	7 US-11-054-515-3236	Sequence 3236, Ap
23	76.5	5.8	243	7 US-11-054-515-3232	Sequence 3232, Ap
24	74.5	5.6	239	7 US-10-054-515-3232	Sequence 34, Appl
25	74.5	5.6	943	6 US-10-475-204-34	Sequence 34, Appl

26	73.5	5.6	207	7 US-11-054-515-3234	Sequence 3234, Ap
27	73	5.5	188	7 US-11-054-515-3235	Sequence 3235, Ap
28	73	5.5	535	6 US-10-131-826A-490	Sequence 490, Ap
29	72	5.5	389	7 US-11-088-686-1	Sequence 1, Appl1
30	72	5.5	389	7 US-11-088-686-3	Sequence 3, Appl1
31	72	5.5	389	7 US-11-088-686-5	Sequence 5, Appl1
32	72	5.5	389	7 US-11-088-686-7	Sequence 7, Appl1
33	72	5.5	389	7 US-11-088-686-9	Sequence 9, Appl1
34	72	5.5	389	7 US-11-088-686-11	Sequence 11, Appl
35	72	5.5	389	7 US-11-088-686-13	Sequence 13, Appl
36	71.5	5.4	1001	6 US-10-467-962B-81	Sequence 81, Appl
37	71.5	5.4	1151	7 US-11-128-420-10	Sequence 10, Appl
38	71.5	5.4	1467	6 US-10-507-956-1	Sequence 1, Appl1
39	71	5.4	447	7 US-11-112-882-4	Sequence 4, Appl1
40	70.5	5.3	369	7 US-11-055-822-32	Sequence 42, Appl
41	70.5	5.3	585	6 US-10-878-556A-42	Sequence 3, Appl1
42	70	5.3	152	6 US-10-742-634-3	Sequence 17, Appl
43	70	5.3	178	6 US-10-742-634-17	Sequence 3, Appl1
44	70	5.3	266	7 US-11-054-515-3229	Sequence 3229, Ap
45	70	5.3	285	6 US-10-131-826A-24	Sequence 24, Appl

ALIGNMENTS

```
RESULT 1
US-11-065-669-8
; Sequence 8, Application US/11065669
; Publication No. US2005024441A1
; GENERAL INFORMATION:
; APPLICANT: McKay, Fabienne
; TITLE OF INVENTION: BARE, INHIBITORS THEREOF AND THEIR USE IN THE
; FILE REFERENCE: 08201.0024-0400
; CURRENT APPLICATION NUMBER: US/11/065,669
; PRIOR FILING DATE: 2005-02-24
; PRIOR APPLICATION NUMBER: 10/045,574
; PRIOR FILING DATE: 2001-11-07
; PRIOR APPLICATION NUMBER: 09/911,777
; PRIOR FILING DATE: 2001-07-24
; PRIOR APPLICATION NUMBER: 60/143,228
; PRIOR FILING DATE: 2001-07-09
; PRIOR APPLICATION NUMBER: PCT/US00/01788
; PRIOR FILING DATE: 2000-01-25
; PRIOR APPLICATION NUMBER: 60/117,169
; PRIOR FILING DATE: 1999-01-25
; NUMBER OF SEQ ID NOS: 26
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 8
; LENGTH: 109
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-065-669-8

Query Match      40.8%; Score 538; DB 7; Length 109;
Best Local Similarity 75.5%; Pred. No. 1.4e-46;
Matches 108; Conservative 0; Mismatches 1; Indels 34; Gaps 2;

QY 93 EAQFAHLTNATIDPSGSHKVSLSWMYHDGRWAKTSNMTFNSGKLIIVNODGFYYLYANI 152
   |||||||
DB 1 EAQFAHLTNATIDPSGSHKVSLSWMYHDGRWAKTSNMTFNSGKLSNM-----YANI 43

QY 153 CFFHHTSGDLATEYQLMYYVTKTSIKLPSSTLTKMGSGTKYSGNSEPHFYSINVGCF 212
   |||||||
DB 44 CFFHHTSGDLATEYQLMYYVTKTSIKIP-----SEPHFYSINVGCF 86

QY 213 FKLRSGEISIEVSNPSLDPDQ 235
   |||||||
DB 87 FKLRSGEISIEVSNPSLDPDQ 109

RESULT 2
```

```
US-10-821-234-1288
; Sequence 1288, Application US/10821234
; Publication No. US20050255114A1
; GENERAL INFORMATION:
; APPLICANT: Labat, Ivan
; APPLICANT: Stache-Crain, Birgit
; APPLICANT: Andarmant, Susan
; APPLICANT: Tang, Y. Tom
; TITLE OF INVENTION: Methods for Diagnosis and Treatment of Preeclampsia
; FILE REFERENCE: 821A
; CURRENT APPLICATION NUMBER: US/10/821,234
; CURRENT FILING DATE: 2004-04-07
; PRIOR APPLICATION NUMBER: US 60/462,047
; PRIOR FILING DATE: 2003-04-07
; NUMBER OF SEQ ID NOS: 1704
; SOFTWARE: pc_seq_genes Version 1.0
; SEQ ID NO 1288
; LENGTH: 281
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-821-234-1288

Query Match          17.9%; Score 236.5; DB 6; Length 281;
Best Local Similarity 25.1%; Pred. No. 3.1e-16;
Matches 67; Conservative 53; Mismatches 102; Indels 45; Gaps 10;

QY 1 YFRAQMD--PNRISEGDGHCIRILRLHENDFODTTLESODTKLIPDSCRRIKQAFQGA 58
   ||:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
DB 37 YFTNELKQMDKRYSGIACF-----LKED---DSYMDPDESMNSPCQVVKM----- 82

QY 59 VQKELOHIVGSOHIRAERAMVDGSMWLDAKRSKLEAOPF-----AHLT-----IN 103
   ||:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
DB 83 ---QRLQVLRKMLRTSEETI-----STVQEKQONISPLVREGRQVAAHITGRGRSN 134
   ||:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
QY 104 ATDIPSGSHKVSU---SSWYHDR-GWAKISNMTFSNGKLIVNODGFYLYANICFRHHE 158
   ||:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
DB 135 TLLSPNSKNEKALGRKINSWESSRSGHSFLSNLHRLNGELVIHKGFFYIYSQTYFRQOE 194
   ||:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
QY 159 TSGDLATEYLQIMVYVTKTSIKIPSHITLMKGSSTKYWGSNEFHYSINVGFFKLRS 218
   ||:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
DB 195 EIKENTKNDKQWQYIYKTYT-SYDPDILMKSARNSCWSKDAEYGLYSIYGGIFELKEN 253
   ||:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
QY 219 EISIEVSNPSLLDPDODATYFGAFKV 245
   ||:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
DB 254 DRIFSVTNEHLIDMDHEASFFGAFLV 280
   ||:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|

RESULT 3
US-11-082-544-10
; Sequence 10, Application US/11082544
; Publication No. US20050249706A1
; GENERAL INFORMATION:
; APPLICANT: Bermudes, G.
; APPLICANT: King, I.
; APPLICANT: Clairmont, C.
; APPLICANT: Lin, S.
; APPLICANT: Belcourt, M.
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR
; TITLE OF INVENTION: TUMOR-TARGETED DELIVERY OF EFFECTOR MOLECULES
; FILE REFERENCE: 8002-059
; CURRENT APPLICATION NUMBER: US/11/082,544
; CURRENT FILING DATE: 2005-03-17
; PRIOR APPLICATION NUMBER: US/09/645,415
; PRIOR FILING DATE: 2000-08-24
; PRIOR APPLICATION NUMBER: 60/157,581
; PRIOR FILING DATE: 1999-10-04
; PRIOR APPLICATION NUMBER: 60/157,637
; PRIOR FILING DATE: 1999-10-04
; NUMBER OF SEQ ID NOS: 61
; SOFTWARE: FaastSeq for Windows Version 3.0
; SEQ ID NO 10
; LENGTH: 266
; TYPE: PRT
```

```
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Fusion construct
US-11-082-544-10

Query Match          17.9%; Score 235.5; DB 7; Length 266;
Best Local Similarity 25.3%; Pred. No. 3.6e-16;
Matches 65; Conservative 51; Mismatches 98; Indels 43; Gaps 9;

QY 9 NRISEDGHCIRILRLHENDFODTTLESODTKLIPDSCRRIKQAFQGAQVKELOHIVG 68
   ||:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
DB 32 DKYSKSGIACF-----LKED---DSYMDPDESMNSPCQVVKM-----QRLQVLR 74
   ||:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
QY 69 SOHIRAERAMVDGSMWLDAKRSKLEAOPF-----AHLT-----INATDIPSGSHK 113
   ||:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
DB 75 KMLIRTSEETI-----STVQEKQONISPLVREGRQVAAHITGRGRSNLTSSPNSKNE 129
   ||:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
QY 114 VSL---SSWYHDR-GWAKISNMTFSNGKLIVNODGFYLYANICFRHHE TSGDLATEYL 168
   ||:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
DB 130 KALGRKINSWESSRSGHSFLSNLHRLNGELVIHKGFFYIYSQTYFRQOEIKENTKNDK 189
   ||:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
QY 169 QLMYVYVTKTSIKIPSHITLMKGSSTKYWGSNEFHYSINVGFFKLRSGEISIEVSNP 226
   ||:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
DB 190 QWQYIYKTYT-SYDPDILMKSARNSCWSKDAEYGLYSIYGGIFELKENDRIFSVTNE 248
   ||:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
QY 229 SLDPDODATYFGAFKV 245
   ||:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
DB 249 HLIDMDHEASFFGAFLV 265
   ||:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|

RESULT 4
US-11-077-272-2
; Sequence 2, Application US/11077272
; Publication No. US20050244927A1
; GENERAL INFORMATION:
; APPLICANT: LEUNG, WOON-LAM SUSAN
; APPLICANT: SMART, JAMES R.
; TITLE OF INVENTION: PROCESS FOR PRODUCING POLYPEPTIDES
; FILE REFERENCE: P2019R1
; CURRENT APPLICATION NUMBER: US/11/077,272
; CURRENT FILING DATE: 2005-03-10
; PRIOR APPLICATION NUMBER: US 60/552,678
; PRIOR FILING DATE: 2004-03-11
; NUMBER OF SEQ ID NOS: 7
; SEQ ID NO 2
; LENGTH: 281
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-077-272-2

Query Match          17.6%; Score 232.5; DB 7; Length 281;
Best Local Similarity 25.1%; Pred. No. 7.6e-16;
Matches 67; Conservative 52; Mismatches 103; Indels 45; Gaps 10;

QY 1 YFRAQMD--PNRISEGDGHCIRILRLHENDFODTTLESODTKLIPDSCRRIKQAFQGA 58
   ||:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
DB 37 YFTNELKQMDKRYSGIACF-----LKED---DSYMDPDESMNSPCQVVKM----- 82

QY 59 VQKELOHIVGSOHIRAERAMVDGSMWLDAKRSKLEAOPF-----AHLT-----IN 103
   ||:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
DB 83 ---QRLQVLRKMLRTSEETI-----STVQEKQONISPLVREGRQVAAHITGRGRSN 134
   ||:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
QY 104 ATDIPSGSHKVSU---SSWYHDR-GWAKISNMTFSNGKLIVNODGFYLYANICFRHHE 158
   ||:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
DB 135 TLLSPNSKNEKALGRKINSWESSRSGHSFLSNLHRLNGELVIHKGFFYIYSQTYFRQOE 194
   ||:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
QY 159 TSGDLATEYLQIMVYVTKTSIKIPSHITLMKGSSTKYWGSNEFHYSINVGFFKLRS 218
   ||:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
DB 195 EIKENTKNDKQWQYIYKTYT-SYDPDILMKSARNSCWSKDAEYGLYSIYGGIFELKEN 253
   ||:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
QY 219 EISIEVSNPSLLDPDODATYFGAFKV 245
   ||:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
DB 254 DRIFSVTNEHLIDMDHEASFFGAFLV 280
   ||:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
```

GenCore version 5.1.6
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM protein - protein search, using SW model

Run on: December 21, 2005, 12:44:31 ; Search time 2.89836 Seconds
(without alignments)
484.925 Million cell updates/sec

Title: US-09-211-297-34

Perfect score: 84
Sequence: 1 VYVVKTSIKIPSHNLM 17

Scoring table: BLOSUM62
Gapop 10.0, Gapext 0.5

Searched: 572060 seqs, 82675679 residues

Total number of hits satisfying chosen parameters: 572060

Minimum DB seq length: 0
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database: Issued_Patents_AA:
1: /cgn2_6/prodata/1/1aa/5-COMB.pep.*
2: /cgn2_6/prodata/1/1aa/6-COMB.pep.*
3: /cgn2_6/prodata/1/1aa/7-COMB.pep.*
4: /cgn2_6/prodata/1/1aa/8-COMB.pep.*
5: /cgn2_6/prodata/1/1aa/9-COMB.pep.*
6: /cgn2_6/prodata/1/1aa/Backlist1.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	84	100.0	17	2	US-09-052-521C-35
2	84	100.0	173	2	US-09-396-937-10
3	84	100.0	173	2	US-09-396-937-12
4	84	100.0	173	2	US-09-396-937-18
5	84	100.0	187	2	US-09-396-937-8
6	84	100.0	188	2	US-09-396-937-14
7	84	100.0	234	2	US-08-996-139-11
8	84	100.0	234	2	US-08-995-659-11
9	84	100.0	234	2	US-09-215-649A-11
10	84	100.0	234	2	US-09-577-800-11
11	84	100.0	234	2	US-09-577-800-11
12	84	100.0	234	2	US-09-466-996-11
13	84	100.0	234	2	US-09-871-856-11
14	84	100.0	234	2	US-09-871-291-11
15	84	100.0	234	2	US-09-877-650-11
16	84	100.0	234	2	US-09-865-363-11
17	84	100.0	234	2	US-09-688-459-11
18	84	100.0	316	1	US-08-882-842-7
19	84	100.0	316	2	US-08-989-362-2
20	84	100.0	316	2	US-09-052-521C-2
21	84	100.0	316	2	US-09-671-658A-2
22	84	100.0	316	2	US-09-396-937-4
23	84	100.0	316	2	US-09-396-937-6
24	84	100.0	316	2	US-09-987-944-8
25	84	100.0	317	2	US-08-996-139-13
26	84	100.0	317	2	US-08-995-659-13
27	84	100.0	317	2	US-09-215-649A-13

ALIGNMENTS

28	74	88.1	317	2	US-09-052-521C-4	Sequence 4, Appl
29	74	88.1	317	2	US-09-577-780-13	Sequence 13, Appl
30	74	88.1	317	2	US-09-577-800-13	Sequence 13, Appl
31	74	88.1	317	2	US-09-466-996-13	Sequence 13, Appl
32	74	88.1	317	2	US-09-871-856-13	Sequence 13, Appl
33	74	88.1	317	2	US-09-871-291-13	Sequence 13, Appl
34	74	88.1	317	2	US-09-396-937-2	Sequence 2, Appl
35	74	88.1	317	2	US-09-877-650-13	Sequence 13, Appl
36	74	88.1	317	2	US-09-865-363-13	Sequence 13, Appl
37	74	88.1	317	2	US-09-688-459-13	Sequence 13, Appl
38	74	88.1	317	2	US-09-957-944-6	Sequence 16, Appl
39	71	84.5	182	2	US-09-396-937-16	Sequence 20, Appl
40	69	82.1	173	2	US-09-396-937-20	Sequence 20, Appl
41	54	64.3	12	2	US-09-628-665-23	Sequence 23, Appl
42	54	64.3	16	2	US-09-628-665-23	Sequence 23, Appl
43	53	63.1	109	2	US-09-911-777-8	Sequence 8, Appl
44	50	59.5	10	2	US-09-628-665-6	Sequence 6, Appl
45	50	59.5	11	2	US-09-628-665-5	Sequence 5, Appl

RESULT 1
US-09-052-521C-35
Sequence 35, Application US/09052521C

Patent No. 6316408

GENERAL INFORMATION:

APPLICANT: Boyle, William J.

TITLE OF INVENTION: Osteoprotegerin Binding Proteins and Receptors

FILE REFERENCE: A-451Bry

CURRENT APPLICATION NUMBER: US/09/052,521C

PRIOR FILING DATE: 1998-03-30

PRIOR APPLICATION NUMBER: 08/880,855

PRIOR FILING DATE: 1997-06-23

PRIOR APPLICATION NUMBER: 08/842,842

NUMBER OF SEQ ID NOS: 40

SOFTWARE: Patentin Ver. 2.1

SEQ ID NO 35

LENGTH: 17

TYPE: PRT

ORGANISM: Artificial Sequence

FEATURE: Description of Artificial Sequence: Synthetic

OTHER INFORMATION: Peptide

US-09-052-521C-35

Query Match 100.0%; Score 84; DB 2; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.7e-07;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 VYVVKTSIKIPSHNLM 17
Db 1 VYVVKTSIKIPSHNLM 17

RESULT 2
US-09-396-937-10

Sequence 10, Application US/09396937

Patent No. 6645300

GENERAL INFORMATION:

APPLICANT: M&E Biotech A/S

APPLICANT: HALKIER, Torben

APPLICANT: HANING, Jeppe

TITLE OF INVENTION: Method for Down-Regulating Osteoprotegerin Ligand

FILE REFERENCE: 22021 Pct 1

CURRENT APPLICATION NUMBER: US/09/396,937

CURRENT FILING DATE: 1999-09-15

NUMBER OF SEQ ID NOS: 35

SOFTWARE: Patentin Ver. 2.1

SEQ ID NO 10

LENGTH: 173
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: DNA encoding
OTHER INFORMATION: murine OPGL, residues 158-316, fused to His tag
US-09-396-937-10

Query Match 100.0%; Score 84; DB 2; Length 173;
Best Local Similarity 100.0%; Pred. No. 2.1e-06;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 VVVVKTSLKIPSSHNLM 17
|||
Db 96 VVVVKTSLKIPSSHNLM 112

RESULT 3
US-09-396-937-12
Sequence 12, Application US/09396937
Patent No. 6645500
GENERAL INFORMATION:
APPLICANT: M&E Biotech A/S
APPLICANT: HALKIER, Torben
APPLICANT: HAANING, Jesper
TITLE OF INVENTION: Method for Down-Regulating Osteoprotegerin Ligand
FILE REFERENCE: 22021 PC 1
CURRENT APPLICATION NUMBER: US/09/396,937
CURRENT FILING DATE: 1999-09-15
NUMBER OF SEQ ID NOS: 35
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 12
LENGTH: 173
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Fusion of
OTHER INFORMATION: murine OPGL, residues 158-316 with C to S
OTHER INFORMATION: mutation, and His tag
US-09-396-937-12

Query Match 100.0%; Score 84; DB 2; Length 173;
Best Local Similarity 100.0%; Pred. No. 2.1e-06;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 VVVVKTSLKIPSSHNLM 17
|||
Db 96 VVVVKTSLKIPSSHNLM 112

RESULT 4
US-09-396-937-18
Sequence 18, Application US/09396937
Patent No. 6645500
GENERAL INFORMATION:
APPLICANT: M&E Biotech A/S
APPLICANT: HALKIER, Torben
APPLICANT: HAANING, Jesper
TITLE OF INVENTION: Method for Down-Regulating Osteoprotegerin Ligand
FILE REFERENCE: 22021 PC 1
CURRENT APPLICATION NUMBER: US/09/396,937
CURRENT FILING DATE: 1999-09-15
NUMBER OF SEQ ID NOS: 35
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 18
LENGTH: 173
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Fusion between
OTHER INFORMATION: murine OPGL, residues 158-316 with tetanus toxoid

OTHER INFORMATION: P2 epitope introduced, and His tag
US-09-396-937-18

Query Match 100.0%; Score 84; DB 2; Length 173;
Best Local Similarity 100.0%; Pred. No. 2.1e-06;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 VVVVKTSLKIPSSHNLM 17
|||
Db 96 VVVVKTSLKIPSSHNLM 112

RESULT 5
US-09-396-937-8
Sequence 8, Application US/09396937
Patent No. 6645500
GENERAL INFORMATION:
APPLICANT: M&E Biotech A/S
APPLICANT: HALKIER, Torben
APPLICANT: HAANING, Jesper
TITLE OF INVENTION: Method for Down-Regulating Osteoprotegerin Ligand
FILE REFERENCE: 22021 PC 1
CURRENT APPLICATION NUMBER: US/09/396,937
CURRENT FILING DATE: 1999-09-15
NUMBER OF SEQ ID NOS: 35
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 8
LENGTH: 187
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Synthetic PCR
OTHER INFORMATION: product with optimum codons for E. coli and P.
OTHER INFORMATION: pasteuris expression
US-09-396-937-8

Query Match 100.0%; Score 84; DB 2; Length 187;
Best Local Similarity 100.0%; Pred. No. 2.3e-06;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 VVVVKTSLKIPSSHNLM 17
|||
Db 110 VVVVKTSLKIPSSHNLM 126

RESULT 6
US-09-396-937-14
Sequence 14, Application US/09396937
Patent No. 6645500
GENERAL INFORMATION:
APPLICANT: M&E Biotech A/S
APPLICANT: HALKIER, Torben
APPLICANT: HAANING, Jesper
TITLE OF INVENTION: Method for Down-Regulating Osteoprotegerin Ligand
FILE REFERENCE: 22021 PC 1
CURRENT APPLICATION NUMBER: US/09/396,937
CURRENT FILING DATE: 1999-09-15
NUMBER OF SEQ ID NOS: 35
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 14
LENGTH: 188
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Fusion of
OTHER INFORMATION: murine OPGL, residues 158-316 modified by
OTHER INFORMATION: introduction of tetanus toxoid P30 epitope, and
US-09-396-937-14

Query Match 100.0%; Score 84; DB 2; Length 188;

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using BW model

Run on: December 21, 2005, 13:02:07 ; Search time 9.36393 Seconds
(without alignments)
758.559 Million cell updates/sec

Title: US-09-211-297-34

Perfect score: 84

Sequence: 1 VYVVKTSIKIPSSHNLM 17

Scoring table:

BLOSUM62
Gapop 10.0, Gapext 0.5

Searched: 1867569 seqs, 417829326 residues

Total number of hits satisfying chosen parameters: 1867569

Minimum DB seq length: 0

Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database: Published Applications_AA_Main:*

- 1: /cgn2_6/prodata/1/pubppaa/US07_PUBCOMB.pep:*
- 2: /cgn2_6/prodata/1/pubppaa/US08_PUBCOMB.pep:*
- 3: /cgn2_6/prodata/1/pubppaa/US09_PUBCOMB.pep:*
- 4: /cgn2_6/prodata/1/pubppaa/US10_PUBCOMB.pep:*
- 5: /cgn2_6/prodata/1/pubppaa/US11_PUBCOMB.pep:*
- 6: /cgn2_6/prodata/1/pubppaa/US11_PUBCOMB.pep:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	84	100.0	17	US-10-825-898-35	Sequence 35, Appl
2	84	100.0	18	US-10-825-898-36	Sequence 36, Appl
3	84	100.0	160	US-09-779-050A-14	Sequence 14, Appl
4	84	100.0	170	US-09-791-153A-76	Sequence 76, Appl
5	84	100.0	170	US-10-289-456-99	Sequence 99, Appl
6	84	100.0	173	US-10-664-801-10	Sequence 10, Appl
7	84	100.0	173	US-10-664-801-12	Sequence 12, Appl
8	84	100.0	173	US-10-664-801-18	Sequence 18, Appl
9	84	100.0	187	US-10-664-801-8	Sequence 8, Appl
10	84	100.0	188	US-10-664-801-14	Sequence 14, Appl
11	84	100.0	193	US-10-289-456-96	Sequence 96, Appl
12	84	100.0	199	US-10-050-902-224	Sequence 224, App
13	84	100.0	199	US-10-050-902-224	Sequence 224, App
14	84	100.0	199	US-10-289-456-86	Sequence 86, Appl
15	84	100.0	244	US-10-167-182-16	Sequence 16, Appl
16	84	100.0	244	US-10-460-623-16	Sequence 16, Appl
17	84	100.0	244	US-10-854-100-16	Sequence 16, Appl
18	84	100.0	244	US-11-125-521-16	Sequence 16, Appl
19	84	100.0	247	US-10-050-902-223	Sequence 223, App
20	84	100.0	247	US-10-050-902-223	Sequence 223, App
21	84	100.0	247	US-10-289-456-85	Sequence 85, Appl
22	84	100.0	249	US-10-338-785A-3	Sequence 3, Appl
23	84	100.0	249	US-10-611-363-3	Sequence 3, Appl
24	84	100.0	294	US-09-871-856-11	Sequence 11, Appl
25	84	100.0	294	US-09-865-363-11	Sequence 11, Appl
26	84	100.0	294	US-09-871-291-11	Sequence 11, Appl
27	84	100.0	294	US-09-877-650-11	Sequence 11, Appl

28	84	100.0	294	4	US-10-405-878-11	Sequence 11, Appl
29	84	100.0	294	5	US-10-802-133-11	Sequence 11, Appl
30	84	100.0	316	3	US-09-957-944-8	Sequence 8, Appl
31	84	100.0	316	3	US-09-079-569-7	Sequence 7, Appl
32	84	100.0	316	3	US-09-873-829-4	Sequence 4, Appl
33	84	100.0	316	3	US-09-933-915A-16	Sequence 16, Appl
34	84	100.0	316	4	US-10-017-910-4	Sequence 4, Appl
35	84	100.0	316	4	US-10-105-057-2	Sequence 2, Appl
36	84	100.0	316	4	US-10-272-411-19	Sequence 19, Appl
37	84	100.0	316	4	US-10-328-052-2	Sequence 2, Appl
38	84	100.0	316	4	US-10-167-182-1	Sequence 1, Appl
39	84	100.0	316	4	US-10-460-623-1	Sequence 1, Appl
40	84	100.0	316	4	US-10-664-801-4	Sequence 4, Appl
41	84	100.0	316	4	US-10-664-801-6	Sequence 6, Appl
42	84	100.0	316	4	US-10-799-345-10	Sequence 10, Appl
43	84	100.0	316	4	US-10-825-898-2	Sequence 2, Appl
44	84	100.0	316	5	US-10-854-300-1	Sequence 1, Appl
45	84	100.0	316	5	US-10-854-300-1	Sequence 1, Appl

ALIGNMENTS

```

RESULT 1
US-10-825-898-35
; Sequence 35, Application US/10825898
; Publication No. US20050003400A1
; GENERAL INFORMATION:
; APPLICANT: BOYLE, WILLIAM
; TITLE OF INVENTION: OSTROPROTEGERIN BINDING PROTEINS AND RECEPTORS
; FILE REFERENCE: A-451K REV 09-10-03 54SEQ
; CURRENT APPLICATION NUMBER: US/10/825,898
; PRIOR FILING DATE: 2004-04-15
; PRIOR APPLICATION NUMBER: US/10/825,898
; PRIOR FILING DATE: 2004-04-15
; PRIOR APPLICATION NUMBER: US 09/052,521
; PRIOR FILING DATE: 1998-03-30
; PRIOR APPLICATION NUMBER: US 08/880,855
; PRIOR FILING DATE: 1997-06-23
; PRIOR APPLICATION NUMBER: US 08/842,842
; PRIOR FILING DATE: 1997-04-16
; NUMBER OF SEQ ID NOS: 54
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 35
; LENGTH: 17
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Oligonucleotide
US-10-825-898-35
Query Match 100.0%; Score 84; DB 5; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.5e-07;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 VYVVKTSIKIPSSHNLM 17
Db 1 VYVVKTSIKIPSSHNLM 17
RESULT 2
US-10-825-898-36
; Sequence 36, Application US/10825898
; Publication No. US20050003400A1
; GENERAL INFORMATION:
; APPLICANT: BOYLE, WILLIAM
; TITLE OF INVENTION: OSTROPROTEGERIN BINDING PROTEINS AND RECEPTORS
; FILE REFERENCE: A-451K REV 09-10-03 54SEQ
; CURRENT APPLICATION NUMBER: US/10/825,898
; PRIOR FILING DATE: 2004-04-15
; PRIOR APPLICATION NUMBER: US/10/825,898
; PRIOR FILING DATE: 2004-04-15
; PRIOR APPLICATION NUMBER: US 09/052,521

```

;; PRIOR FILING DATE: 1998-03-30
;; PRIOR APPLICATION NUMBER: US 08/880,855
;; PRIOR FILING DATE: 1997-06-23
;; PRIOR APPLICATION NUMBER: US 08/842,842
;; PRIOR FILING DATE: 1997-04-16
;; NUMBER OF SEQ ID NOS: 54
;; SOFTWARE: PatentIn version 3.1
;; SEQ ID NO 36
;; LENGTH: 18
;; TYPE: PRT
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: Synthetic Oligonucleotide
US-10-825-898-36

Query Match 100.0%; Score 84; DB 5; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.6e-07;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1 VVVVKTSLKIPSSHNL 17
Db 1 VVVVKTSLKIPSSHNL 17

RESULT 3
US-09-779-050A-14
;; Sequence 14, Application US/09779050A
;; Patent No. US20020160416A1
;; GENERAL INFORMATION:
;; APPLICANT: BOYLE, WILLIAM
;; APPLICANT: HSU, HAILING
;; TITLE OF INVENTION: RECEPTOR FROM TNF FAMILY
;; FILE REFERENCE: A-570B
;; CURRENT APPLICATION NUMBER: US/09/779,050A
;; CURRENT FILING DATE: 2001-02-12
;; PRIOR APPLICATION NUMBER: 60/181,800
;; PRIOR FILING DATE: 2000-02-11
;; NUMBER OF SEQ ID NOS: 52
;; SOFTWARE: PatentIn version 3.0
;; SEQ ID NO 14
;; LENGTH: 160
;; TYPE: PRT
;; ORGANISM: Mus musculus
US-09-779-050A-14

Query Match 100.0%; Score 84; DB 3; Length 160;
Best Local Similarity 100.0%; Pred. No. 1.8e-06;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1 VVVVKTSLKIPSSHNL 17
Db 83 VVVVKTSLKIPSSHNL 99

RESULT 4
US-09-791-153A-76
;; Sequence 76, Application US/09791153A
;; Publication No. US20030103978A1
;; GENERAL INFORMATION:
;; APPLICANT: Deshpande, Rajendra
;; APPLICANT: Hitz, Anna
;; APPLICANT: Boyle, William
;; APPLICANT: Sullivan, John
;; TITLE OF INVENTION: SELECTIVE BINDING AGENTS OF OSTEOPROTEGERIN BINDING PROTEIN
;; FILE REFERENCE: A-633A
;; CURRENT APPLICATION NUMBER: US/09/791,153A
;; CURRENT FILING DATE: 2001-07-17
;; PRIOR APPLICATION NUMBER: 09/511,139
;; PRIOR FILING DATE: 2000-02-23
;; NUMBER OF SEQ ID NOS: 154
;; SOFTWARE: PatentIn version 3.0
;; SEQ ID NO 76
;; LENGTH: 170

;; TYPE: PRT
;; ORGANISM: Mus musculus
US-09-791-153A-76

Query Match 100.0%; Score 84; DB 3; Length 170;
Best Local Similarity 100.0%; Pred. No. 1.9e-06;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1 VVVVKTSLKIPSSHNL 17
Db 93 VVVVKTSLKIPSSHNL 109

RESULT 5
US-10-289-456-99
;; Sequence 99, Application US/10289456
;; Publication No. US2004003211A1
;; GENERAL INFORMATION:
;; APPLICANT: Bachmann, Martin
;; APPLICANT: Maurer, Patrick
;; APPLICANT: Soehn, Gunther
;; TITLE OF INVENTION: Antigen Arrays for Treatment of Bone Disease
;; FILE REFERENCE: 1700.0330001
;; CURRENT APPLICATION NUMBER: US/10/289,456
;; CURRENT FILING DATE: 2002-11-07
;; PRIOR APPLICATION NUMBER: PCT/IB02/00166
;; PRIOR FILING DATE: 2002-01-21
;; PRIOR APPLICATION NUMBER: US 10/050,902
;; PRIOR FILING DATE: 2002-01-18
;; PRIOR APPLICATION NUMBER: US 60/396,635
;; PRIOR FILING DATE: 2002-07-19
;; PRIOR APPLICATION NUMBER: US 60/331,045
;; PRIOR FILING DATE: 2001-11-07
;; NUMBER OF SEQ ID NOS: 170
;; SOFTWARE: PatentIn version 3.2
;; SEQ ID NO 99
;; LENGTH: 170
;; TYPE: PRT
;; ORGANISM: Mus sp.
US-10-289-456-99

Query Match 100.0%; Score 84; DB 4; Length 170;
Best Local Similarity 100.0%; Pred. No. 1.9e-06;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1 VVVVKTSLKIPSSHNL 17
Db 84 VVVVKTSLKIPSSHNL 100

RESULT 6
US-10-664-801-10
;; Sequence 10, Application US/10664801
;; Publication No. US20040115199A1
;; GENERAL INFORMATION:
;; APPLICANT: M&E Biotech A/S
;; APPLICANT: HALLIER, Torben
;; APPLICANT: Jeppesen
;; TITLE OF INVENTION: Method for Down-Regulating Osteoprotegerin Ligand
;; FILE REFERENCE: 22021 PC 1
;; CURRENT APPLICATION NUMBER: US/10/664,801
;; CURRENT FILING DATE: 2003-09-17
;; PRIOR APPLICATION NUMBER: US/09/396,937
;; PRIOR FILING DATE: 1999-09-15
;; NUMBER OF SEQ ID NOS: 35
;; SOFTWARE: PatentIn Ver. 2.1
;; SEQ ID NO 10
;; LENGTH: 173
;; TYPE: PRT
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: Description of Artificial Sequence: DNA encoding

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OW protein - protein search, using bw model

Run on: December 21, 2005, 13:03:52; Search time 0.529508 Seconds
(without alignments)
228.978 Million cell updates/sec

Title: US-09-211-297-34

Perfect score: 84
Sequence: 1 VYVVKTSIKIPSSHNL 17

Scoring table: BLOSUM62
Gapop 10.0, Gapext 0.5

Searched: 53982 seqs, 7132107 residues

Total number of hits satisfying chosen parameters: 53982

Minimum DB seq length: 0
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database: Published Applications_AA_New.*
1: /cgn2_6/ptodata/2/pubpaa/US08_NEW_PUB.pdb.*
2: /cgn2_6/ptodata/2/pubpaa/US06_NEW_PUB.pdb.*
3: /cgn2_6/ptodata/2/pubpaa/US07_NEW_PUB.pdb.*
4: /cgn2_6/ptodata/2/pubpaa/PCT_NEW_PUB.pdb.*
5: /cgn2_6/ptodata/2/pubpaa/US05_NEW_PUB.pdb.*
6: /cgn2_6/ptodata/2/pubpaa/US10_NEW_PUB.pdb.*
7: /cgn2_6/ptodata/2/pubpaa/US11_NEW_PUB.pdb.*
8: /cgn2_6/ptodata/2/pubpaa/US60_NEW_PUB.pdb.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	53	63.1	109	7	US-11-065-669-8
2	37	44.0	717	6	US-10-793-626-3022
3	35	41.7	269	6	US-10-821-234-1684
4	34	40.5	113	6	US-10-793-626-3282
5	34	40.5	351	6	US-10-467-657-5088
6	33.5	39.9	374	7	US-11-060-023-10
7	33	39.3	39	6	US-10-467-657-2174
8	33	39.3	96	6	US-10-467-657-8984
9	33	39.3	155	7	US-11-069-642-97
10	33	39.3	198	7	US-11-069-642-25
11	33	39.3	208	6	US-10-880-388-81
12	33	39.3	238	7	US-11-069-642-127
13	33	39.3	431	7	US-11-069-642-1
14	33	39.3	437	7	US-11-069-642-92
15	33	39.3	438	7	US-11-069-642-47
16	33	39.3	438	7	US-11-069-642-49
17	33	39.3	438	7	US-11-069-642-51
18	33	39.3	438	7	US-11-069-642-53
19	33	39.3	438	7	US-11-069-642-55
20	33	39.3	438	7	US-11-069-642-57
21	33	39.3	438	7	US-11-069-642-59
22	33	39.3	438	7	US-11-069-642-61
23	33	39.3	438	7	US-11-069-642-63
24	33	39.3	438	6	US-10-131-826A-310
25	33	39.3	619	6	US-10-763-712A-35

26	33	39.3	734	7	US-11-093-274-40	Sequence 40, Appl
27	33	39.3	949	7	US-11-077-550-68	Sequence 68, Appl
28	33	39.3	1420	7	US-11-077-550-110	Sequence 110, Appl
29	32	38.1	64	6	US-10-467-657-7122	Sequence 7122, Appl
30	32	38.1	101	7	US-11-053-076-51	Sequence 51, Appl
31	32	38.1	111	7	US-11-053-076-163	Sequence 163, Appl
32	32	38.1	215	6	US-10-793-626-596	Sequence 596, Appl
33	32	38.1	215	6	US-10-793-626-2258	Sequence 2258, Appl
34	32	38.1	257	6	US-10-467-662B-73	Sequence 73, Appl
35	32	38.1	317	6	US-10-689-742-166	Sequence 166, Appl
36	32	38.1	356	7	US-11-055-822-972	Sequence 972, Appl
37	32	38.1	356	7	US-11-055-822-1052	Sequence 1052, Appl
38	32	38.1	437	7	US-11-082-389-180	Sequence 180, Appl
39	32	38.1	477	7	US-11-055-822-1050	Sequence 1050, Appl
40	32	38.1	477	7	US-11-055-822-1050	Sequence 1050, Appl
41	32	38.1	478	6	US-10-793-626-768	Sequence 768, Appl
42	32	38.1	567	6	US-10-131-826A-476	Sequence 476, Appl
43	32	38.1	1234	6	US-10-467-657-4224	Sequence 4224, Appl
44	32	38.1	2725	7	US-11-113-424-52	Sequence 52, Appl
45	31	36.9	102	7	US-11-053-076-162	Sequence 162, Appl

ALIGNMENTS

RESULT 1
US-11-065-669-8
; Sequence 8, Application US/11065669
; Publication No. US2005024411A1
; GENERAL INFORMATION:
; APPLICANT: Mackay, Sienne
; APPLICANT: Kalled, Susan
; TITLE OF INVENTION: BAPF, INHIBITORS THEREOF AND THEIR USE IN THE
; TITLE OF INVENTION: MODULATION OF B-CELL RESPONSE
; FILE REFERENCE: 08201.0024-04000
; CURRENT APPLICATION NUMBER: US/11/065,669
; CURRENT FILING DATE: 2005-02-24
; PRIOR APPLICATION NUMBER: 10/045,574
; PRIOR FILING DATE: 2001-11-07
; PRIOR APPLICATION NUMBER: 09/911,777
; PRIOR FILING DATE: 2001-07-24
; PRIOR APPLICATION NUMBER: 60/143,228
; PRIOR FILING DATE: 2001-07-09
; PRIOR APPLICATION NUMBER: PCT/US00/01788
; PRIOR FILING DATE: 2000-01-25
; PRIOR APPLICATION NUMBER: 60/117,169
; PRIOR FILING DATE: 1999-01-25
; NUMBER OF SEQ ID NOS: 26
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 8
; LENGTH: 109
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-065-669-8
Query Match 63.1%; Score 53; DB 7; Length 109;
Best Local Similarity 91.7%; Pred. No. 0.0067;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1 VYVVKTSIKIPS 12
DB 63 VYVVKTSIKIPS 74
RESULT 2
US-10-793-626-3022
; Sequence 3022, Application US/10793626
; Publication No. US2005025478A1
; GENERAL INFORMATION:
; APPLICANT: KIMBERLY, WILLIAM JOHN
; TITLE OF INVENTION: STAPHYLOCOCCUS EPIDERMIDIS NUCLEIC ACIDS AND PROTEINS
; FILE REFERENCE: PU148005
; CURRENT APPLICATION NUMBER: US/10/793,626

```

; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: synthetic
; OTHER INFORMATION: amino acid sequence
US-10-793-626-3282
Query Match          44.0%; Score 37; DB 6; Length 717;
Best Local Similarity 46.2%; Pred. No. 39;
Matches 6; Conservative 4; Mismatches 3; Indels 0; Gaps 0;

OY      2 YVVKTSIKIPSSH 14
Db      198 YVKGKVKILNNH 210

RESULT 3
US-10-821-234-1684
; Sequence 1684, Application US/10821234
; Publication No. US20050255114A1
; GENERAL INFORMATION:
; APPLICANT: Labat, Ivan
; APPLICANT: Stache-Crain, Birgit
; APPLICANT: Andarmani, Susan
; APPLICANT: Tang, Y. Tom
; TITLE OF INVENTION: Methods for Diagnosis and Treatment of Preeclampsia
; FILE REFERENCE: 821A
; CURRENT APPLICATION NUMBER: US/10/821,234
; CURRENT FILING DATE: 2004-04-07
; PRIOR APPLICATION NUMBER: US 60/462,047
; PRIOR FILING DATE: 2003-04-07
; NUMBER OF SEQ ID NOS: 1704
; SOFTWARE: pc_seq_genes Version 1.0
; SEQ ID NO 1684
; LENGTH: 269
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-821-234-1684

Query Match          41.7%; Score 35; DB 6; Length 269;
Best Local Similarity 50.0%; Pred. No. 28;
Matches 6; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

OY      6 TSIKIPSSHLM 17
Db      186 TDIKATGHNTII 197

RESULT 4
US-10-793-626-3282
; Sequence 3282, Application US/10793626
; Publication No. US20050255478A1
; GENERAL INFORMATION:
; APPLICANT: KIMMERLY, WILLIAM JOHN
; TITLE OF INVENTION: STAPHYLOCOCCUS EPIDERMIDIS NUCLEIC ACIDS AND PROTEINS
; FILE REFERENCE: PUJ480US
; CURRENT APPLICATION NUMBER: US/10/793,626
; CURRENT FILING DATE: 2004-03-04
; PRIOR APPLICATION NUMBER: 60/164,258
; PRIOR FILING DATE: 1999-11-09
; NUMBER OF SEQ ID NOS: 4472
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 3282
; LENGTH: 113
; TYPE: PRT
; ORGANISM: Artificial Sequence
```

```

; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: synthetic
; OTHER INFORMATION: amino acid sequence
US-10-793-626-3282
Query Match          40.5%; Score 34; DB 6; Length 113;
Best Local Similarity 42.9%; Pred. No. 16;
Matches 6; Conservative 4; Mismatches 4; Indels 0; Gaps 0;

OY      1 YVVKTSIKIPSSH 14
Db      56 VSVASTLMKLPNTH 69

RESULT 5
US-10-467-657-5088
; Sequence 5088, Application US/10467657
; Publication No. US20050260581A1
; GENERAL INFORMATION:
; APPLICANT: CHIRON SPA
; APPLICANT: FONTANA Maria Rita
; APPLICANT: PIZZA Mariagrazia
; APPLICANT: MASIGNANI Vega
; APPLICANT: MONACI Elisabetta
; TITLE OF INVENTION: GONOCOCCAL PROTEINS AND NUCLEIC ACIDS
; FILE REFERENCE:
; CURRENT APPLICATION NUMBER: US/10/467,657
; CURRENT FILING DATE: 2003-08-11
; PRIOR APPLICATION NUMBER: GB-0103424.8
; PRIOR FILING DATE: 2001-02-12
; NUMBER OF SEQ ID NOS: 9218
; SOFTWARE: SeqWIn99, version 1.04
; SEQ ID NO 5088
; LENGTH: 351
; TYPE: PRT
; ORGANISM: Neisseria gonorrhoeae
US-10-467-657-5088

Query Match          40.5%; Score 34; DB 6; Length 351;
Best Local Similarity 40.0%; Pred. No. 58;
Matches 6; Conservative 4; Mismatches 5; Indels 0; Gaps 0;

OY      2 YVVKTSIKIPSSHLM 16
Db      275 HIIPNNKRPISHNL 289

RESULT 6
US-11-060-023-10
; Sequence 10, Application US/11060023
; Publication No. US2005025531A1
; GENERAL INFORMATION:
; APPLICANT: Aventis Pharma Deutschland GmbH
; TITLE OF INVENTION: Process for identifying modulators of G protein coupled
; FILE REFERENCE: AVE D-2000/A03 englissh
; CURRENT APPLICATION NUMBER: US/11/060,023
; CURRENT FILING DATE: 2005-02-17
; PRIOR APPLICATION NUMBER: US/09/899,295
; PRIOR FILING DATE: 2003-07-06
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 10
; LENGTH: 374
; TYPE: PRT
; ORGANISM: Mus musculus
US-11-060-023-10

Query Match          39.9%; Score 33.5; DB 7; Length 374;
Best Local Similarity 47.1%; Pred. No. 76;
Matches 8; Conservative 4; Mismatches 2; Indels 3; Gaps 1;

OY      1 YVVKTSI--KIPSSH 14
```

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: December 21, 2005, 12:34:10 ; Search time 11.5656 Seconds
(without alignments)
645.834 Million cell updates/sec

Title: US-09-211-297-34

Perfect score: 84

Sequence: 1 YVYVKTSTKIPSSHLM 17

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 2443163 seqs, 439378781 residues

Total number of hits satisfying chosen parameters: 2443163

Minimum DB seq length: 0

Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Database :

1: A_Geneseq_21:*
2: geneeqp1980s:*
3: geneeqp1990s:*
4: geneeqp2000s:*
5: geneeqp2001s:*
6: geneeqp2002s:*
7: geneeqp2003as:*
8: geneeqp2003bs:*
9: geneeqp2004s:*
9: geneeqp2005s:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	84	100.0	17	2 AAW63198	AAW63198 Murine OS
2	84	100.0	18	2 AAW63199	AAW63199 Murine OS
3	84	100.0	129	3 AAY91023	AAY91023 Mouse OBM
4	84	100.0	125	6 ABR39854	ABR39854 RANK Lig
5	84	100.0	155	7 ADC03334	ADC03334 Murine re
6	84	100.0	155	7 ADI53055	ADI53055 Human RAN
7	84	100.0	160	3 AAB08272	AAB08272 Amino aci
8	84	100.0	170	4 AAU08386	AAU08386 Mouse PLA
9	84	100.0	170	7 ADJ82132	ADJ82132 Protein f
10	84	100.0	173	3 AAY84422	AAY84422 A murine
11	84	100.0	173	3 AAY84425	AAY84425 DNA encod
12	84	100.0	173	3 AAY84421	AAY84421 Amino aci
13	84	100.0	187	3 AAY84420	AAY84420 Amino aci
14	84	100.0	188	3 AAY84423	AAY84423 An osteop
15	84	100.0	193	7 ADJ82129	ADJ82129 Protein f
16	84	100.0	199	5 ABR94285	ABR94285 Mouse RAN
17	84	100.0	199	5 ABR94285	ABR94285 Mouse rec
18	84	100.0	199	5 ABR94285	ABR94285 Mouse rec
19	84	100.0	216	7 ADJ82119	ADJ82119 Protein f
20	84	100.0	244	2 AAB16999	AAB16999 Murine RA
21	84	100.0	247	5 ABR94284	ABR94284 Mouse RAN
22	84	100.0	247	5 ABR94284	ABR94284 Mouse rec
23	84	100.0	247	7 ADJ82118	ADJ82118 Protein f
24	84	100.0	249	6 ADA50081	ADA50081 Mouse wtl

25	84	100.0	294	2 AAW69956	AAW69956 NF-KB rec
26	84	100.0	294	2 AAW68292	AAW68292 NF-KB rec
27	84	100.0	294	2 AAE08737	AAE08737 Murine re
28	84	100.0	294	4 AAE04425	AAE04425 Murine re
29	84	100.0	294	4 AAE01992	AAE01992 Murine RAN
30	84	100.0	294	5 AAE26102	AAE26102 Mouse RAN
31	84	100.0	294	7 ADB16986	ADB16986 Murine re
32	84	100.0	294	7 ADC73000	ADC73000 Murine RA
33	84	100.0	294	7 ADC78266	ADC78266 Murine RA
34	84	100.0	294	7 ADG46721	ADG46721 Murine re
35	84	100.0	294	7 ADW09027	ADW09027 Murine re
36	84	100.0	316	2 AAW83017	AAW83017 Osteoclast
37	84	100.0	316	2 AAW83194	AAW83194 Human ost
38	84	100.0	316	2 AAW59654	AAW59654 Amino aci
39	84	100.0	316	2 AAY17874	AAY17874 Murine TR
40	84	100.0	316	3 AAY91024	AAY91024 Mouse OBM
41	84	100.0	316	3 AAY84418	AAY84418 Amino aci
42	84	100.0	316	3 AAY84419	AAY84419 Amino aci
43	84	100.0	316	5 AAU78289	AAU78289 Mouse TRA
44	84	100.0	316	5 ADR29338	ADR29338 Mouse RAN
45	84	100.0	316	6 ABR42071	ABR42071 Human RAN

ALIGNMENTS

RESULT 1
AAW63198 standard; peptide; 17 AA.
ID AAW63198;

11-FEB-1999 (first entry)

Murine osteoprotegerin binding protein BF loop peptide.

OS Osteoprotegerin binding protein; OPG binding protein; arthritis;
XX osteoporosis; osteoclast maturation; bone disease; metastasis; ODA;
XX hypercalcaemia; osteoclast differentiation and activation receptor;
KW Paget's disease.

XX Mus sp.

XX WO9846751-A1.

XX 22-OCT-1998.

XX 15-APR-1998; 98WO-US007584.

XX 16-APR-1997; 97US-00842842.

XX 23-JUN-1997; 97US-0080855.

XX 30-MAR-1998; 98US-00052521.

XX (AMGE-) AMGEN INC.

XX Boyle WJ;

XX WPI; 1998-594578/50.

XX Nucleic acid encoding osteoprotegerin binding protein - useful for, e.g. treating bone diseases by modulating osteoclast differentiation and for diagnosis.

XX Example 11; Page 55; 47pp; English.

XX The present sequence represents peptide from murine osteoprotegerin (OPG) binding protein. Host cells transfected with vectors containing nucleic acid molecules encoding OPG binding protein are used to produce recombinant OPG binding protein. OPG binding protein is used in binding assays to determine osteoprotegerin (OPG) in biological samples, to screen for specific binding agents (particularly agonists and antagonists, including intracellular proteins); to raise Ab (useful in immunoassays for detection of OPG binding protein) and to identify compounds that

CC modulate binding of OPG binding protein to osteoclast differentiation and
 CC activation receptor (OPAR). The nucleic acid molecule encoding OPG
 CC binding protein can be used to detect OPG binding protein-encoding
 CC sequences, e.g. screening for related sequences, also to produce
 CC transgenic animal models, while complementary sequences are used for
 CC antisense regulation of OPG binding protein expression. Modulators of OPG
 CC binding protein, particularly soluble forms of OPG binding protein or Ab,
 CC are used to treat or prevent bone diseases, e.g. osteoporosis, bone loss
 CC caused by arthritis or metastases, hypercalcaemia, Paget's disease,
 CC periodontal disease, osteoporosis, loosening of prostheses, optionally in
 CC combination with agents that promote bone growth

CC Sequence 17 AA:

SO Query Match 100.0%; Score 84; DB 2; Length 17;

Best Local Similarity 100.0%; Pred. No. 1.4e-07; Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 VYVVKTSIKIPSSHNLM 17
 |||||
 DB 1 VYVVKTSIKIPSSHNLM 17

RESULT 2
 AAW83199
 ID AAW83199 standard; peptide; 18 AA.
 XX
 AC AAW83199;

DT 11-FEB-1999 (first entry)

DE Murine osteoprotegerin binding protein EF loop-Cys peptide.

XX Osteoprotegerin binding protein; OPG binding protein; arthritis;
 KW osteoporosis; osteoclast maturation; bone disease; metastasis; OPAR;
 KW hypercalcaemia; osteoclast differentiation and activation receptor;
 KW Paget's disease.

XX Mus sp.

XX MO9846751-A1.

XX 22-OCT-1998.

PD 15-APR-1998; 98WO-US007584.

XX 16-APR-1997; 97US-00842842.

PR 23-JUN-1997; 97US-00880855.

PR 30-MAR-1998; 98US-00052521.

XX (AMGE-) AMGEN INC.

XX Boyle WJ;

XX WPI, 1998-594578/50.

XX Nucleic acid encoding osteoprotegerin binding protein - useful for, e.g.
 PT treating bone diseases by modulating osteoclast differentiation and for
 PT diagnosis.

XX Example 11; Page 55; 47pp; English.

XX The present sequence represents peptide from murine osteoprotegerin (OPG)
 CC binding protein. Host cells transfected with vectors containing nucleic
 CC acid molecules encoding OPG binding protein are used to produce
 CC recombinant OPG binding protein. OPG binding protein is used in binding
 CC assays to determine osteoprotegerin (OPG) in biological samples; to screen
 CC for specific binding agents (particularly agonists and antagonists,
 CC including intracellular proteins); to raise Ab (useful in immunoassays
 CC for detection of OPG binding protein) and to identify compounds that
 CC modulate binding of OPG binding protein to osteoclast differentiation and
 CC activation receptor (OPAR). The nucleic acid molecule encoding OPG
 CC binding protein can be used to detect OPG binding protein-encoding

CC sequences, e.g. screening for related sequences, also to produce
 CC transgenic animal models, while complementary sequences are used for
 CC antisense regulation of OPG binding protein expression. Modulators of OPG
 CC binding protein, particularly soluble forms of OPG binding protein or Ab,
 CC are used to treat or prevent bone diseases, e.g. osteoporosis, bone loss
 CC caused by arthritis or metastases, hypercalcaemia, Paget's disease,
 CC periodontal disease, osteoporosis, loosening of prostheses, optionally in
 CC combination with agents that promote bone growth

CC Sequence 18 AA:

SO Query Match 100.0%; Score 84; DB 2; Length 18;

Best Local Similarity 100.0%; Pred. No. 1.4e-07; Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 VYVVKTSIKIPSSHNLM 17
 |||||
 DB 1 VYVVKTSIKIPSSHNLM 17

RESULT 3
 AAY91023
 ID AAY91023 standard; protein; 139 AA.
 XX
 AC AAY91023;

DT 05-SEP-2000 (first entry)

DE Mouse OBM protein sequence SEQ ID NO:8.

XX Mouse, osteoclastogenesis inhibitory factor binding molecule; OCIF; OBM;
 KW osteoclast; bone absorption promoting factor; vitamin D3; PTH;
 KW parathyroid hormone.

XX Mus sp.

XX JP2000102390-A.

XX 11-APR-2000.

XX 30-SEP-1998; 98JP-00292971.

XX 30-SEP-1998; 98JP-00292971.

XX (SNOW) SNOW BRAND MILK PROD CO LTD.

XX (YSNE-) YS NEW TECHNOLOGY KENKUTUSHO.

XX WPI, 2000-332087/29.

XX N-PSDB; AAA39155.

XX A DNA and preparation of a protein by using it.

XX Example 2; Page 14; 18pp; Japanese.

XX The present invention describes a genomic DNA encoding a protein having
 CC an activity of supporting or promoting differentiation and maturation of
 CC osteoclasts. The genomic DNA encoding a protein has the following
 CC properties: (a) combines specifically with osteoclastogenesis inhibitory
 CC factor (OCIF) and has a high affinity; (b) shows a molecular weight (mw)
 CC of 30,000 to 40,000 by SDS-PAGE (sodium dodecyl sulfate-polyacrylamide
 CC gel electrophoresis) under a nonreductive condition and the apparent mw
 CC when crosslinked with monomer type OCIF is 90,000 to 110,000; and (c) has
 CC an activity of supporting or promoting differentiation and maturation of
 CC osteoclast in the co-culture of mouse osteoblast-like stroma cell and
 CC mouse spleen cell in the presence of a bone absorption promoting factor
 CC such as active type vitamin D3 and parathyroid hormone (PTH). The protein
 CC can be used as a drug and a research reagent. The present sequence
 CC represents a mouse OCIF binding molecule (OBM) from the present invention
 XX
 SO Sequence 139 AA:
 Query Match 100.0%; Score 84; DB 3; Length 139;
 Best Local Similarity 100.0%; Pred. No. 1.5e-06;

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using SW model

Run on: December 21, 2005, 12:47:51 ; Search time 1.92295 Seconds
(without alignments)
850.612 Million cell updates/sec

Title: US-09-211-297-34

Perfect score: 84

Sequence: 1 VYVVKTSIKIPSSHNL 17

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 283416 seqs, 96216763 residues

Total number of hits satisfying chosen parameters: 283416

Minimum DB seq length: 0
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database :
1: p1r1:*
2: p1r2:*
3: p1r3:*
4: p1r4:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	45	53.6	206	2 G86279	Fla117.27 protein
2	44.5	53.0	311	2 B70441	ribose-phosphate d
3	43	51.2	232	1 I83349	CS6 subunits chape
4	43	51.2	377	2 S67448	hypothetical prote
5	41	48.8	612	2 A13493	oligopeptide-bind
6	40	47.6	115	2 F81358	probable periplasm
7	40	47.6	311	2 C23701	olfactory receptor
8	40	47.6	1235	2 T17457	SARA protein - Afr
9	39.5	47.0	917	2 T05430	hypothetical prote
10	39	46.4	176	2 C86824	hypothetical prote
11	39	46.4	262	2 T49066	hypothetical prote
12	39	46.4	288	2 B98278	hypothetical prote
13	39	46.4	288	2 A13005	conserved hypothet
14	39	46.4	334	2 A70101	hypothetical prote
15	39	46.4	360	2 T15639	hypothetical prote
16	39	46.4	603	2 T40528	palmitoyl-protein
17	39	46.4	659	2 F72568	probable acylamino
18	39	46.4	799	2 B71478	probable cell divi
19	39	46.4	1109	2 B70127	DNA-directed RNA p
20	39	46.4	1227	2 T48028	hypothetical prote
21	39	46.4	1802	2 S69703	HKAI protein precu
22	38.5	45.8	400	2 A46297	beta-1,6-N-acetyl
23	38.5	45.8	699	2 T16109	hypothetical prote
24	38	45.2	135	2 PNO500	G protein-coupled
25	38	45.2	294	2 B69445	conserved hypothet
26	38	45.2	332	2 H84129	sugar ABC transpor
27	38	45.2	510	1 S15620	LI protein - human
28	38	45.2	672	2 E90294	hypothetical prote
29	38	45.2	899	2 G71453	hypothetical prote

30	38	45.2	1038	2 S52522	hypothetical prote
31	38	45.2	1517	2 T38912	hypothetical integ
32	37.5	44.6	119	2 AH3459	hypothetical prote
33	37	44.0	72	2 AB2528	hypothetical prote
34	37	44.0	76	2 AH2120	hypothetical prote
35	37	44.0	174	2 F97114	uncharacterized co
36	37	44.0	291	2 S28299	hypothetical prote
37	37	44.0	307	2 T34143	hypothetical prote
38	37	44.0	327	2 G83921	hypothetical prote
39	37	44.0	334	2 E75153	glyceraledehyde 3-p
40	37	44.0	370	2 S52699	hypothetical prote
41	37	44.0	377	2 AB0087	probable flagellar
42	37	44.0	433	2 AD1164	H+-transporting AT
43	37	44.0	433	2 AD1523	UDP-N-acetylmuramo
44	37	44.0	452	2 TC6561	nicotinic acetylch
45	37	44.0	506	1 ACRYG1	

ALIGNMENTS

RESULT 1
G86279
Fla117.27 protein - Arabidopsis thaliana
C:Species: Arabidopsis thaliana (mouse-ear cress)
C:Date: 02-Mar-2001 #sequence_revision 02-Mar-2001 #text_change 09-Jul-2004
C:Accession: G86279
R:Theologos, A.; Becker, J.R.; Palm, C.J.; Federpiet, N.A.; Kaul, S.; White, O.; Alonso, J.; Chung, M.K.; Conn, L.; Conway, A.B.; Conway, A.R.; Creasy, T.H.; Dewart, K.; Jensen, N.F.; Hughes, B.; Hulzar, L.
Nature 408, 816-820, 2000
A:Authors: Hunter, J.L.; Jenkins, J.; Johnson-Hopson, C.; Khan, S.; Khaykin, E.; Kim, C.; Li, J.H.; Li, Y.; Lin, X.; Liu, S.X.; Liu, Z.A.; Luo, J.S.; Maiti, R.; Marziani, R.; Rizzo, M.; Rooney, T.; Rowley, D.; Sakano, H.
A:Authors: Salzberg, S.L.; Schwartz, J.R.; Shinn, P.; Southwick, A.M.; Sun, H.; Tallon, K.; Wu, D.; Yu, G.; Fraser, C.M.; Venter, J.C.; Davis, R.W.
A>Title: Sequence and analysis of chromosome 1 of the plant Arabidopsis.
A:Reference number: A86141; MUID:21016719; PMID:11130712
A:Accession: G86279
A:Status: preliminary
A:Status: preliminary
A:Molecule type: DNA
A:Residues: 1-206 <STO>
A:Cross-references: UNIPROT:Q9M9R4; UNIPARC:UPI00000A0A22; GB:AE005172; NID:97262692; PI:Genetics:
A:Map position: 1
Query Match
Best Local Similarity 53.6%; Score 45; DB 2; Length 206;
Matches 10; Conservative 0; Mismatches 6; Indels 0; Gaps 0;
QY 1 VYVVKTSIKIPSSHNL 16
DB 142 VYFVATSPFNPSYHRL 157
RESULT 2
B70441
ribose-phosphate diphosphokinase (EC 2.7.6.1) - Aquifex aeolicus
N:Alternate names: phosphoribosylpyrophosphate synthetase
C:Species: Aquifex aeolicus
C:Date: 08-May-1998 #sequence_revision 08-May-1998 #text_change 09-Jul-2004
C:Accession: B70441
R:Decker, G.; Warren, P.V.; Gaasterland, T.; Young, W.G.; Lenox, A.L.; Graham, D.E.; V.
Nature 392, 353-358, 1998
A>Title: The complete genome of the hyperthermophilic bacterium Aquifex aeolicus.
A:Reference number: A70300; MUID:98196666; PMID:9537320
A:Status: preliminary; nucleic acid sequence not shown; translation not shown
A:Molecule type: DNA
A:Residues: 1-311 <AOF>
A:Cross-references: UNIPROT:Q67556; UNIPARC:UPI000005668B; GB:AE000748; NID:92983960; PI:Experimental source: strain VFS

GenCore version 5.1.6
Copyright (c) 1993 - 2005 CompuGen Ltd

OM protein - protein search, using sw model

Run on: December 21, 2005, 12:35:06 ; Search time 11.7049 Seconds
(without alignments)
1024.696 Million cell updates/sec

Title:	US-09-211-297-34
Perfect score:	84
Sequence:	1 VYVVKTSIKIPSSHNL 17

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

```
Searched:      2166443 begs, 705528306 residues
Total number of hits satisfying chosen parameters: 2166443
```

```
Minimum DB seq length: 0
Maximum DB seq length: 2000000000
```

```
Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries
```

```
Database :      un1prot_05.80:*
            1: un1prot_sprot:*
            2: un1prot_trembl:*
```

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed and is derived by analysis of the total score distribution.

SUMMARIES

Result	No.	Score	Query Match	Length	ID	Description
1	84	100.0	316	1	TNFI1_MOUSE	O35235 m tumor nec
2	84	100.0	318	1	TNFI1_RAT	O9eeez r tumor nec
3	74	88.1	244	2	O54A98_HUMAN	O54A98 homo sapien
4	74	88.1	317	1	TNFI1_HUMAN	O14788 h tumor nec
5	74	88.1	317	2	O5T9Y4_HUMAN	O5T9Y4 homo sapien
6	47	56.0	378	2	O5L899_BACIFR	O5L899 bacteroides
7	47	56.0	378	2	O64NJ9_BACFR	O64NJ9 bacteroides
8	45	53.6	206	2	O9M9R4_ARATH	O9m9r4 arabidopsis
9	45	53.6	312	2	O8VGJ2_MOUSE	O8vgj2 mus musculi
10	45	53.6	315	2	O7TRH2_MOUSE	O7trh2 mus musculi
11	45	53.6	315	2	O8VFU3_MOUSE	O8vfu3 mus musculi
12	45	53.6	315	2	O8VFU4_MOUSE	O8vf4 mus musculi
13	45	53.6	320	2	O8VFP2_MOUSE	O8vfp2 mus musculi
14	44.5	52.0	311	1	KP8S_AQUAE	O67556 aquifex aeo
15	44	52.4	311	2	O8VGC2_MOUSE	O8vgc2 mus musculi
16	44	52.4	406	2	O9LKAZ_ARATH	O9lkaz arabidopsis
17	44	52.4	420	2	O8LP85_ARATH	O8lp85 arabidopsis
18	44	52.4	504	1	ACHE_XENLA	P49580 xenopus lae
19	44	52.4	727	2	O9WF9F_CHICK	O9wf9f gallus galli
20	43	51.2	192	2	O6VZE6_CNPV	O6vze6 canarypox v
21	43	51.2	232	1	GSSCL_ECOLI	P53518 escherichia
22	43	51.2	350	2	O923H4_MOUSE	O923h4 mus musculi
23	43	51.2	377	1	YDA5_SCHRO	O10347 schizosacch
24	42	50.0	125	1	ATG8_PICPA	O8njf4 pictia past
25	42	50.0	176	2	O9K571_LACLC	O9k571 lactococcus
26	42	50.0	205	2	O8NA88_HUMAN	O8na88 homo sapien
27	42	50.0	217	2	O6QA70_HUMAN	O6qa70 homo sapien
28	42	50.0	225	2	O8AGU1_HUMAN	O8agu1 homo sapien
29	42	50.0	288	2	O6W061_MOUSE	O6w061 mus musculi
30	42	50.0	310	2	O8VFD8_MOUSE	O8vfd8 mus musculi
31	42	50.0	312	2	O8VFB8_MOUSE	O8vfb8 mus musculi

32	42	50.0	314	1	ORP24_HUMAN	ORP24	home sapien
33	42	50.0	314	2	ORP14_HUMAN	ORP14	home sapien
34	42	50.0	336	2	ORF08_CANCA	ORF08	candida gla
35	42	50.0	485	2	OS9WH5_CANAL	OS9WH5	candida alb
36	42	50.0	505	2	OS63H5_GCHON	OS63H5	hynops mono
37	42	50.0	530	2	OR157_PLAF7	OR157	plasmodium
38	42	50.0	778	1	DACT1_MOUSE	DACT1	mus musculum
39	42	50.0	836	1	DACT1_HUMAN	DACT1	mus sapien
40	42	50.0	877	2	OSCTV9_CRYPV	OSCTV9	cryptospori
41	42	50.0	897	2	OSCOMP0_CRYHO	OSCOMP0	cryptospori
42	42	50.0	992	1	ANR18_HUMAN	ANR18	home sapien
43	42	50.0	992	2	Q5SY86_HUMAN	Q5SY86	home sapien
44	42	50.0	1072	2	Q4WRN9_ASFPU	Q4WRN9	aspergillus
45	42	50.0	1776	2	Q7R2L9_GIALA	Q7R2L9	giardia lam

ALIGNMENTS

ID	TFNFI1_MOUSE	STANDARD	PRT: 316 AA.
AC	035235	Q35306; Q9JUK8; Q9JUK9; Q9R1Y0;	
DT	16-Oct-2001	(Rel. 40, Created)	
DT	16-Oct-2001	(Rel. 40, Last sequence update)	
DT	13-Sep-2005	(Rel. 48, Last annotation update)	
DE	Tumor necrosis factor ligand superfamily member 11 (Receptor activator		
DE	of nuclear factor kappa B ligand) (RANKL) (TNF-related activation-		
DE	induced cytokine) (TRANCE) (Osteoprotegerin ligand) (OPG) (Osteoclast		
DE	differentiation factor) (ODF) (Contains: Tumor necrosis factor ligand		
DE	superfamily member 11, membrane form; Tumor necrosis factor ligand		
DE	superfamily member 11, soluble form).		
GN	Name=Trnfsf11; Synonyms=Opgl; Rankl; Trance;		
OS	Mus musculus (Mouse).		
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;		
OC	Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;		
OC	Muridea; Muridae; Murinae; Mus.		
OX	NCBI_TaxID=10090;		
RN	[1]		
RP	NUCLEOTIDE SEQUENCE (ISOFORM 1).		
RC	TISSUE=Hydrionema;		
RX	MEDLINE=97460112; PubMed=9312132; DOI=10.1074/jbc.272.40.25190;		
RX	Wong B. R., Ruo J., Arron J., Robinson E., Orlinick Y., Chao M., Y.,		
RA	Kalachikov S., Cayani E., Bartlett F.S. III, Frankel W.N., Lee S.Y.,		
RA	Choi Y.;		
RT	"TRANCE is a novel ligand of the tumor necrosis factor receptor family		
RT	that activates C-Jun N-terminal kinase in T cells."		
RL	J. Biol. Chem. 272:25190-25194(1997).		
RN	[2]		
RP	NUCLEOTIDE SEQUENCE (ISOFORM 1).		
RC	TISSUE=Thymic Lymphoma;		
RX	MEDLINE=96032977; PubMed=9367155; DOI=10.1038/36593;		
RA	Anderson D.M., Maraskovsky E., Billingsley W.L., Dougal W.C.,		
RA	Tometsko M.E., Roux E.R., Teepe M.C., Dubose R.F., Cosman D.,		
RA	Galibert L.;		
RT	"A homologue of the TNF receptor and its ligand enhance T-cell growth		
RT	and dendritic-cell function."		
RL	Nature 390:175-179(1997).		
RN	[3]		
RP	NUCLEOTIDE SEQUENCE (ISOFORM 1).		
RC	TISSUE=Bone marrow;		
RX	MEDLINE=96227661; PubMed=9566710; DOI=10.1016/S0092-8674(00)81569-X;		
RA	Lacey D.L., Timms E., Tan H.-L., Kelley M.J., Dunstan C.R.,		
RA	Burgess T., Elliott R., Colombero A., Elliott G., Scully S., Hu H.,		
RA	Sullivan J., Hawkins N., Davy E., Capparello C., Eli A., Qian Y.-X.,		
RA	Kaufman S., Sarsol I., Shalhoub V., Senaldi G., Guo J., Delaney J.,		
RA	Boyle W.J.;		
RT	"Osteoprotegerin ligand is a cytokine that regulates osteoclast		
RT	differentiation and activation"		
RL	Cell 93:165-176(1998).		
RN	[4]		
RP	NUCLEOTIDE SEQUENCE (ISOFORM 1).		
RC	TISSUE=Bone marrow stroma;		

RX MEDLINE=98188248; PubMed=9520411; DOI=10.1073/pnas.95.7.3597;
 RA Yasuda H., Shima N., Nakagawa N., Yamaguchi K., Kinoshita M., Tsuda E.,
 RA Mochizuki S.-I., Tomoyasu A., Yano K., Soto M., Murakami A.,
 RA Morinaga T., Higashio K., Udagawa N., Takahashi N., Suda T.;
 RT "Osteoclast differentiation factor is a ligand for
 RT osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical
 RT to TRANCE/RANKL.";
 RL Proc. Natl. Acad. Sci. U.S.A. 95:3597-3602(1998).
 RN [5]
 RP NUCLEOTIDE SEQUENCE (ISOFORM 1).
 RC STRAIN=129;
 RX MEDLINE=99214075; PubMed=10196481; DOI=10.1016/S0378-1119(99)00025-6;
 RA Kodaira K., Kodaira K., Mizuno A., Yasuda H., Shima N., Murakami A.,
 RA Ueda M., Higashio K.;
 RT "Cloning and characterization of the gene encoding mouse osteoclast
 RT differentiation factor.";
 RL Gene 230:121-127(1999).
 RN [6]
 RP NUCLEOTIDE SEQUENCE (ISOFORMS 1; 2 AND 3).
 RX MEDLINE=21150053; PubMed=11250921; DOI=10.1210/en.142.4.1419;
 RA Ikeda T., Kasei M., Utsuyama M., Hirokawa K.;
 RT "Determination of three isoforms of the receptor activator of nuclear
 RT factor-kappaB ligand and their differential expression in bone and
 RT thymus.";
 RL Endocrinology 142:1419-1426(2001).
 RN [7]
 RP PROTEIN SEQUENCE OF 139-147, PROCESSING, AND N-GLYCOSYLATION
 RX MEDLINE=99240759; PubMed=10224132; DOI=10.1074/jbc.274.19.13613;
 RA Lum L., Wong B.R., Josien R., Becherer J.D., Erdjument-Bromage H.,
 RA Schloendorff J., Tempst P., Choi Y., Blobel C.P.;
 RT "Evidence for a role of a tumor necrosis factor-alpha (TNF-alpha)-
 RT converting enzyme-like protease in shedding of TRANCE, a TNF family
 RT member involved in osteoclastogenesis and dendritic cell survival.";
 RL J. Biol. Chem. 274:13613-13618(1999).
 RN [8]
 RP X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 158-316.
 RX MEDLINE=21464816; PubMed=11581298;
 RA Lam J., Nelson C.A., Ross F.P., Teitelbaum S.L., Fremont D.H.;
 RT "Crystal structure of the TRANCE/RANKL cytokine reveals determinants
 RT of receptor-ligand specificity.";
 RL J. Clin. Invest. 108:971-979(2001).
 RN [9]
 RP X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 137-316.
 RX MEDLINE=21839021; PubMed=11733492; DOI=10.1074/jbc.M106525200;
 RA Ito S., Wakabayashi K., Ubukata O., Hayashi S., Okada F., Hata T.;
 RT "Crystal structure of the extracellular domain of mouse RANK ligand at
 RT 2.2-A resolution.";
 RL J. Biol. Chem. 277:6631-6636(2002).
 CC -1- FUNCTION: Cytokine that binds to TNFRSF1B/OPG and to
 CC TNFRSF1A/RANK. Osteoclast differentiation and activation factor.
 CC Augments the ability of dendritic cells to stimulate naive T-cell
 CC proliferation. May be an important regulator of interactions
 CC between T cells and dendritic cells and may play a role in the
 CC regulation of the T cell-dependent immune response. May also play
 CC an important role in enhanced bone-resorption in humoral
 CC hypercalcaemia of malignancy.
 CC -1- SUBUNIT: Homotrimer.
 CC -1- SUBCELLULAR LOCATION: Type II membrane protein and secreted
 CC (isoforms 1 and 2); Cytoplasmic (isoform 3).
 CC -1- ALTERNATIVE PRODUCTS:
 CC Event=Alternative splicing; Named isoforms=3;
 CC Name=1;
 CC IsoId=O35235-1; Sequence=Displayed;
 CC Name=2;
 CC IsoId=O35235-2; Sequence=VSP_006449;
 CC Name=3;
 CC IsoId=O35235-3; Sequence=VSP_006448;
 CC -1- TISSUE SPECIFICITY: Highly expressed in thymus and lymph nodes,
 CC but not in nonlymphoid tissues and is abundantly expressed in T
 CC cells but not in B cells. A high level expression is also seen in
 CC the trabecular bone and lung.
 CC -1- PTM: N-glycosylated.
 CC -1- PMW: The soluble form of isoform 1 derives from the membrane form

CC by proteolytic processing. The cleavage may be catalyzed by
 CC ADAM17. A further shorter soluble form was observed.
 CC -1- DISEASE: Deficiency in Tnfrsf1 results in failure to form lobulo-
 CC alveolar mammary structures during pregnancy, resulting in death
 CC of newborns. "Ranke-deficient mice show severe osteopetrosis, with
 CC no osteoclasts, marrow spaces, or tooth eruption, and exhibit
 CC profound growth retardation at several skeletal sites, including
 CC the limbs, skull, and vertebrae and have marked chondroplasia,
 CC with thick, irregular growth plates and a relative increase in
 CC hypertrophic chondrocytes.
 CC -1- SIMILARITY: Belongs to the tumor necrosis factor family.
 CC -----
 CC This Swiss-Prot entry is copyrighted. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use as long as its content is in no way modified and this statement is not
 CC removed.
 CC -----
 DR EMBL; AF013170; AAC71061.1; -; mRNA.
 DR EMBL; AF019048; AAB86812.1; -; mRNA.
 DR EMBL; AF053713; AAC40113.1; -; mRNA.
 DR EMBL; AB008426; BAA25425.1; -; mRNA.
 DR EMBL; AB022039; BAA36970.1; -; Genomic_DNA.
 DR EMBL; AB032771; BAA97257.1; -; mRNA.
 DR EMBL; AB032772; BAA97258.1; -; mRNA.
 DR EMBL; AB036798; BAA97259.1; -; mRNA.
 DR PDB; 1J0A; X-ray; A/B/C=157-316.
 DR PDB; 1J7Z; X-ray; X/Y/Z=156-316.
 DR EMBL; ENSMUSG0000022015; Mus musculus.
 DR MG1; MG1.1100089; Tnf5f11.
 DR GO; GO:0016021; C:integral to membrane; TAS.
 DR GO; GO:0005515; F:protein binding; IPI.
 DR GO; GO:0045453; P:bone resorption; IDA.
 DR GO; GO:0007515; P:lymph gland development; TAS.
 DR GO; GO:0009887; P:organogenesis; IMP.
 DR GO; GO:0001503; P:ossification; IMP.
 DR GO; GO:0045672; P:positive regulation of osteoclast different. . .; IDA.
 DR GO; GO:0051260; P:protein homooligomerization; IDA.
 DR InterPro; IPR006052; TNF family.
 DR InterPro; IPR003636; TNF_subf.
 DR Pfam; PF00229; TNF_1.
 DR ProDom; PD002012; TNF_subf; 1.
 DR SMART; SM00207; TNF_1.
 DR PROSITE; PS00251; TNF_1; FALSE_NEG.
 DR PROSITE; PSS0049; TNF_2; 1.
 KW 3D-structure; Alternative splicing; Cytokine; Developmental protein;
 KW Differentiation; Direct protein sequencing; Glycoprotein; Receptor;
 KW Signal-anchor; Transmembrane.
 FT CHAIN 1 316
 FT CHAIN 139 316
 FT TOPO_DOM 1 48
 FT TRANSMEM 49 69
 FT TOPO_DOM 70 316
 FT SITE 138 139
 FT CARBOHYD 197 197
 FT CARBOHYD 262 262
 FT VARSPPLIC 1 117
 FT VARSPPLIC 14 44
 FT CONFLICT 99 99
 FT CONFLICT 141 143
 FT STRAND 164 169
 FT TURN 171 172
 FT STRAND 181 182
 FT STRAND 186 187
 FT TURN 191 192
 FT STRAND 194 196
 FT STRAND 198 201
 /FTId=VSP_006449.
 G -> D (in Ref. 2).
 Missing (in Ref. 5).
 /FTId=VSP_006448.
 SSEEKSGRGPVHEGPHAPAPAPAPPA -> TP (in
 isoform 2).
 /FTId=VSP_006449.
 G -> D (in Ref. 2).
 Missing (in Ref. 5).

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: December 21, 2005, 12:35:06 ; Search time 18.5902 Seconds
(without alignments)
1024.696 Million cell updates/sec

Title: US-09-211-297-32

Perfect score: 148
Sequence: 1 NAASIPGSHKVTLSWYHGRGMAKIS 27

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 2166443 seqs, 705528306 residues
Total number of hits satisfying chosen parameters: 2166443

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Uniprot_05.80:*
1: uniprot_sprot:*
2: uniprot_trembl:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result LNo.	Score	Query Match Length	ID	Description
1	148	100.0	316 1 TNF11_MOUSE	035235 m tumor nec
2	140	94.6	318 1 TNF11_RAT	096922 r tumor nec
3	136	91.9	244 2 054A98_HUMAN	054A98 homo sapien
4	136	91.9	317 1 TNF11_HUMAN	014788 h tumor nec
5	136	91.9	317 2 0579Y4_HUMAN	0579Y4 homo sapien
6	88	59.5	117 2 05X1H0_RABIT	05X1H0 oryctolagus
7	76	51.4	95 2 06UWL7_HUMAN	06UWL7 homo sapien
8	76	51.4	95 2 06UWL7_HUMAN	06UWL7 homo sapien
9	61.5	41.6	157 2 09C4K2_9EURY	09C4K2 uncultured
10	59	39.9	456 1 MNTM_BRUCE	09C4K2 uncultured
11	59	39.9	456 1 MNTM_BRUCE	09C4K2 uncultured
12	59	39.9	456 1 MNTM_BRUCE	09C4K2 uncultured
13	58.5	39.5	157 2 09C4G1_9EURY	09C4G1 uncultured
14	58.5	39.5	157 2 09C4H5_9EURY	09C4H5 uncultured
15	58.5	39.5	157 2 09C4H7_9EURY	09C4H7 uncultured
16	58.5	39.5	157 2 09C4I3_9EURY	09C4I3 uncultured
17	58.5	39.5	157 2 09C4J1_9EURY	09C4J1 uncultured
18	58.5	39.5	163 2 07ZAB6_9EURY	07ZAB6 uncultured
19	58	39.2	371 2 08QOC2_METWA	08QOC2 methanobact
20	57	38.5	255 2 041VP8_AZOVI	041VP8 azotobacter
21	56.5	38.2	157 2 09C4G6_9EURY	09C4G6 uncultured
22	56.5	38.2	157 2 09C4H8_9EURY	09C4H8 uncultured
23	56.5	38.2	162 2 06SEI7_9EURY	06SEI7 uncultured
24	56.5	38.2	211 2 07SNC5_9ARCH	07SNC5 uncultured
25	56.5	38.2	224 2 06VVF0_9ARCH	06VVF0 uncultured
26	56.5	38.2	235 2 06VVF2_9ARCH	06VVF2 uncultured
27	56.5	38.2	235 2 06VVF3_9ARCH	06VVF3 uncultured
28	56.5	38.2	235 2 06VVF5_9ARCH	06VVF5 uncultured
29	56.5	38.2	235 2 06VVF8_9ARCH	06VVF8 uncultured
30	56.5	38.2	235 2 05EGK0_9EURY	05EGK0 uncultured
31	56.5	38.2	254 2 05EGK6_9EURY	05EGK6 uncultured

32	56.5	38.2	254 2	05EGK5_9EURY	05EGK5 uncultured
33	56.5	38.2	254 2	05EGJ9_9EURY	05EGJ9 uncultured
34	56.5	38.2	561 2	064CT0_9ARCH	064CT0 uncultured
35	56	37.8	334 2	07NRU9_CHRYO	07NRU9 chromobacte
36	56	37.8	756 2	041ZG3_AZOVI	041ZG3 azotobacter
37	55.5	37.5	162 2	06J1Z3_9EURY	06J1Z3 uncultured
38	55.5	37.5	224 2	06VVE9_9ARCH	06VVE9 uncultured
39	55.5	37.5	254 2	05EGJ8_9EURY	05EGJ8 uncultured
40	55.5	37.5	254 2	05EGJ6_9EURY	05EGJ6 uncultured
41	55.5	37.5	561 2	0648Y3_9ARCH	0648Y3 uncultured
42	55.5	37.5	561 2	06VUA1_9ARCH	06VUA1 uncultured
43	55	37.2	606 2	04TR89_9SPHN	04TR89 erythrobact
44	54.5	36.8	156 2	06ZX88_9EURY	06ZX88 uncultured
45	54.5	36.8	157 2	09C4H0_9EURY	09C4H0 uncultured

ALIGNMENTS

RESULT 1
TNF11_MOUSE STANDARD; PRT; 316 AA.
AC 035235; 035306; 09JYK8; 09JYK9; 09R1Y0;
DT 16-OCT-2001 (Rel. 40, Created)
DT 16-OCT-2001 (Rel. 40, Last sequence update)
DT 13-SEP-2005 (Rel. 48, Last annotation update)
DE Tumor necrosis factor ligand superfamily member 11 (Receptor activator
DE of nuclear factor kappa B ligand) (RANKL) (TNF-related activation-
DE induced cytokine) (TRANCE) (Osteoprotegerin ligand) (OPG) (Osteoclast
DE differentiation factor) (ODF) [Contains: Tumor necrosis factor ligand
DE superfamily member 11, membrane form; Tumor necrosis factor ligand
DE superfamily member 11, soluble form]
GN Name=TNF11; Synonyms=opgl, Rankl, Trance;
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC Muridae; Muridae; Murinae; Mus.
OK NCBI_TaxID=10090;
RN [1]
RP NUCLEOTIDE SEQUENCE (ISOFORM 1).
RC TISSUE=Hybridoma;
RX MEDLINE=97460112; PubMed=9312132; DOI=10.1074/jbc.272.40.25190;
RA Wong B.R., Rho J., Arron J., Robinson E., Orlinick J., Chao M.,
RA Kalachikov S., Cayani E., Bartlett F.S. III, Frankel W.N., Lee S.Y.,
RA Choi Y.,
RA "TRANCE is a novel ligand of the tumor necrosis factor receptor family
RA that activates c-Jun N-terminal kinase in T cells.";
RA J. Biol. Chem. 272:25190-25194(1997).
RN [2]
RP NUCLEOTIDE SEQUENCE (ISOFORM 1).
RC TISSUE=Thymic lymphoma;
RX MEDLINE=98032977; PubMed=9367155; DOI=10.1038/36593;
RA Anderson D.M., Maraskovsky E., Billingsley W.L., Dougall W.C.,
RA Tometsko M.E., Roux E.R., Teepe M.C., Dubose R.F., Cosman D.,
RA Galibert L.,
RA "A homologue of the TNF receptor and its ligand enhance T-cell growth
RA and dendritic-cell function.";
RA Nature 390:175-179(1997).
RN [3]
RP NUCLEOTIDE SEQUENCE (ISOFORM 1).
RC TISSUE=Bone marrow;
RX MEDLINE=98227661; PubMed=9568710; DOI=10.1016/S0092-8674(00)81569-X;
RA Lacey D.L., Timms E., Tan H.-L., Kelley M.J., Dunstan C.R.,
RA Burgess T., Elliott R., Colombero A., Elliott G., Scully S., Hu H.,
RA Sullivan J., Hawkins N., Davy E., Capparelli C., Eli A., Qian Y.-X.,
RA Kaufman S., Sarosi I., Shalhoub V., Senaldi G., Guo J., Delaney J.,
RA Boyle W.J.,
RA "Osteoprotegerin ligand is a cytokine that regulates osteoclast
RA differentiation and activation.";
RA Cell 93:165-176(1998).
RN [4]
RP NUCLEOTIDE SEQUENCE (ISOFORM 1).
RC TISSUE=Bone marrow stroma;

RX MEDLINE=98188248; PubMed=9520411; DOI=10.1073/pnas.95.7.3597;
 RA Yasuda H., Shima N., Nakagawa N., Yamaguchi K., Kinosaki M., Tsuda E.,
 RA Mochizuki S.-I., Tomoyasu A., Yano K., Soto M., Murakami A.,
 RA Morinaga T., Higashio K., Udagawa N., Takahashi N., Suda T.;
 RT Osteoclast differentiation factor is a ligand for
 RT osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical
 RT to TRANCE/RANKL.";
 RL Proc. Natl. Acad. Sci. U.S.A. 95:3597-3602(1998).
 RN [5]
 RP NUCLEOTIDE SEQUENCE (ISOFORM 1).
 RC STRAIN=129;
 RX MEDLINE=99214075; PubMed=10196481; DOI=10.1016/S0378-1119(99)00025-6;
 RA Kodaira K., Kodaira K., Mizuno A., Yasuda H., Shima N., Murakami A.,
 RA Ueda M., Higashio K.;
 RT Cloning and characterization of the gene encoding mouse osteoclast
 RT differentiation factor.";
 RL Gene 230:121-127(1999).
 RN [6]
 RP NUCLEOTIDE SEQUENCE (ISOFORMS 1; 2 AND 3).
 RX MEDLINE=21150053; PubMed=11250923; DOI=10.1210/en.142.4.1419;
 RA Ikeda T., Kasei M., Utsuyama M., Hirokawa K.;
 RT Determination of three isoforms of the receptor activator of nuclear
 RT factor-kappaB ligand and their differential expression in bone and
 RT thymus.";
 RL Endocrinology 142:1419-1426(2001).
 RN [7]
 RP PROTEIN SEQUENCE OF 139-147, PROCESSING, AND N-GLYCOSYLATION.
 RX MEDLINE=99240759; PubMed=1024132; DOI=10.1074/jbc.274.19.1613;
 RA Lum L., Wong B.R., Josien R., Becherer J.D., Erdjument-Bromage H.,
 RA Schenck J., Tempst P., Choi Y., Blobel C.P.;
 RT Evidence for a role of a tumor necrosis factor-alpha (TNF-alpha)-
 RT converting enzyme-like protease in shedding of TRANCE, a TNF family
 RT member involved in osteoclastogenesis and dendritic cell survival.";
 RL J. Biol. Chem. 274:13613-13618(1999).
 RN [8]
 RP X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 158-316.
 RX MEDLINE=21464816; PubMed=11581298;
 RA Lam J., Nelson C.A., Ross F.P., Teitelbaum S.L., Fremont D.H.;
 RT Crystal structure of the TRANCE/RANKL cytokine reveals determinants
 RT of receptor-ligand specificity.";
 RL J. Clin. Invest. 108:971-979(2001).
 RN [9]
 RP X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 137-316.
 RX MEDLINE=21839021; PubMed=11733492; DOI=10.1074/jbc.M106525200;
 RA Ito S., Wakabayashi K., Ushikata O., Hayashi S., Okada F., Hata T.;
 RT Crystal structure of the extracellular domain of mouse RANK ligand at
 RT 2.2-A resolution.";
 RL J. Biol. Chem. 277:6631-6636(2002).
 CC -1- FUNCTION: Cytokine that binds to TNFRSF11B/OPG and to
 CC TNFRSF11A/RANK. Osteoclast differentiation and activation factor.
 CC Augments the ability of dendritic cells to stimulate naive T-cell
 CC proliferation. May be an important regulator of interactions
 CC between T cells and dendritic cells and may play a role in the
 CC regulation of the T cell-dependent immune response. May also play
 CC an important role in enhanced bone-resorption in humoral
 CC hypercalcaemia of malignancy.
 CC -1- SUBUNIT: Homotrimer.
 CC -1- SUBCELLULAR LOCATION: Type II membrane protein and secreted
 CC (isoforms 1 and 2); Cytoplasmic (isoform 3).
 CC -1- ALTERNATIVE PRODUCTS:
 CC Event=Alternative splicing; Named isoforms=3;
 CC Name=1;
 CC IsoId=035235-1; Sequence=Displayed;
 CC Name=2;
 CC IsoId=035235-2; Sequence=VSP_006449;
 CC Name=3;
 CC IsoId=035235-3; Sequence=VSP_006448;
 CC -1- TISSUE SPECIFICITY: Highly expressed in thymus and lymph nodes,
 CC but not in nonlymphoid tissues and is abundantly expressed in T
 CC cells but not in B cells. A high level expression is also seen in
 CC the trabecular bone and lung.
 CC -1- PTM: N-glycosylated.
 CC -1- PTM: The soluble form of isoform 1 derives from the membrane form

CC by proteolytic processing. The cleavage may be catalyzed by
 CC ADAM17. A further shorter soluble form was observed.
 CC -1- DISEASE: Deficiency in TNfrsf11 results in failure to form lobulo-
 CC alveolar mammary structures during pregnancy, resulting in death
 CC of newborns. Transc-deficient mice show severe osteopetrosis, with
 CC no osteoclasts, marrow spaces, or tooth eruption, and exhibit
 CC profound growth retardation at several skeletal sites, including
 CC the limbs, skull, and vertebrae and have marked chondrodysplasia,
 CC with thick, irregular growth plates and a relative increase in
 CC hypertrophic chondrocytes.
 CC -1- SIMILARITY: Belongs to the tumor necrosis factor family.
 CC This Swiss-Prot entry is copyrighted. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use as long as its content is in no way modified and this statement is not
 CC removed.
 CC -----
 DR EMBL; AF013170; AAC71061.1; -; mRNA.
 DR EMBL; AF019048; AAB86812.1; -; mRNA.
 DR EMBL; AF053713; AAC40113.1; -; mRNA.
 DR EMBL; AB008426; BAA25425.1; -; mRNA.
 DR EMBL; AB022039; BAA36970.1; -; Genomic_DNA.
 DR EMBL; AB032771; BAA97257.1; -; mRNA.
 DR EMBL; AB032772; BAA97258.1; -; mRNA.
 DR EMBL; AB036798; BAA97259.1; -; mRNA.
 DR PDB; 1IC4; X-ray; A/B/C=157-316.
 DR PDB; 1UT2; X-ray; X/Y/Z=156-316.
 DR Ensemble; ENSMUSG000002015; Mus musculus.
 DR MGI; MGI:1100089; Thgef11.
 DR GO; GO:0016021; C:integral to membrane; TAS.
 DR GO; GO:0005515; F:protein binding; IPI.
 DR GO; GO:0045453; F:bone resorption; IDA.
 DR GO; GO:007515; P:lymph gland development; TAS.
 DR GO; GO:0009687; P:organogenesis; IMP.
 DR GO; GO:0001503; P:osteification; IMP.
 DR GO; GO:0045672; P:positive regulation of osteoclast different. . .; IDA.
 DR GO; GO:0051260; P:protein homooligomerization; IDA.
 DR InterPro; IPR006052; TNF_family.
 DR InterPro; IPR003636; TNF_subf.
 DR Pfam; PF00229; TNF_1.
 DR ProDom; PD002012; TNF_subf; 1.
 DR SMART; SM00207; TNF_1.
 DR PROSITE; PS00251; TNF_1; FALSE_NEG.
 DR PROSITE; PSS0049; TNF_2; 1.
 KW 3D-structure; Alternative splicing; Cytokine; Developmental protein;
 KW Differentiation; Direct protein sequencing; Glycoprotein; Receptor;
 KW Signal-anchor; Transmembrane.
 FT CHAIN 1 316
 FT CHAIN 139 316
 FT TOPO_DOM 1 48
 FT TRANSMEM 49 69
 FT TOPO_DOM 70 316
 FT SITE 138 139
 FT CARBOHYD 197 197
 FT CARBOHYD 262 262
 FT VARSPPLIC 1 117
 FT VARSPPLIC 14 44
 FT CONFLICT 99 99
 FT CONFLICT 141 143
 FT STRAND 164 169
 FT TURN 171 172
 FT STRAND 181 182
 FT STRAND 186 187
 FT TURN 191 192
 FT STRAND 194 196
 FT STRAND 198 201
 /FTId=VSP_006449.
 G -> D (in Ref. 2).
 Missing (in Ref. 5).
 /FTId=VSP_006448.
 SSEEKSGPQVPHRPLHAPSAAPAPPPA -> TP (in
 isoform 2).
 /FTId=VSP_006449.
 G -> D (in Ref. 2).
 Missing (in Ref. 5).

CC modulate binding of OPG binding protein to osteoclast differentiation and
 CC activation receptor (OPAR). The nucleic acid molecule encoding OPG
 CC binding protein can be used to detect OPG binding protein-encoding
 CC sequences, e.g. screening for related sequences, also to produce
 CC transgenic animal models, while complementary sequences are used for
 CC antisense regulation of OPG binding protein expression. Modulators of OPG
 CC binding protein, particularly soluble forms of OPG binding protein or Ab,
 CC are used to treat or prevent bone diseases, e.g. osteoporosis, bone loss
 CC caused by arthritis or metastases, hypercalcaemia, Paget's disease,
 CC periodontal disease, osteoporosis, loosening of prostheses, optionally in
 CC combination with agents that promote bone growth

SO Sequence 27 AA:

Query Match 100.0%; Score 148; DB 2; Length 27;
 Best Local Similarity 100.0%; Pred. No. 7,8e-15;
 Matches 27; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 NAASIPSGSHKVTLSWYHGRGMAKIS 27
 Db 1 NAASIPSGSHKVTLSWYHGRGMAKIS 27

RESULT 2
 AAW83197 standard; peptide; 28 AA.
 AC AAW83197;
 DT 11-FEB-1999 (first entry)
 DE Murine osteoprotegerin binding protein BB' loop-Cys peptide.
 XX
 KM Osteoprotegerin binding protein; OPG binding protein; arthritis;
 KM osteoporosis; osteoclast maturation; bone disease; metastases; ODR;
 KM hypercalcaemia; osteoclast differentiation and activation receptor;
 KM Paget's disease.
 XX
 OS Mus sp.
 XX W09846751-A1.
 PN 22-OCT-1998.
 PD 15-APR-1998; 98WO-US007584.
 PF 16-APR-1997; 97US-00842842.
 PR 23-JUN-1997; 97US-00880855.
 PR 30-MAR-1998; 98US-00052521.
 XX
 PA (AMGE-) AMGEN INC.
 PI Boyle WJ;
 DR WPI; 1998-594578/50.
 XX
 PT Nucleic acid encoding osteoprotegerin binding protein - useful for, e.g.,
 PT treating bone diseases by modulating osteoclast differentiation and for
 PT diagnosis.
 PT
 PS Example 11; Page 55; 47pp; English.
 XX
 CC The present sequence represents peptide from murine osteoprotegerin (OPG)
 CC binding protein. Host cells transfected with vectors containing nucleic
 CC acid molecules encoding OPG binding protein are used to produce
 CC recombinant OPG binding protein. OPG binding protein is used in binding
 CC assays to determine osteoprotegerin (OG) in biological samples; to screen
 CC for specific binding agents (particularly agonists and antagonists,
 CC including intracellular proteins); to raise Ab (useful in immunoassays
 CC for detection of OPG binding protein) and to identify compounds that
 CC modulate binding of OPG binding protein to osteoclast differentiation and
 CC activation receptor (OPAR). The nucleic acid molecule encoding OPG
 CC binding protein can be used to detect OPG binding protein-encoding

CC sequences, e.g. screening for related sequences, also to produce
 CC transgenic animal models, while complementary sequences are used for
 CC antisense regulation of OPG binding protein expression. Modulators of OPG
 CC binding protein, particularly soluble forms of OPG binding protein or Ab,
 CC are used to treat or prevent bone diseases, e.g. osteoporosis, bone loss
 CC caused by arthritis or metastases, hypercalcaemia, Paget's disease,
 CC periodontal disease, osteoporosis, loosening of prostheses, optionally in
 CC combination with agents that promote bone growth

SO Sequence 28 AA:

Query Match 100.0%; Score 148; DB 2; Length 28;
 Best Local Similarity 100.0%; Pred. No. 8.1e-16;
 Matches 27; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 NAASIPSGSHKVTLSWYHGRGMAKIS 27
 Db 1 NAASIPSGSHKVTLSWYHGRGMAKIS 27

RESULT 3
 ABR39854 standard; protein; 155 AA.
 AC ABR39854;
 DT 11-AUG-2003 (first entry)
 DE RANK ligand (RANKL) protein fragment.
 XX
 KM RANK; receptor activator of necrosis factor KB; RANK ligand; RANKL;
 KM mouse.
 XX
 OS Mus sp.
 XX W02003014077-A2.
 PN 20-FEB-2003.
 PD 09-AUG-2002; 2002WO-US025287.
 PF 09-AUG-2001; 2001US-0311163P.
 PR 22-MAR-2002; 2002US-00105057.
 XX
 PA (BARN-) BARNES-JEWISH HOSPITAL.
 PI Lam J, Ross FP, Teitelbaum SL, Nelson CA, Fremont DH;
 DR WPI; 2003-256526/25.
 XX
 PT Composition for identifying a compound with Receptor Activator of
 PT Necrosis Factor KB, RANK modulating activity and for identifying RANK or
 PT osteoprotegerin modulating compound, has a protein complex in crystalline
 PT form.
 PT
 PS Disclosure; Fig 3; 66pp; English.
 XX
 CC The invention relates to a composition (I) comprising a protein complex
 CC in crystalline form, where the complex comprises an amino acid sequence
 CC of a Receptor Activator of Necrosis Factor KB (RANK) ligand (RANKL)
 CC ectodomain. (I) is useful for identifying a compound with RANK modulating
 CC activity, and for identifying a RANK or OPG modulating compound. (I) is
 CC useful to intelligently design mutants that have altered biological
 CC properties and for identifying and/or designing compounds that bind RANK
 CC as an approach towards developing new therapeutic agents. (I) is also
 CC useful to computationally screen small molecule databases for chemical
 CC entities or compounds that can bind in whole, or in part, to RANK or
 CC RANKL. The present sequence represents a murine RANKL protein fragment

SO Sequence 155 AA:

Query Match 100.0%; Score 148; DB 6; Length 155;
 Best Local Similarity 100.0%; Pred. No. 6.6e-15;

GenCore version 5.1.6
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: December 21, 2005, 12:47:51 ; Search time 3.0541 Seconds
(without alignments)
850.612 Million cell updates/sec

Title: US-09-211-297-32

Perfect score: 148
Sequence: 1 NAASIPSGSHKVTLSWYHDRGMAKIS 27

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 283416 seqs, 96216763 residues

Total number of hits satisfying chosen parameters: 283416

Minimum DB seq length: 0
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database :
1: p1r1:*
2: p1r2:*
3: p1r3:*
4: p1r4:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	59	39.9	456	2 AC3323	manganese transpor
2	49	33.1	369	2 C97484	outer membrane pro
3	49	33.1	369	2 AC2702	outer membrane pro
4	49	33.1	417	2 A96610	probable pectinase
5	49	33.1	747	2 F87263	TPR domain protein
6	49	33.1	780	2 G72724	probable penicillin
7	49	33.1	827	1 A36895	endopeptidase Ia (
8	48.5	32.8	199	2 AD2486	hypothetical prote
9	48.5	32.8	570	2 E29525	methyl coenzyme M
10	48	32.4	245	2 B86889	zinc ABC transport
11	48	32.4	452	2 E84186	hypothetical prote
12	48	32.4	831	2 T00323	chitinase (EC 3.2.
13	48	32.4	1888	2 T39009	hypothetical prote
14	47.5	32.1	197	2 B96568	hypothetical prote
15	47.5	32.1	230	2 A96565	hypothetical prote
16	47	31.8	398	2 I49443	gene 284 protein -
17	47	31.8	406	2 AG0548	probable ABC-trans
18	47	31.8	442	2 T50687	proline transport
19	47	31.8	479	2 S42864	protein kinase (EC
20	47	31.8	532	2 D96835	probable glycerol
21	47	31.8	576	2 A53982	capsid protein - E
22	47	31.8	693	2 A41617	dopamine transport
23	47	31.8	1520	2 T30820	carbamoyl-phosphat
24	46.5	31.4	172	2 E96518	protein T286.12 [1
25	46.5	31.4	197	2 A96568	hypothetical prote
26	46.5	31.4	637	2 S01509	NADH dehydrogenas
27	46	31.1	336	2 F84056	hypothetical prote
28	46	31.1	336	2 F95925	probable cell-wall
29	46	31.1	350	2 T32215	hypothetical prote

30	46	31.1	394	1 S77216	hypothetical prote
31	46	31.1	512	2 A54400	protein kinase (EC
32	46	31.1	605	1 O0B83R	BVRF2 (EC-RF3) pro
33	46	31.1	686	2 T15795	hypothetical prote
34	45.5	30.7	263	2 AD0851	secretory protein
35	45.5	30.7	756	2 A13275	phosphoenolpyruvat
36	45	30.4	105	2 T38761	hypothetical prote
37	45	30.4	112	2 E83817	hypothetical prote
38	45	30.4	205	2 A75165	thymidylate kinase
39	45	30.4	278	2 C43670	integral membrane
40	45	30.4	288	2 A05062	probable mbpy prot
41	45	30.4	325	2 S58146	hypothetical prote
42	45	30.4	334	2 T40042	conserved hypotnet
43	45	30.4	345	2 F90194	truncation synthe
44	45	30.4	365	2 A2782	transcription regu
45	45	30.4	365	2 F97561	hypothetical prote

ALIGNMENTS

RESULT 1
AC3323
manganese transport protein mntH [imported] - Brucella melitensis (strain 16M)
C/Species: Brucella melitensis
C/Date: 01-Feb-2002 #sequence_revision 01-Feb-2002 #text_change 09-Jul-2004
C/Accession: AC3323
R/DeiVecchio, V.G.; Kaputral, V.; Redkar, R.J.; Patra, G.; Mujer, C.; Los, T.; Ivanova, .; Mazur, M.; Goldstein, E.; Selkov, E.; Elzer, P.H.; Hagius, S.; O'Callaghan, D.; Leless proc. Natl. Acad. Sci. U.S.A. 99, 443-448, 2002
A/Title: The genome sequence of the facultative intracellular pathogen Brucella melitensis
A/Reference number: AD3252; PMID:11756688
A/Accession: AC3323
A/Molecule type: DNA
A/Status: preliminary
A/Residues: 1-456 <KUR>
A/Cross-references: UNIPROT:O8YI76; UNIPARC:UPI0000057D23; GB:AE008917; PIDN:AAL51750.1;
A/Experimental source: strain 16M
C/Genetics:
A/Gene: BMEI0569
A/Map position: 1
C/Superfamily: natural resistance-associated macrophage protein 1

Query Match 39.9%; Score 59; DB 2; Length 456;
Best Local Similarity 45.8%; Pred. No. 0.94;
Matches 11; Conservative 4; Mismatches 9; Indels 0; Gaps 0;
QY 4 SIPSGSHKVTLSWYHDRGMAKIS 27
DB 6 SCPSGARVETFGWRERGERASWS 29

RESULT 2
C97484
outer membrane protein a2 precursor [imported] - Agrobacterium tumefaciens (strain C58,
C/Species: Agrobacterium tumefaciens
C/Date: 30-Sep-2001 #sequence_revision 30-Sep-2001 #text_change 09-Jul-2004
C/Accession: C97484
R/Goodner, B.; Hinkle, G.; Gattung, S.; Miller, N.; Blanchard, M.; Qurollo, B.; Goldman, A.; Liu, F.; Williams, C.; Allinger, M.; Doughy, D.; Scott, C.; Lappas, C.; Markelz, B.; Science 294, 2333-2328, 2001
A/Title: Genome Sequence of the Plant Pathogen and Biotechnology Agent Agrobacterium tur
A/Reference number: A97359; MUID:21608551; PMID:11743194
A/Accession: C97484
A/Status: preliminary
A/Molecule type: DNA
A/Residues: 1-369 <KUR>
A/Cross-references: UNIPROT:Q8UGL7, UNIPARC:UPI000000D19FA; GB:AE007869; PIDN:AAK86828.1;
C/Genetics:
A/Gene: AGR_C 1878
A/Map position: circular chromosome
Query Match 33.1%; Score 49; DB 2; Length 369;

Best Local Similarity 30.4%; Pred. No. 22;
Matches 7; Conservative 6; Mismatches 10; Indels 0; Gaps 0;

Qy 1 NAASIPSGSHKVTLSWYHNRGM 23

Db 305 NAAGVPTGASALITNDMSNRDAM 327

RESULT 3

outer membrane protein Atu1020 [imported] - Agrobacterium tumefaciens (strain C58, Dupont
C/Species: Agrobacterium tumefaciens
C/Date: 11-Jan-2002 #sequence_revision 11-Jan-2002 #text_change 09-Jul-2004
C/Accession: AC2702
R/wood, D.W.; Setubal, J.C.; Kaul, R.; Minks, D.; Chen, L.; Wood, G.E.; Chen, Y.; Woo, I.
erage, G.; Gillet, W.; Grant, C.; Guenther, D.; Kutyavin, T.; Levy, R.; Li, M.; McClell
; Karp, P.; Romero, P.; Zhang, S.
Science 294, 2317-2323, 2001
A/Authors: Yoo, H.; Tao, Y.; Biddle, P.; Jung, M.; Krespan, W.; Perry, M.; Gordon-Kamm,
ser, E.W.
A/Title: The Genome of the Natural Genetic Engineer Agrobacterium tumefaciens C58.
A/Reference number: AB2577; MUID:21608550; PMID:11743193
A/Accession: AC2702
A/Status: Preliminary
A/Molecule type: DNA
A/Residues: 1-369 <KUR>
A/Cross-references: UNIPROT:O8UGL7; UNIPARC:UPI00000D19FA; GB:AE00668; PIDN:AA142033.1;
A/Experimental source: strain C58 (Dupont)
C/Genetics:
A/Gene: Atu1020
A/Map position: circular chromosome

Query Match 33.1%; Score 49; DB 2; Length 369;
Best Local Similarity 30.4%; Pred. No. 22;
Matches 7; Conservative 6; Mismatches 10; Indels 0; Gaps 0;

Qy 1 NAASIPSGSHKVTLSWYHNRGM 23

Db 305 NAAGVPTGASALITNDMSNRDAM 327

RESULT 4

A96610
probable pectinacetylsterase precursor T8L23.6 [imported] - Arabidopsis thaliana
C/Species: Arabidopsis thaliana (mouse-ear cress)
C/Date: 02-Mar-2001 #sequence_revision 02-Mar-2001 #text_change 09-Jul-2004
C/Accession: A96610
R/Theologis, A.; Ecker, J.R.; Palm, C.J.; Federpiel, N.A.; Kaul, S.; White, O.; Alonso,
Chin, C.W.; Chung, M.K.; Conn, L.; Conway, A.B.; Conway, A.R.; Creasy, T.H.; Dewar, K.;
ansen, N.F.; Hughes, B.; Hulzar, L.
Nature 408, 816-820, 2000
A/Authors: Hunter, J.L.; Jenkins, J.; Johnson-Hopson, C.; Khan, S.; Khaykin, E.; Kim, C.
C.A.; Li, U.H.; Li, Y.; Liu, X.; Liu, S.X.; Liu, Z.A.; Lutos, J.S.; Maiti, R.; Marziani,
Rizzo, M.; Rooney, T.; Rowley, D.; Sakano, H.
A/Authors: Salber, S.L.; Schwartz, J.R.; Shinn, P.; Southwick, A.M.; Sun, H.; Tallon,
ker, M.; Wu, D.; Yu, G.; Fraser, C.M.; Venter, J.C.; Davis, R.W.
A/Title: Sequence and analysis of chromosome 1 of the plant Arabidopsis.
A/Reference number: A96141; MUID:21016719; PMID:11130712
A/Accession: A96610
A/Status: Preliminary
A/Molecule type: DNA
A/Residues: 1-417 <STO>
A/Cross-references: UNIPROT:Q9FVU3; UNIPARC:UPI00000483B1; GB:AE005173; NID:g11055858; F
C/Genetics:
A/Gene: T8L23.6
A/Map position: 1

Query Match 33.1%; Score 49; DB 2; Length 417;
Best Local Similarity 34.6%; Pred. No. 25;
Matches 9; Conservative 6; Mismatches 11; Indels 0; Gaps 0;

Qy 1 NAASIPSGSHKVTLSWYHNRGM 26

Db 1 NAASIPSGSHKVTLSWYHNRGM 26

Db 374 NSPAIKKGIJAVGDWYERGAKL 399

RESULT 5

F87263
TPR domain protein [imported] - Caulobacter crescentus
C/Species: Caulobacter crescentus
C/Date: 20-Apr-2001 #sequence_revision 20-Apr-2001 #text_change 09-Jul-2004
C/Accession: F87263
R/Nierman, W.C.; Feildlyum, T.V.; Paulsen, I.T.; Nelson, K.E.; Eisen, J.; Heidelberg, J.
B.; Laub, M.T.; Deboy, R.T.; Dodson, R.J.; Durkin, A.S.; Gatt, M.L.; Haft, D.H.; Kolon
n, U.; Ermolaeva, M.; White, O.; Salzberg, S.L.; Shapiro, L.; Venter, J.C.; Fraser, C.M.
Proc. Natl. Acad. Sci. U.S.A. 98, 4136-4141, 2001
A/Title: Complete Genome Sequence of Caulobacter crescentus.
A/Reference number: AB7249; MUID:21173698; PMID:11259647
A/Accession: F87263
A/Status: Preliminary
A/Molecule type: DNA
A/Residues: 1-747 <STO>
A/Cross-references: UNIPROT:Q9ABV1; UNIPARC:UPI00000C6F34; GB:AE005673; NID:g13421226; P
C/Genetics:
A/Gene: CC0119

Query Match 33.1%; Score 49; DB 2; Length 747;
Best Local Similarity 43.5%; Pred. No. 46;
Matches 10; Conservative 4; Mismatches 9; Indels 0; Gaps 0;

Qy 1 NAASIPSGSHKVTLSWYHNRGM 23

Db 138 NLAAESQAHATLSPNHELGM 160

RESULT 6

G72724
probable penicillin acylase APE0336 - Aeropyrum pernix (strain K1)
C/Species: Aeropyrum pernix
C/Date: 20-Aug-1999 #sequence_revision 20-Aug-1999 #text_change 09-Jul-2004
C/Accession: G72724
R/Kawarabayashi, Y.; Hino, Y.; Horikawa, H.; Yamazaki, S.; Halkawa, Y.; Jin-no, K.; Takah
awa, H.; Takamiya, M.; Masuda, S.; Funahashi, T.; Tanaka, T.; Kudo, Y.; Yamazaki, J.; Ki
DNA Res. 6, 83-101, 1999
A/Title: Complete genome sequence of an aerobic hyper-thermophilic Crenarchaeon, Aeropyru
A/Reference number: A72450; MUID:9310339; PMID:10382966
A/Accession: G72724
A/Status: Preliminary
A/Molecule type: DNA
A/Residues: 1-780 <KAM>
A/Cross-references: UNIPROT:Q9YFA5; UNIPARC:UPI00000SDAD8; DDBJ:AP000059; NID:g5103911; I
A/Experimental source: strain K1
C/Genetics:
A/Gene: APE0336

Query Match 33.1%; Score 49; DB 2; Length 780;
Best Local Similarity 50.0%; Pred. No. 48;
Matches 10; Conservative 3; Mismatches 7; Indels 0; Gaps 0;

Qy 4 SIPSGSHKVTLSWYHNRGM 23

Db 734 SLPGSGSVPLSSFYDNLVW 753

RESULT 7

A36895
endopeptidase Ia (EC 3.4.21.53) 2 - Myxococcus xanthus
N/Alternate names: ATP-dependent proteinase BspA; ATP-dependent proteinase Iond; ATP-depe
N/Contains: adenosinetriphosphatase (EC 3.6.1.3)
C/Species: Myxococcus xanthus
C/Date: 09-Apr-1999 #sequence_revision 09-Apr-1999 #text_change 09-Jul-2004
C/Accession: A36895; A36894
R/Ito, N.; Inouye, S.; Komano, T.
J. Bacteriol. 175, 4545-4549, 1993
A/Title: The Iond gene is homologous to the lon gene encoding an ATP-dependent protease
A/Reference number: A36895; MUID:93322335; PMID:8331083

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: December 21, 2005, 12:44:31 Search time 4.60328 Seconds
(without alignments)
484.925 Million cell updates/sec

Title: US-09-211-297-32

Perfect score: 148
Sequence: 1 NAASIPGSHKVTLSWYHGRMAKIS 27

Scoring table: BLOSUM62
Gapop 10.0, Gapext 0.5

Searched: 572060 seqs, 82675679 residues

Total number of hits satisfying chosen parameters: 572060

Minimum DB seq length: 0
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database: Issued_Patents_AA:*

1: /cgn2_6/ptodata/1/1aa/5-COMB.pep:.*
2: /cgn2_6/ptodata/1/1aa/6-COMB.pep:.*
3: /cgn2_6/ptodata/1/1aa/H-COMB.pep:.*
4: /cgn2_6/ptodata/1/1aa/RTUS-COMB.pep:.*
5: /cgn2_6/ptodata/1/1aa/RE-COMB.pep:.*
6: /cgn2_6/ptodata/1/1aa/Backfile1.pep:.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	148	100.0	28	2	US-09-052-521C-34
2	148	100.0	77	2	US-09-632-287A-10
3	148	100.0	77	2	US-10-286-696-11
4	148	100.0	173	2	US-09-396-937-10
5	148	100.0	173	2	US-09-396-937-12
6	148	100.0	173	2	US-09-396-937-18
7	148	100.0	173	2	US-09-396-937-20
8	148	100.0	182	2	US-09-396-937-16
9	148	100.0	187	2	US-09-396-937-8
10	148	100.0	188	2	US-09-396-937-14
11	148	100.0	294	2	US-08-996-139-11
12	148	100.0	294	2	US-08-995-659-11
13	148	100.0	294	2	US-09-215-649A-11
14	148	100.0	294	2	US-09-577-780-11
15	148	100.0	294	2	US-09-577-800-11
16	148	100.0	294	2	US-09-466-496-11
17	148	100.0	294	2	US-09-871-856-11
18	148	100.0	294	2	US-09-871-291-11
19	148	100.0	294	2	US-09-877-650-11
20	148	100.0	294	2	US-09-865-363-11
21	148	100.0	294	2	US-09-868-459-11
22	148	100.0	316	1	US-08-942-842-7
23	148	100.0	316	1	US-08-989-362-2
24	148	100.0	316	2	US-09-052-521C-2
25	148	100.0	316	2	US-09-671-658A-2
26	148	100.0	316	2	US-09-396-937-4
27	148	100.0	316	2	US-09-396-937-6

28	148	100.0	316	2	US-09-957-944-8	Sequence 8, Appl
29	136	91.9	77	2	US-09-632-287A-11	Sequence 11, Appl
30	136	91.9	77	2	US-10-286-696-11	Sequence 11, Appl
31	136	91.9	317	2	US-08-996-139-13	Sequence 13, Appl
32	136	91.9	317	2	US-08-995-659-13	Sequence 13, Appl
33	136	91.9	317	2	US-09-215-649A-13	Sequence 13, Appl
34	136	91.9	317	2	US-09-052-521C-4	Sequence 13, Appl
35	136	91.9	317	2	US-09-577-780-13	Sequence 13, Appl
36	136	91.9	317	2	US-09-577-800-13	Sequence 13, Appl
37	136	91.9	317	2	US-09-466-496-13	Sequence 13, Appl
38	136	91.9	317	2	US-09-871-856-13	Sequence 13, Appl
39	136	91.9	317	2	US-09-871-291-13	Sequence 13, Appl
40	136	91.9	317	2	US-09-396-937-2	Sequence 2, Appl
41	136	91.9	317	2	US-09-877-650-13	Sequence 13, Appl
42	136	91.9	317	2	US-09-865-363-13	Sequence 13, Appl
43	136	91.9	317	2	US-09-688-459-13	Sequence 13, Appl
44	136	91.9	317	2	US-09-957-944-6	Sequence 6, Appl
45	135	91.2	27	2	US-09-052-521C-33	Sequence 33, Appl

ALIGNMENTS

RESULT 1
US-09-052-521C-34
Sequence 34, Application US/09052521C
Patent No. 6316408
GENERAL INFORMATION:
APPLICANT: Boyle, William J.
TITLE OF INVENTION: Osteoprotegerin Binding Proteins and Receptors
FILE REFERENCE: A-451Bv
CURRENT APPLICATION NUMBER: US/09/052,521C
PRIOR FILING DATE: 1996-03-30
PRIOR APPLICATION NUMBER: 08/880,855
PRIOR FILING DATE: 1997-06-23
PRIOR APPLICATION NUMBER: 08/842,842
PRIOR FILING DATE: 1997-04-16
NUMBER OF SEQ ID NOS: 40
SOFTWARE: Patentin Ver. 2.1
SEQ ID NO 34
LENGTH: 28
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-09-052-521C-34
Query Match 100.0%, Score 148, DB 2, Length 28;
Best Local Similarity 100.0%, Pred. No. 5.5e-15;
Matches 27; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 NAASIPGSHKVTLSWYHGRMAKIS 27
DB 1 NAASIPGSHKVTLSWYHGRMAKIS 27
RESULT 2
US-09-632-287A-10
Sequence 10, Application US/09632287A
Patent No. 6521422
GENERAL INFORMATION:
APPLICANT: Hsu, Hailing
APPLICANT: Wooden, Scott K
TITLE OF INVENTION: Fm, A No. 6521422e1 Member of the TNF Ligand Supergene Family
FILE REFERENCE: 01017/35650A
CURRENT APPLICATION NUMBER: US/09/632,287A
PRIOR FILING DATE: 2000-08-03
PRIOR APPLICATION NUMBER: US 60/147,294
PRIOR FILING DATE: 1999-08-04
NUMBER OF SEQ ID NOS: 22
SOFTWARE: Patentin Ver. 2.0

SEQ ID NO 10
LENGTH: 77
TYPE: PRT
ORGANISM: Mouse
US-09-632-287A-10

Query Match 100.0%; Score 148; DB 2; Length 77;
Best Local Similarity 100.0%; Pred. No. 1.9e-14;
Matches 27; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1 NAASIPSGSHKVTLSWYHDSGMAKIS 27
|||||
Db 14 NAASIPSGSHKVTLSWYHDSGMAKIS 40

RESULT 3
US-10-286-696-10
Sequence 10, Application US/10286696
Patent No. 6852839
GENERAL INFORMATION:
APPLICANT: Heu, Hailing
APPLICANT: Wooden, Scott K
APPLICANT: Boyle, William J
TITLE OF INVENTION: Fhm, A No. 6852839e1 Member of the TNF Ligand Supergene Family
FILE REFERENCE: 01017/35550A
CURRENT APPLICATION NUMBER: US/10/286,696
CURRENT FILING DATE: 2002-11-01
PRIOR APPLICATION NUMBER: US 60/147,294
PRIOR FILING DATE: 1999-08-04
NUMBER OF SEQ ID NOS: 22
SOFTWARE: Patentln Ver. 2.0
SEQ ID NO 10
LENGTH: 77
TYPE: PRT
ORGANISM: Mouse
US-10-286-696-10

Query Match 100.0%; Score 148; DB 2; Length 77;
Best Local Similarity 100.0%; Pred. No. 1.9e-14;
Matches 27; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1 NAASIPSGSHKVTLSWYHDSGMAKIS 27
|||||
Db 14 NAASIPSGSHKVTLSWYHDSGMAKIS 40

RESULT 4
US-09-396-937-10
Sequence 10, Application US/09396937
Patent No. 6645500
GENERAL INFORMATION:
APPLICANT: M&E Biotech A/S
APPLICANT: HALKIER, Torben
APPLICANT: HAANING, Jesper
TITLE OF INVENTION: Method for Down-Regulating Osteoprotegerin Ligand
TITLE OF INVENTION: Activity
FILE REFERENCE: 22021 PC 1
CURRENT APPLICATION NUMBER: US/09/396,937
CURRENT FILING DATE: 1999-09-15
NUMBER OF SEQ ID NOS: 35
SOFTWARE: Patentln Ver. 2.1
SEQ ID NO 10
LENGTH: 173
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: DNA encoding
OTHER INFORMATION: murine OPGL, residues 158-316, fused to His tag
US-09-396-937-10

Query Match 100.0%; Score 148; DB 2; Length 173;
Best Local Similarity 100.0%; Pred. No. 5e-14;
Matches 27; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1 NAASIPSGSHKVTLSWYHDSGMAKIS 27
|||||
Db 27 NAASIPSGSHKVTLSWYHDSGMAKIS 53

RESULT 5
US-09-396-937-12
Sequence 12, Application US/09396937
Patent No. 6645500
GENERAL INFORMATION:
APPLICANT: M&E Biotech A/S
APPLICANT: HALKIER, Torben
APPLICANT: HAANING, Jesper
TITLE OF INVENTION: Method for Down-Regulating Osteoprotegerin Ligand
TITLE OF INVENTION: Activity
FILE REFERENCE: 22021 PC 1
CURRENT APPLICATION NUMBER: US/09/396,937
CURRENT FILING DATE: 1999-09-15
NUMBER OF SEQ ID NOS: 35
SOFTWARE: Patentln Ver. 2.1
SEQ ID NO 12
LENGTH: 173
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Fusion of
OTHER INFORMATION: murine OPGL, residues 158-316 with C to S
US-09-396-937-12

Query Match 100.0%; Score 148; DB 2; Length 173;
Best Local Similarity 100.0%; Pred. No. 5e-14;
Matches 27; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1 NAASIPSGSHKVTLSWYHDSGMAKIS 27
|||||
Db 27 NAASIPSGSHKVTLSWYHDSGMAKIS 53

RESULT 6
US-09-396-937-18
Sequence 18, Application US/09396937
Patent No. 6645500
GENERAL INFORMATION:
APPLICANT: M&E Biotech A/S
APPLICANT: HALKIER, Torben
APPLICANT: HAANING, Jesper
TITLE OF INVENTION: Method for Down-Regulating Osteoprotegerin Ligand
TITLE OF INVENTION: Activity
FILE REFERENCE: 22021 PC 1
CURRENT APPLICATION NUMBER: US/09/396,937
CURRENT FILING DATE: 1999-09-15
NUMBER OF SEQ ID NOS: 35
SOFTWARE: Patentln Ver. 2.1
SEQ ID NO 18
LENGTH: 173
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Fusion between
OTHER INFORMATION: murine OPGL, residues 158-316 with tetanus toxoid
OTHER INFORMATION: P2 epitope introduced, and His tag
US-09-396-937-18

Query Match 100.0%; Score 148; DB 2; Length 173;
Best Local Similarity 100.0%; Pred. No. 5e-14;
Matches 27; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1 NAASIPSGSHKVTLSWYHDSGMAKIS 27
|||||
Db 27 NAASIPSGSHKVTLSWYHDSGMAKIS 53

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using SW model

Run on: December 21, 2005, 13:02:07 ; Search time 14.8721 Seconds
(without alignments)
758.559 Million cell updates/sec

Title: US-09-211-297-32

Perfect score: 148

Sequence: 1 NAASIPSGSHKVTLSWYHGRGMAKIS 27

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 1867569 seqs, 417829326 residues

Total number of hits satisfying chosen parameters: 1867569

Minimum DB seq length: 0

Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Published Applications_AA_Main:*
1: /cgn2_6/prodata/1/pubpaa/US07_PUBCOMB.pep:*
2: /cgn2_6/prodata/1/pubpaa/US08_PUBCOMB.pep:*
3: /cgn2_6/prodata/1/pubpaa/US09_PUBCOMB.pep:*
4: /cgn2_6/prodata/1/pubpaa/US10_PUBCOMB.pep:*
5: /cgn2_6/prodata/1/pubpaa/US10_PUBCOMB.pep:*
6: /cgn2_6/prodata/1/pubpaa/US11_PUBCOMB.pep:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	148	100.0	27	US-10-825-898-33	Sequence 33, Appl
2	148	100.0	28	US-10-825-898-34	Sequence 34, Appl
3	148	100.0	77	US-10-286-696-10	Sequence 10, Appl
4	148	100.0	77	US-10-890-368-10	Sequence 10, Appl
5	148	100.0	77	US-10-889-948-10	Sequence 10, Appl
6	148	100.0	160	US-09-779-050A-14	Sequence 14, Appl
7	148	100.0	170	US-09-791-153A-76	Sequence 76, Appl
8	148	100.0	170	US-10-289-456-99	Sequence 99, Appl
9	148	100.0	173	US-10-664-801-10	Sequence 10, Appl
10	148	100.0	173	US-10-664-801-12	Sequence 12, Appl
11	148	100.0	173	US-10-664-801-18	Sequence 18, Appl
12	148	100.0	173	US-10-664-801-20	Sequence 20, Appl
13	148	100.0	182	US-10-664-801-16	Sequence 16, Appl
14	148	100.0	187	US-10-664-801-8	Sequence 8, Appl
15	148	100.0	188	US-10-664-801-14	Sequence 14, Appl
16	148	100.0	193	US-10-289-456-96	Sequence 96, Appl
17	148	100.0	199	US-10-050-902-224	Sequence 224, Appl
18	148	100.0	199	US-10-050-902-224	Sequence 224, Appl
19	148	100.0	199	US-10-289-456-86	Sequence 86, Appl
20	148	100.0	244	US-10-167-182-16	Sequence 16, Appl
21	148	100.0	244	US-10-460-623-16	Sequence 16, Appl
22	148	100.0	244	US-10-854-100-16	Sequence 16, Appl
23	148	100.0	244	US-11-135-521-16	Sequence 16, Appl
24	148	100.0	247	US-10-050-902-223	Sequence 223, Appl
25	148	100.0	247	US-10-050-898-223	Sequence 223, Appl
26	148	100.0	247	US-10-289-456-85	Sequence 85, Appl
27	148	100.0	249	US-10-338-785A-3	Sequence 3, Appl

28	148	100.0	249	US-10-611-363-3	Sequence 3, Appl
29	148	100.0	294	US-09-871-856-11	Sequence 11, Appl
30	148	100.0	294	US-09-865-163-11	Sequence 11, Appl
31	148	100.0	294	US-09-871-291-11	Sequence 11, Appl
32	148	100.0	294	US-09-877-650-11	Sequence 11, Appl
33	148	100.0	294	US-10-405-878-11	Sequence 11, Appl
34	148	100.0	294	US-10-802-133-11	Sequence 11, Appl
35	148	100.0	316	US-09-957-944-8	Sequence 8, Appl
36	148	100.0	316	US-09-079-569-7	Sequence 7, Appl
37	148	100.0	316	US-09-873-829-4	Sequence 4, Appl
38	148	100.0	316	US-09-933-915A-16	Sequence 16, Appl
39	148	100.0	316	US-10-017-910-4	Sequence 4, Appl
40	148	100.0	316	US-10-105-057-2	Sequence 2, Appl
41	148	100.0	316	US-10-272-411-19	Sequence 19, Appl
42	148	100.0	316	US-10-272-328A-19	Sequence 19, Appl
43	148	100.0	316	US-10-326-052-2	Sequence 2, Appl
44	148	100.0	316	US-10-167-182-1	Sequence 1, Appl
45	148	100.0	316	US-10-460-623-1	Sequence 1, Appl

ALIGNMENTS

```

RESULT 1
US-10-825-898-33
; Sequence 33, Application US/10825898
; Publication No. US20050003400A1
; GENERAL INFORMATION:
; APPLICANT: BOYLE, WILLIAM
; TITLE OF INVENTION: OSTROPROTEGERIN BINDING PROTEINS AND RECEPTORS
; FILE REFERENCE: A-451K REV 09-10-03 54SEQ
; CURRENT FILING DATE: 2004-04-15
; PRIOR APPLICATION NUMBER: US/10/825,898
; PRIOR FILING DATE: 2004-04-15
; PRIOR APPLICATION NUMBER: US 09/052,521
; PRIOR FILING DATE: 1998-03-30
; PRIOR FILING DATE: 1998-03-30
; PRIOR APPLICATION NUMBER: US 08/880,855
; PRIOR FILING DATE: 1997-06-23
; PRIOR APPLICATION NUMBER: US 08/842,842
; PRIOR FILING DATE: 1997-04-16
; NUMBER OF SEQ ID NOS: 54
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 33
; LENGTH: 27
; TYPE: PRP
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Oligonucleotide
US-10-825-898-33

Query Match          100.0%; Score 148; DB 5; Length 27;
Best local similarity 100.0%; Pred. No. 6.8e-13;
Matches 27; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 NAASIPSGSHKVTLSWYHGRGMAKIS 27
Db      1 NAASIPSGSHKVTLSWYHGRGMAKIS 27

RESULT 2
US-10-825-898-34
; Sequence 34, Application US/10825898
; Publication No. US20050003400A1
; GENERAL INFORMATION:
; APPLICANT: BOYLE, WILLIAM
; TITLE OF INVENTION: OSTROPROTEGERIN BINDING PROTEINS AND RECEPTORS
; FILE REFERENCE: A-451K REV 09-10-03 54SEQ
; CURRENT FILING DATE: 2004-04-15
; PRIOR APPLICATION NUMBER: US/10/825,898
; PRIOR FILING DATE: 2004-04-15
; PRIOR APPLICATION NUMBER: US 09/052,521
; PRIOR FILING DATE: 2004-04-15
; PRIOR APPLICATION NUMBER: US 09/052,521

```

;; PRIOR FILING DATE: 1998-03-30
;; PRIOR APPLICATION NUMBER: US 08/880,855
;; PRIOR FILING DATE: 1997-06-23
;; PRIOR APPLICATION NUMBER: US 08/842,842
;; PRIOR FILING DATE: 1997-04-16
;; NUMBER OF SEQ ID NOS: 54
;; SOFTWARE: PatentIn version 3.1
;; SEQ ID NO 34
;; LENGTH: 28
;; TYPE: PRT
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: Synthetic Oligonucleotide
US-10-825-898-34

Query Match 100.0%; Score 148; DB 5; Length 28;
Best Local Similarity 100.0%; Pred. No. 7,1e-13;
Matches 27; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 NAASIPSGSHKVTLSWYHDSGMWAKIS 27
Db 1 NAASIPSGSHKVTLSWYHDSGMWAKIS 27

RESULT 3
US-10-286-696-10
;; Sequence 10, Application US/10286696
;; Publication No. US20030129706A1
;; GENERAL INFORMATION:
;; APPLICANT: Hsu, Hailing
;; APPLICANT: Wooden, Scott K
;; APPLICANT: Boyle, William J
;; TITLE OF INVENTION: Fhm, A No. US20030129706A1 Member of the TNF Ligand Supergene F
;; FILE REFERENCE: 01017/35550A
;; CURRENT APPLICATION NUMBER: US/10/286,696
;; CURRENT FILING DATE: 2002-11-01
;; PRIOR APPLICATION NUMBER: US 60/147,294
;; PRIOR FILING DATE: 1999-08-04
;; NUMBER OF SEQ ID NOS: 22
;; SOFTWARE: PatentIn Ver. 2.0
;; SEQ ID NO 10
;; LENGTH: 77
;; TYPE: PRT
;; ORGANISM: Mouse
US-10-286-696-10

Query Match 100.0%; Score 148; DB 4; Length 77;
Best Local Similarity 100.0%; Pred. No. 2e-12;
Matches 27; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 NAASIPSGSHKVTLSWYHDSGMWAKIS 27
Db 14 NAASIPSGSHKVTLSWYHDSGMWAKIS 40

RESULT 4
US-10-890-368-10
;; Sequence 10, Application US/10890368
;; Publication No. US20040248324A1
;; GENERAL INFORMATION:
;; APPLICANT: Hsu et al.
;; TITLE OF INVENTION: FHM, A NOVEL MEMBER OF THE TNF LIGAND SUPERGENE FAMILY: MATERIALS
;; FILE REFERENCE: 01017/35550D
;; CURRENT APPLICATION NUMBER: US/10/890,368
;; CURRENT FILING DATE: 2004-07-13
;; PRIOR APPLICATION NUMBER: US 10/286,696
;; PRIOR FILING DATE: 2002-11-01
;; PRIOR APPLICATION NUMBER: US 09/632,287
;; PRIOR FILING DATE: 2000-08-03
;; PRIOR APPLICATION NUMBER: US 60/147,294
;; PRIOR FILING DATE: 1999-08-04
;; NUMBER OF SEQ ID NOS: 22

;; SOFTWARE: PatentIn Ver. 2.0
;; SEQ ID NO 10
;; LENGTH: 77
;; TYPE: PRT
;; ORGANISM: Mouse
US-10-890-368-10

Query Match 100.0%; Score 148; DB 5; Length 77;
Best Local Similarity 100.0%; Pred. No. 2e-12;
Matches 27; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 NAASIPSGSHKVTLSWYHDSGMWAKIS 27
Db 14 NAASIPSGSHKVTLSWYHDSGMWAKIS 40

RESULT 5
US-10-889-948-10
;; Sequence 10, Application US/10889948
;; Publication No. US20040265913A1
;; GENERAL INFORMATION:
;; APPLICANT: Hsu et al.
;; TITLE OF INVENTION: FHM, A NOVEL MEMBER OF THE TNF LIGAND SUPERGENE FAMILY: ANTIBODY
;; FILE REFERENCE: 01017/35550C
;; CURRENT APPLICATION NUMBER: US/10/889,948
;; CURRENT FILING DATE: 2004-07-13
;; PRIOR APPLICATION NUMBER: US 10/286,696
;; PRIOR FILING DATE: 2002-11-01
;; PRIOR APPLICATION NUMBER: US 09/632,287
;; PRIOR FILING DATE: 2000-08-03
;; PRIOR APPLICATION NUMBER: US 60/147,294
;; PRIOR FILING DATE: 1999-08-04
;; NUMBER OF SEQ ID NOS: 22
;; SOFTWARE: PatentIn Ver. 2.0
;; SEQ ID NO 10
;; LENGTH: 77
;; TYPE: PRT
;; ORGANISM: Mouse
US-10-889-948-10

Query Match 100.0%; Score 148; DB 5; Length 77;
Best Local Similarity 100.0%; Pred. No. 2e-12;
Matches 27; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 NAASIPSGSHKVTLSWYHDSGMWAKIS 27
Db 14 NAASIPSGSHKVTLSWYHDSGMWAKIS 40

RESULT 6
US-09-779-050A-14
;; Sequence 14, Application US/09779050A
;; Patent No. US20020160416A1
;; GENERAL INFORMATION:
;; APPLICANT: BOYLE, WILLIAM
;; APPLICANT: HSU, HAILING
;; TITLE OF INVENTION: RECEPTOR FROM TNF FAMILY
;; FILE REFERENCE: A-570B
;; CURRENT APPLICATION NUMBER: US/09/779,050A
;; CURRENT FILING DATE: 2001-02-12
;; PRIOR APPLICATION NUMBER: 60/181,800
;; PRIOR FILING DATE: 2000-02-11
;; NUMBER OF SEQ ID NOS: 52
;; SOFTWARE: PatentIn version 3.0
;; SEQ ID NO 14
;; LENGTH: 160
;; TYPE: PRT
;; ORGANISM: Mus musculus
US-09-779-050A-14

Query Match 100.0%; Score 148; DB 3; Length 160;
Best Local Similarity 100.0%; Pred. No. 4,2e-12;

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: December 21, 2005, 13:03:52; Search time 0.840984 Seconds
(without alignments)
228.978 Million cell updates/sec

Title: US-09-211-297-32

Perfect score: 148

Sequence: 1 NAASIPSGSHKVTLSWYHGRGWAKIS 27

Scoring table: BLOSUM62

Gapop 10.0, Gapext 0.5

Searched: 53982 seqs, 7132107 residues

Total number of hits satisfying chosen parameters: 53982

Minimum DB seq length: 0

Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Database: Published Applications_AA_New*

1: /cgn2_6/ptodata/2/pubpa/US08_NEW_PUB.pdb.*
2: /cgn2_6/ptodata/2/pubpa/US06_NEW_PUB.pdb.*
3: /cgn2_6/ptodata/2/pubpa/US07_NEW_PUB.pdb.*
4: /cgn2_6/ptodata/2/pubpa/PCT_NEW_PUB.pdb.*
5: /cgn2_6/ptodata/2/pubpa/US05_NEW_PUB.pdb.*
6: /cgn2_6/ptodata/2/pubpa/US10_NEW_PUB.pdb.*
7: /cgn2_6/ptodata/2/pubpa/US11_NEW_PUB.pdb.*
8: /cgn2_6/ptodata/2/pubpa/US60_NEW_PUB.pdb.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	132	89.2	109	US-11-065-669-8	Sequence 8, Appl
2	53.5	36.1	1649	US-10-995-561-974	Sequence 974, Appl
3	53.5	36.1	1694	US-11-135-855-36	Sequence 36, Appl
4	53.5	36.1	1709	US-10-995-561-973	Sequence 973, Appl
5	53.5	36.1	1709	US-11-135-855-35	Sequence 35, Appl
6	46	30.4	532	US-11-152-747-2	Sequence 2, Appl
7	45	30.4	53	US-10-467-657-4496	Sequence 4496, Appl
8	44	29.7	401	US-10-510-386-68	Sequence 68, Appl
9	43.5	29.4	367	US-10-821-234-1569	Sequence 1569, Appl
10	43.5	29.4	401	US-11-097-749-3	Sequence 3, Appl
11	43.5	29.4	863	US-11-097-749-2	Sequence 2, Appl
12	43	29.1	245	US-10-793-626-2910	Sequence 2910, Appl
13	43	29.1	588	US-10-793-626-3328	Sequence 3328, Appl
14	42.5	28.7	447	US-11-112-882-4	Sequence 4, Appl
15	41	27.7	272	US-10-467-657-2730	Sequence 2730, Appl
16	41	27.7	288	US-10-131-826A-316	Sequence 316, Appl
17	41	27.7	987	US-10-770-726-61	Sequence 61, Appl
18	40.5	27.4	250	US-10-454-437-388	Sequence 388, Appl
19	40.5	27.4	378	US-11-080-091-3	Sequence 3, Appl
20	40.5	27.4	378	US-11-080-091-11	Sequence 11, Appl
21	40.5	27.4	378	US-11-087-177-39	Sequence 39, Appl
22	40.5	27.4	378	US-11-087-177-41	Sequence 41, Appl
23	40.5	27.4	488	US-10-821-234-1000	Sequence 1000, Appl
24	40	27.0	296	US-11-074-176-166	Sequence 166, Appl
25	40	27.0	362	US-10-821-234-1148	Sequence 1148, Appl

26	40	27.0	651	6	US-10-821-234-1480	Sequence 1480, Appl
27	40	27.0	2261	6	US-10-995-561-600	Sequence 600, Appl
28	40	27.0	2516	6	US-10-647-968A-2	Sequence 2, Appl
29	39.5	26.7	343	7	US-11-080-991-86	Sequence 86, Appl
30	39.5	26.7	393	6	US-10-821-234-1043	Sequence 1043, Appl
31	39	26.4	199	6	US-10-467-657-8058	Sequence 8058, Appl
32	39	26.4	261	6	US-10-617-034A-12	Sequence 12, Appl
33	39	26.4	282	6	US-10-467-657-810	Sequence 810, Appl
34	39	26.4	309	7	US-11-109-156-24	Sequence 24, Appl
35	39	26.4	309	7	US-11-109-156-39	Sequence 39, Appl
36	39	26.4	311	6	US-10-467-657-1638	Sequence 1638, Appl
37	39	26.4	322	6	US-10-821-234-1354	Sequence 1354, Appl
38	39	26.4	322	6	US-10-878-556A-59	Sequence 59, Appl
39	39	26.4	998	6	US-10-510-524-1	Sequence 1, Appl
40	39	26.4	1467	6	US-10-507-956-1	Sequence 9, Appl
41	38.5	26.0	366	7	US-11-091-334-9	Sequence 38, Appl
42	38.5	26.0	484	6	US-10-873-528-38	Sequence 67, Appl
43	38.5	26.0	617	6	US-10-878-556A-67	Sequence 6006, Appl
44	38.5	26.0	659	6	US-10-467-657-6006	Sequence 122, Appl
45	38	25.7	179	6	US-10-467-657-122	

ALIGNMENTS

```

RESULT 1
US-11-065-669-8
; Sequence 8, Application US/11065669
; Publication No. US2005024411A1
; GENERAL INFORMATION:
; APPLICANT: Mackay, Fabienne
; APPLICANT: Kalled, Susan
; TITLE OF INVENTION: BAF, INHIBITORS THEREOF AND THEIR USE IN THE
; FILE REFERENCE: 08201.0024-04000
; CURRENT APPLICATION NUMBER: US/11/065,669
; CURRENT FILING DATE: 2005-02-24
; PRIOR APPLICATION NUMBER: 10/045,574
; PRIOR FILING DATE: 2001-11-07
; PRIOR APPLICATION NUMBER: 09/911,777
; PRIOR FILING DATE: 2001-07-24
; PRIOR APPLICATION NUMBER: 60/143,228
; PRIOR FILING DATE: 2001-07-09
; PRIOR APPLICATION NUMBER: PCT/US00/01788
; PRIOR FILING DATE: 2000-01-25
; PRIOR APPLICATION NUMBER: 60/117,169
; PRIOR FILING DATE: 1999-01-25
; NUMBER OF SEQ ID NOS: 26
; SOFTWARE: Patentin Ver. 2.1
; SEQ ID NO 8
; LENGTH: 109
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-065-669-8

Query Match      89.2%; Score 132; DB 7; Length 109;
Best Local Similarity 85.2%; Pred. No. 3.2e-12;
Matches 23; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

CY      1 NAASIPSGSHKVTLSWYHGRGWAKIS 27
DB      11 NATDIPSGSHKVTLSWYHGRGWAKIS 37

RESULT 2
US-10-995-561-974
; Sequence 974, Application US/10995561
; Publication No. US20050272054A1
; GENERAL INFORMATION:
; APPLICANT: CARGILL, Michele et al.
; TITLE OF INVENTION: GENETIC POLYMORPHISMS ASSOCIATED WITH
; TITLE OF INVENTION: CARDIOVASCULAR DISORDERS AND DRUG RESPONSE, METHODS OF
; TITLE OF INVENTION: DETECTION AND USES THEREOF

```

```
FILE REFERENCE: CL001559
CURRENT APPLICATION NUMBER: US/10/995,561
CURRENT FILING DATE: 2004-11-24
NUMBER OF SEQ ID NOS: 85702
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 974
LENGTH: 1649
TYPE: PRT
ORGANISM: Homo sapiens
US-10-995-561-974

Query Match          36.1% Score 53.5; DB 6; Length 1649;
Best Local Similarity 31.2% Pred. No. 4.2;
Matches 10; Conservative 5; Mismatches 6; Indels 11; Gaps 1;

QY 3 ASIPSG-----SHKVTLSWYHNRGW 23
DB 1269 AAVPEGAPITVTCADPAHAAPTLYTWYHNGRW 1300

RESULT 3
US-11-135-855-36
Sequence 36, Application US/11135855
Publication No. US20050255557A1
GENERAL INFORMATION:
APPLICANT: SMITHKLINE BEECHAM CORPORATION
TITLE OF INVENTION: NOVEL COMPOUNDS
FILE REFERENCE: GP50013
CURRENT APPLICATION NUMBER: US/11/135,855
CURRENT FILING DATE: 2005-05-24
PRIOR APPLICATION NUMBER: US/10/203,708
PRIOR FILING DATE: 2002-08-13
PRIOR APPLICATION NUMBER: PCT/US01/04703
PRIOR FILING DATE: 2001-02-14
PRIOR APPLICATION NUMBER: 60/182,172
PRIOR FILING DATE: 2000-02-14
PRIOR APPLICATION NUMBER: 60/186,084
PRIOR FILING DATE: 2000-02-29
NUMBER OF SEQ ID NOS: 46
SOFTWARE: FastSeq for Windows Version 3.0
SEQ ID NO 36
LENGTH: 1694
TYPE: PRT
ORGANISM: Homo sapiens
US-11-135-855-36

Query Match          36.1% Score 53.5; DB 7; Length 1694;
Best Local Similarity 31.2% Pred. No. 4.3;
Matches 10; Conservative 5; Mismatches 6; Indels 11; Gaps 1;

QY 3 ASIPSG-----SHKVTLSWYHNRGW 23
DB 1263 AAVPEGAPITVTCADPAHAAPTLYTWYHNGRW 1294

RESULT 4
US-10-995-561-973
Sequence 973, Application US/10995561
Publication No. US20050272054A1
GENERAL INFORMATION:
APPLICANT: CARGILL, Michele et al.
TITLE OF INVENTION: GENETIC POLYMORPHISMS ASSOCIATED WITH
CARDIOVASCULAR DISORDERS AND DRUG RESPONSE, METHODS OF
TITLE OF INVENTION: DETECTION AND USES THEREOF
FILE REFERENCE: CL001559
CURRENT APPLICATION NUMBER: US/10/995,561
CURRENT FILING DATE: 2004-11-24
NUMBER OF SEQ ID NOS: 85702
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 973
LENGTH: 1709
TYPE: PRT
```

```
ORGANISM: Homo sapiens
US-10-995-561-973

Query Match          36.1% Score 53.5; DB 6; Length 1709;
Best Local Similarity 31.2% Pred. No. 4.3;
Matches 10; Conservative 5; Mismatches 6; Indels 11; Gaps 1;

QY 3 ASIPSG-----SHKVTLSWYHNRGW 23
DB 1269 AAVPEGAPITVTCADPAHAAPTLYTWYHNGRW 1300

RESULT 5
US-11-135-855-35
Sequence 35, Application US/11135855
Publication No. US20050255557A1
GENERAL INFORMATION:
APPLICANT: SMITHKLINE BEECHAM CORPORATION
TITLE OF INVENTION: NOVEL COMPOUNDS
FILE REFERENCE: GP50013
CURRENT APPLICATION NUMBER: US/11/135,855
CURRENT FILING DATE: 2005-05-24
PRIOR APPLICATION NUMBER: US/10/203,708
PRIOR FILING DATE: 2002-08-13
PRIOR APPLICATION NUMBER: PCT/US01/04703
PRIOR FILING DATE: 2001-02-14
PRIOR APPLICATION NUMBER: 60/182,172
PRIOR FILING DATE: 2000-02-14
PRIOR APPLICATION NUMBER: 60/186,084
PRIOR FILING DATE: 2000-02-29
NUMBER OF SEQ ID NOS: 46
SOFTWARE: FastSeq for Windows Version 3.0
SEQ ID NO 35
LENGTH: 1709
TYPE: PRT
ORGANISM: Homo sapiens
US-11-135-855-35

Query Match          36.1% Score 53.5; DB 7; Length 1709;
Best Local Similarity 31.2% Pred. No. 4.3;
Matches 10; Conservative 5; Mismatches 6; Indels 11; Gaps 1;

QY 3 ASIPSG-----SHKVTLSWYHNRGW 23
DB 1263 AAVPEGAPITVTCADPAHAAPTLYTWYHNGRW 1294

RESULT 6
US-11-152-747-2
Sequence 2, Application US/11152747
Publication No. US20050251881A1
GENERAL INFORMATION:
APPLICANT: E. I. du Pont de Nemours, Inc.
APPLICANT: Cheng, Qiong
APPLICANT: Tao, Luan
TITLE OF INVENTION: CAROTENOID KETOYLASE GENE
FILE REFERENCE: CL-1849 US NA
CURRENT APPLICATION NUMBER: US/11/152,747
CURRENT FILING DATE: 2005-06-14
PRIOR APPLICATION NUMBER:
PRIOR FILING DATE:
NUMBER OF SEQ ID NOS: 47
SOFTWARE: Microsoft Office 97
SEQ ID NO 2
LENGTH: 532
TYPE: PRT
ORGANISM: Rhodococcus erythropolis AN12
US-11-152-747-2

Query Match          31.1% Score 46; DB 7; Length 532;
Best Local Similarity 39.3% Pred. No. 16;
Matches 11; Conservative 4; Mismatches 7; Indels 6; Gaps 2;
```